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 Minimal eliciting doses for objective allergic reactions were found for 13 priority 
allergens and over 1800 individuals from published clinical literature or unpublished 
clinical data. Allergic populations did not vary when analyzed by age or geographic 
region. Results of this study show there are sufficient clinical data from food allergic 
individuals to use for risk assessment purposes for several allergenic foods.  
Of 186 food products bearing advisory statements regarding peanut or 16 
products that had peanut listed as a minor ingredient, 8.6% and 37.5% contained 
detectable levels of peanut (>2.5 ppm whole peanut). An additional market survey of 215 
nutrition bars with peanuts as a minor ingredient and/or an advisory statement for peanuts 
found 24.6% tested positive for peanut compared to 4% of products with no mention of 
peanuts on the label. Probabilistic risk assessment showed the risk of reaction among 
peanut allergic consumers from advisory labeled nutrition bars was significant but brand-
dependent. The probabilistic approach provides the food industry with a quantitative 
method to assist with determining when advisory labeling is most appropriate. 
Agricultural commodity cross-contamination of soybean was detected in 62.8% of 
samples representing all forms of wheat flour. Conservative probabilistic risk 
assessments predict a risk of allergic reaction occurring in the most sensitive soy-allergic 
individuals.  Experimental milling and stream separation with spiked soy in wheat 
 
 
samples did not produce a soy-free wheat flour stream. Additional cleaning measures will 
be needed to remove soy before wheat milling begins. 
LC-MS/MS identified fourteen known allergens in industry representative soy 
product samples, including all subunits of Gly m 5 (β-conglycinin) and Gly m 6 
(glycinin), the Kunitz trypsin inhibitor, Gly m Bd 28K, and Gly m Bd 30K. Method 
refinements or different techniques might be necessary to detect low abundance proteins 
such as Gly m 3 and 4. The relative amount of an allergen in a sample correlated 
positively to the intensity of IgE binding at the expected molecular weight using sera 
from soy-allergic individuals. 
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CHAPTER 1: LITERATURE REVIEW 
Introduction  
Recognized by the “Father of Medicine” Hippocrates, food allergies and 
intolerances have been documented for millennia (Adams, 1886). However, the incidence 
of food allergies and related diseases did not take prominence in medical literature until 
the 20
th
 century. Currently, the only treatment available for food allergic individuals is a 
strict avoidance diet which can cause anxiety issues for all involved (de Blok et al., 2007; 
Taylor et al., 1986a). The prevalence of food allergies is globally on the rise and a 
significant amount of research is dedicated to find the cause, treatment, and cure for food 
allergies. This review will focus on the types of adverse reactions to food, with special 
attention paid to food allergy: its mechanisms, prevalence, diagnosis, and treatments. 
Additionally, thresholds of reactivity for allergic individuals and populations and risk 
assessment methods for food allergens based upon the threshold distribution will be 
presented within the framework of current regulations and relevant food industry 
situations.  
Food sensitivities 
 As stated by Taylor (1987), “food sensitivity has become the accepted term to 
describe the broad range of individualistic adverse reactions to foods.” Food sensitivities 
are separated into primary and secondary subclassifications. Primary sensitivities are 
more common than secondary sensitivities and include true immunologically mediated 
food allergies and other non-immunological food intolerances (Figure 1). Food 
hypersensitivities/allergies are separated into immunoglobulin E (IgE)-mediated 
immediate reactions and non-IgE cell-mediated delayed reactions. Non-immunological 
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food intolerances are further classified as anaphylactoid reactions, metabolic food 
disorders, and idiosyncratic reactions. Most food intolerances have mild symptoms and 
individuals can tolerate minor exposures as part of a restrictive diet without eliciting 
symptoms. In comparison, allergic individuals must follow a more restrictive avoidance 
diet due to the potential severity of their disease and lower thresholds for some 
individuals (Taylor and Hefle, 2006b). Secondary sensitivities can result in the same 
ailments as primary sensitivities due to the effects from numerous gastrointestinal 
conditions or drug treatments. Secondary conditions are usually temporary but can 
enhance the chances of developing permanent food allergies, lactose intolerance, or 
celiac disease (Taylor, 1987).  
 
Figure 1 – Classifications of different types of food sensitivities (Modified from Taylor and Hefle 
(2001)). 
Food Sensitivity 
Primary 
Food Allergies  
(Immunological) 
IgE-mediated 
(Immediate reaction) 
Non-IgE-cell-
mediated  
(Delayed reaction) 
Food Intolerances  
(Non-immunological) 
Anaphylactoid 
reactions 
Metabolic reactons 
Idiosyncratic 
reactions 
Secondary 
Secondary to GI 
disorders 
Secondary to drug 
treatment 
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Food intolerance 
 Food intolerances include all individualistic adverse reactions to foods where an 
abnormal immune system response is not the cause of the symptoms (Taylor and Hefle, 
2006b). As previously stated, the major categories of food intolerances include 
anaphylactoid reactions, metabolic food disorders, and idiosyncratic reactions.  
Anaphylactoid reactions 
 Anaphylactoid reactions are characterized by the release of histamine and other 
mediators from mast cells and basophils without the interaction of IgE or other 
immunoglobulins (Taylor et al., 1989). The occurrence of anaphylactoid reactions to 
foods is debatable as the release of mediators occurs through an as of yet unknown 
mechanism and there have been no foodborne substances identified that trigger the 
spontaneous release of histamine (Taylor and Hefle, 2006b; Taylor et al., 1989). The 
most evidence available for the existence of anaphylactoid reactions is the lack of 
immunological evidence in certain possible cases of food allergy, such as strawberries, 
shellfish, and chocolate (Hefle, 1996; Taylor et al., 1989). As the mechanism behind 
these reactions is unknown, an avoidance diet is required to avoid any adverse reactions. 
Metabolic food disorders  
 Metabolic food disorders are the result of inherited genetic deficiencies and the 
loss of ability to metabolize a food component or an enhancement of the individual’s 
sensitivity to a foodborne chemical due to the loss of normal cellular or enzymatic 
function (Taylor et al., 1989). The two best known metabolic food disorders are lactose 
intolerance and favism, with favism affecting over 100 million individuals worldwide 
(Taylor et al., 1989).  
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Lactose intolerance is characterized through the deficiency of the lactase (β-
galactosidase) enzyme in the intestinal mucosa (Lomer et al., 2008; Taylor and Hefle, 
2006b). Lactase will hydrolyze lactose into glucose and galactose to be absorbed in the 
small intestine. Unhydrolyzed lactose will reach the colon, where it is fermented by the 
natural gut microbiota into carbon dioxide, hydrogen, and water which causes abdominal 
pain, diarrhea, and flatulence (Lomer et al., 2008). Some level of lactose can be tolerated 
by many individuals with lactose intolerance. Avoidance of milk products with large 
doses of lactose is necessary to treat lactose intolerance. Additionally, ingesting another 
source of β-galactosidase, such as a purified lactase enzyme in pill form or the bacterial 
form of the enzyme found in yogurt, can also lessen symptoms. Lactose is then 
hydrolyzed by the ingested enzyme before it reaches the gut bacteria (Lomer et al., 2008).  
Favism affects individuals with a deficiency of the glucose-6-phosphate 
dehydrogenase enzyme (G6PDH) in their red blood cells (Taylor et al., 1989). These 
individuals’ red blood cells are then susceptible to oxidative damage. Fava beans produce 
natural oxidants and favism symptoms are consistent with hemolytic disease, including 
pallor, fatigue, and dyspnea. Favism is self-limiting and usually not serious but renal 
failure can occur in severe cases (Taylor et al., 1989). Avoidance of fava beans is 
necessary for G6PDH-deficient individuals and is not particularly difficult for most on a 
Western diet. 
Idiosyncratic reactions 
 Idiosyncratic reactions are adverse reactions to food that occur through unknown 
mechanisms (Taylor and Hefle, 2006b). Symptoms can range from mild and self-limiting 
to severe, life-threatening reactions. Just as the symptoms vary, a wide range of 
5 
 
underlying mechanisms could be involved with these reactions (Taylor et al., 1989). 
While many cause-effect relationships have not been clearly established for idiosyncratic 
reactions, sulfite-induced asthma and aspartame-induced urticaria are two of the proven 
relationships. Double-blind placebo-controlled food challenges (DBPCFC) are the 
method of choice to prove or disprove the cause-effect relationships in idiosyncratic 
reactions and have been successful in proving sulfite-induced asthma (Taylor et al., 
1986b; Taylor et al., 1989). Sulfites are used by the food industry to prevent enzymatic 
and nonenzymatic browning, as broad spectrum antimicrobial agents, as dough 
conditioning agents, to provide antioxidant protection, and as bleaching agents and must 
be labeled if used in a fashion that leads to residual levels above 10 parts per million 
(ppm) or mg/kg in the product (Taylor et al., 1986b). 
Food hypersensitivity  
Immune system overview  
 The immune system is a collection of effector cells and molecules that protect the 
host from infectious agents and other harmful substances. For the host to be properly 
protected, the immune system must accomplish four main tasks. The first task, 
immunological recognition, is the detection of an infection by white blood cells and/or 
lymphocytes. The second task, if possible, is to contain and eliminate the infection. The 
third task is immune regulation. Failure of proper immune regulation can be physically 
destructive to the hosts and in some cases lead to allergic responses or autoimmune 
diseases. The fourth task is to generate immunological memory and protect the host 
against recurring disease from a single pathogen. Both the innate and adaptive immune 
6 
 
systems are involved in these tasks and will be discussed further below (Murphy et al., 
2008). 
 When an infectious agent overcomes an individual’s physical and chemical 
barriers to enter the body, the first defenses they encounter are the phagocytic white 
blood cells (the neutrophils, monocytes, and macrophages) of the innate immune system. 
The phagocytic cells ingest and kill microbes through the production of toxic chemicals 
and degradative enzymes. Natural killer cells (NK cells) lack antigen-specific receptors 
found in the adaptive immune system but are able to recognize general receptor patterns 
and kill an abnormal cell when present. Additionally, the innate immune system provides 
the ability to discriminate between self and non-self through the help of pathogen-
associated molecular patterns (PAMPs) and pattern recognition receptors (PRRs) that 
recognize specific sections of microbes’ cell walls and unmethylated DNA common in 
many pathogens but not associated with the human body. Activation of the PRRs will in 
turn initiate the adaptive immune system. Dendritic cells and macrophages are additional 
innate cells that will activate the adaptive immune system through the uptake and 
presentation of antigens to other cells. The innate immune system only takes hours to 
respond, but is unable to form memory and relies on the adaptive immune system to 
develop specific defenses towards individual pathogens. There are two main types of 
adaptive immune cells, B lymphocytes (B cells) and T lymphocytes (T cells). The B cells 
bind to antigen presenting cells and differentiate into antibody producing plasma cells. 
Antibodies are Y-shaped proteins specific to a particular antigen and help facilitate a 
pathogen’s destruction and removal. Antibodies can bind and neutralize a pathogen, 
enhance phagocyte uptake, or activate the complement system to remove an infectious 
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agent. Separate T cells provide regulation to the immune system, kill infected cells, or 
help and instruct the B cells as to what immunoglobulin type to produce and when to 
secrete antibodies. The adaptive immune system also facilitates the differentiation of 
some cells into memory cells that provide the long-lasting immunity against a specific 
pathogen (Murphy et al., 2008). 
 Proper immune system function is required for a healthy and stable host to be 
protected from pathogens, but a hypersensitivity reaction can be elicited by an adaptive 
immune system response to inherently harmless antigens such as pollen, food, and drugs. 
Coombs and Gell (1975) separated hypersensitivity reactions into four classes displayed 
in Figure 2. Type I (IgE, soluble antigen), II (IgG, cell-surface antigen), and III (IgG, 
soluble antigen) hypersensitivity reactions are humoral immune responses and antibody-
mediated with the distinctions coming from the type of antigen recognized and the class 
of antibody interacting. Type IV hypersensitivities are delayed, T cell mediated reactions 
and can further be divided by the type of antigen and T cell involved. 
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Figure 2 – Four classes of hypersensitivity reactions. From Murphy et al. (2008). 
Food hypersensitivity, also known as true food allergies, are a worldwide public 
health concern in westernized nations and defined as abnormal immunologic responses to 
a particular food or food component (Taylor and Hefle, 2006b). Food allergies are 
typically reactions against naturally occuring proteins in food and can be immediate 
hypersensitivity, IgE-mediated reactions (Type I) or cell-mediated, delayed 
hypersensitivities (Type IV). Immediate, IgE-mediated reactions involve the formation 
IgE antibodies and recognition of specific allergenic proteins in food. IgE-mediated 
reactions are the most important of food sensitivities due to the rapid onset time of 
possible life-threatening symptoms (Taylor and Hefle, 2006b). Cell-mediated reactions 
are usually confined to the gastrointestinal tract with localized, non life-threatening 
symptoms occurring hours after ingestion of the antigen due to the interaction of a 
sensitized T cell lymphocyte and a specific antigen (Taylor and Hefle, 2006b). 
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Cell-mediated hypersensitivity  
 Non-IgE-mediated food allergies are Type IV food hypersensitivity reactions. 
Reactions are T cell-mediated with symptoms occurring 6-24 hours after the ingestion of 
the antigen. Symptoms often peak after 48 hours and the associated inflammatory 
response slowly subsides. Currently, an avoidance diet is the only treatment for complete 
symptom prevention associated with cell-mediated food allergies. Examples of cell-
mediated hypersensitivity reactions include celiac disease, food protein-induced 
enterocolitis, food protein-induced enteropathy, food protein-induced proctitis, allergic 
eosinophilic gastroenteritis, and allergic eosinophilic esophagitis. Cell-mediated reactions 
and/or IgE-antigen complexs could play a combined role in some of these diseases. 
(Sampson, 2004). Delayed hypersensitivities are not as well studied as IgE-mediated food 
allergies. Most mechanisms are unknown, although the cause-and-effect relationship is 
established. Celiac disease, also known as celiac sprue or gluten-sensitive entheropathy, 
is a malabsorption syndrome associated with ingestion of gluten from a number of grains 
but mostly wheat, barley, and rye. Celiac disease affects 0.7% of individuals in the 
United States and is the most studied of the delayed hypesensitivities (Rubio-Tapia et al., 
2012; Taylor and Hefle, 2006b).  
 Celiac disease is clinically presented as a local inflammatory response in the 
intestial tract. The inflammation damages and reduces the number of epithelial cells and 
levels of mucosal enzymes critical to digestion and absorption (Taylor and Hefle, 2006b). 
Individuals genetically susceptible to celiac disease express the human leukocyte antigen 
(HLA)-DQ2 or HLA-DQ8. Up to 40% of individuals carry these HLA haplotypes 
suggesting environmental factors play a large role in the development of celiac disease. 
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These HLA types are necessary for the development of celiac disease, but their absence 
virtually excludes the diagnosis (Niewinski, 2008). Diagnosis of celiac disease is 
confirmed by observation of and subsequent reversal of villous atrophy, crypt 
hyperplasia, and cellular infilitrate after the removal of gluten from the diet (Spergel, 
2006). Gluten peptides elicit both an innate and adaptive immune response in celiac 
disease, with CD4
+
 T cells in the lamina propria recognizing gluten peptides processed 
and presented by antigen-presenting cells (Niewinski, 2008). Symptoms generally 
include diarrhea, abdominal distension, and failure to thrive in children with diarrhea, 
constipation, weight loss, weakness, short stature, flatus, abdominal pain, and vomiting 
presenting in adults (Niewinski, 2008). The only proven treatment for celiac disease is a 
strict, life-long avoidance diet of gluten. However, future therapies could degrade gluten 
into peptides safe for consumption, inhibit activation of gluten-reactive T cells, or block 
gluten from binding to the HLA-DQ2 or HLA-DQ8 molecules (Sollid and Khosla, 2005).  
IgE-mediated hypersensitivity and food allergy  
 The protective immune response involves a myriad of cells, proteins, signals, and 
antibodies. The biological role of IgE involves protective immunity, especially in 
response to parasitic worms. However, certain individuals will produce IgE antibodies to 
innocuous, non-parasitic antigens that trigger inappropriate IgE responses known as Type 
I hypersensitivity reactions (Murphy et al., 2008). A true food allergy is an immediate 
Type I, IgE antibody mediated hypersensitivity reaction to a naturally occurring food 
component, most often a protein. Type I reactions are distinguished by IgE recognition of 
specific epitopes (linear or conformational) within a soluble antigen to trigger mast cell 
activation (Murphy et al., 2008; Pomes, 2010; Untersmayr and Jensen-Jarolim, 2006). In 
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addition to foods, certain drugs and environmental substances such as pollens, molds, bee 
venoms, dust mites, and animal danders have been shown to elicit IgE formation and 
cause allergic reactions (Taylor and Hefle, 2006b). In food allergy, symptoms typically 
develop in less than 10 minutes up to 2 hours after consumption of the offending food. 
Symptoms of a food allergy can be mild to severe and include hives, itching, skin rash, 
swelling of the lips, face, tongue, throat, and other body parts, wheezing, nasal 
congestion, abdominal pain, diarrhea, nausea, vomiting, dizziness, lightheadedness, or 
fainting. Anaphylaxis is a reaction that involves multiple organ systems, including any 
combination of the respiratory, cardiovascular, gastrointestinal, and cutaneous systems 
(FDA, 2009; Taylor and Hefle, 2006b). An anaphylactic reaction and its associated 
symptoms do not have to be life-threatening. However, most life-threatening or fatal food 
allergic reactions are anaphylactic in nature and disrupt respiratory and/or cardiovascular 
function (Taylor and Hefle, 2006b).  
 The mechanism involved in IgE-mediated food allergic reactions is shown in 
Figure 3. There are two stages of developing an IgE-mediated food allergy, the 
sensitization phase and the elicitation phase (Taylor and Hefle, 2006b). Sensitization can 
occur at any age in life and does not always occur upon the first exposure to an allergen. 
Sensitization is symptomless and consists of allergen absorption, processing and 
presentation, T cell and B cell activation, development of oral tolerance or allergic 
sensitivity, and synthesis of antigen-specific IgE antibodies by plasma cells (Fraser et al., 
2001; Taylor and Hefle, 2006b). The allergen-specific IgE attaches to the surface of mast 
cells in various connective tissues (gastrointestinal system, respiratory tract, skin) and 
basophils in the blood. Cross-linking of allergens to IgE on the surface of the mast cell or 
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basophil membrane triggers the release of histamine and other chemotactic mediators 
responsible for clinical allergic symptoms (Fraser et al., 2001; Taylor and Hefle, 2006b). 
Histamine, prostaglandins, and leukotrienes can elicit contraction of the smooth muscles 
in the blood vessels, gastrointestinal tract, and respiratory tract, as well as increase 
vascular permeability and vasodilation, increase mucus production, and increase 
chemotaxis of eosinophils, neutrophils and mononuclear cells. The mediators are released 
into the bloodstream and can trigger systemic reactions involving multiple tissues and 
organs (Fraser et al., 2001; Taylor and Hefle, 2006b). 
 
Figure 3 – Mechanism of IgE-mediated food allergy. Adapted from Taylor and Hefle (2006b). 
Nearly all foods with naturally occurring protein could potentially elicit allergic 
reactions in specific individuals. However, exposure to food proteins does not always 
result in the formation of protein-specific IgE antibodies and only a small percentage of 
food proteins have been identified as allergens (Hefle et al., 1996). Most food allergens 
are water- or salt-soluble glycoproteins with acidic isoelectric endpoints that are 
comparatively stable to processing, cooking, proteolysis, and the digestive processes 
(Taylor and Lehrer, 1996). However, classes of allergens do exist that are heat labile, 
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most notably allergens in fresh fruits, raw vegetables, and soy that are cross-reactive with 
the major birch pollen allergens (Geroldinger-Simic et al., 2011; Mittag et al., 2004; 
Vieths et al., 1996). While a wide variety of foods are consumed across the globe, 
relatively few are frequent causes of allergies (Hefle et al., 1996). The most common 
allergenic foods or food groups, referred to as the “Big 8” food allergens consists of milk, 
eggs, wheat, peanuts, tree nuts, soybeans, fish, and crustacean shellfish. The major 
allergenic foods are responsible for 90% of IgE-mediated food allergies (FAO, 1995). In 
addition to the “Big 8” there have been over 150 other allergenic foods reported (Hefle et 
al., 1996).  
Prevalence of IgE-mediated food allergy 
Food allergies are a worldwide health concern as an estimated 5 – 10% of 
children and 3 – 4% of adults in westernized countries are affected (Osborne et al., 2011; 
Rona et al., 2007; Sicherer and Sampson, 2010). Awareness of food allergy is increasing 
and up to 35% of individuals self-diagnose a food allergy. While specific causes have not 
been identified, the prevalence of food allergies is increasing across the globe (Altman 
and Chiaramonte, 1996; Lack, 2008; Rona et al., 2007; Sicherer and Sampson, 2010; 
Sloan and Powers, 1986).  
Multiple theories exist regarding the increasing prevalence of food allergy: 
genetic factors, Caesarean section births, the hygiene hypothesis, time and route of first 
exposure to food allergens, changes in dietary habits, food processing, and levels of 
vitamin D exposure (Lack, 2008; Sicherer and Sampson, 2010). No large scale change in 
population genetics can account for the rise in food allergy. Epigenetics is the study of 
heritable and non-heritable changes of gene function that occur without a change in the 
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nucleotide sequence of DNA. Epigenetic changes due to shifts in diet and environmental 
exposures have been linked to the development of asthma and allergic rhinitis but not 
food allergy (Kouzarides, 2007; North and Ellis, 2011). The hygiene hypothesis proposed 
that increased rates of infection early in life had a protective effect on the development of 
allergies, asthma, and other atopic diseases (Strachan, 2000). Germ free mice had 
abolished TH1 immune responses and were unable to achieve oral tolerance. However, 
exposure to intestinal bacteria during the neonate stage restored proper regulation of the 
TH2 immune response and development of oral tolerance (Pistiner et al., 2008; Renz‐
Polster et al., 2005; Sudo et al., 1997). The dual-allergen-exposure hypothesis states that 
tolerance occurs due to oral exposure to food and allergic sensitization occurs due to 
cutaneous exposure (Lack, 2008). Low dose cutaneous exposure is taken up through 
Langerhans cells and leads to a TH2 response and IgE production by B-cells. Oral 
exposure leads to TH1 and regulatory T-cell response in the gut to induce tolerance. 
Cutaneous exposure to peanut and peanut oil on abraded skin increased peanut 
sensitization and the risk of food allergies to peanut in mice and humans (Lack, 2008; 
Strid et al., 2004). Inflammation due to eczema reduces the effectiveness of the epidermal 
barrier protein and opens an opportunity for allergen protein exposure and creation of 
food-allergen specific T-cells in the open skin (Howell et al., 2007; van Reijsen et al., 
1998). Low levels of peanut are accessible in the household environment to infants after 
cleaning, providing a cutaneous exposure to those at risk (Perry et al., 2004). Time of 
peanut introduction into the diet had a significant effect on the prevalence of peanut 
allergy among Jewish school children (du Toit et al., 2008). Israeli Jewish children 
consumed more peanut in their first year of life than their UK counterparts and the 
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prevalence of peanut allergy was 0.17% in Israel versus 1.85% in the UK; variations in 
atopy, social class, or genetic background did not have a significant effect (du Toit et al., 
2008). Additionally, the form of peanut consumed may determine if an allergic response 
is formed. The stability and allergenicity of allergenic proteins may be altered through 
food processing. For example, the roasting of peanuts modifies the stability of peanut 
allergens through the Maillard reaction and the modified peanut allergens have increased 
IgE binding capacity (Maleki et al., 2000). However, convincing evidence does not exist 
to link changes in dietary habits or food processing and a rise in the prevalence of food 
allergy (Lack, 2008). 
In the U.S., milk, eggs, and peanuts are the most frequent allergenic foods in 
children, while adults are more likely to have allergies to crustacean shellfish, peanuts, 
and tree nuts (Sicherer and Sampson, 2010). Many children will outgrow their food 
allergies and become tolerant to milk, eggs, soy, and wheat. Allergies to peanut, tree nuts, 
and crustacean shellfish are rarely outgrown (Sicherer and Sampson, 2010; Skolnick et 
al., 2001; Wood, 2003). Milk and egg allergies are common across the globe but other 
major food allergens will vary by region based on cultural and dietary habits (Lack, 
2008). Food allergies are potentially life-threatening. In the past 25 years, three studies 
found an average of 6 identified fatal anaphylactic reactions per year to foods in the U.S. 
(Bock et al., 2001; Sampson et al., 1992; Yunginger et al., 1988); additional fatalities 
may occur as the system for recording such events is faulty. Restaurants and educational 
settings were, and still are, the most common locations of fatal allergic reactions, and 
peanut is responsible for over 50% of food allergy related fatalities in the U.S. (Keet and 
Wood, 2007). Food companies are required to declare when an ingredient is derived from 
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the major allergenic foods of milk, eggs, fish, crustacean shellfish, peanuts, soybeans, 
tree nuts, and wheat, plus or minus a few others depending on the country (Gendel, 
2012). However, these labeling laws apply only to packaged foods and ingredients and do 
not require allergen labeling within a restaurant or cafeteria setting. 
Diagnosis of Food Allergy 
The diagnosis of food allergy is a challenging task, but the effects of a correct 
medical diagnosis of food allergy, positive or negative, have been shown to positively 
impact an individual’s quality of life (Hourihane et al., 2011). Diagnosing a food allergy 
begins with a detailed review of the patient’s medical history and a physical examination 
to determine causal foods and distinguish allergy from other diseases and conditions. In 
vitro and in vivo laboratory tests are used to confirm the diagnosis of a specific causal 
food. However, in vitro and in vivo tests only detect a patient’s sensitization (presence of 
specific IgE antibodies to a food) and absolute clinical reactivity cannot be predicted 
(Sicherer and Sampson, 2010). A physician-supervised food challenge provides the 
strongest evidence of a clinical food allergy.  
For IgE-mediated disorders, skin prick tests (SPTs) provide a rapid in vivo 
method to detect sensitization. Negative SPT responses accurately predicted the absence 
of IgE-mediated allergic reactivity (>90%), but a positive test response does not prove 
food allergy (specificity and positive predictive accuracy, <100%) (Pucar et al., 2001; 
Sicherer and Sampson, 2010). A negative SPT or a negative physician-supervised food 
challenge (or both) confirm the absence of clinical allergy (Sicherer and Sampson, 2010). 
In vitro diagnostic tests for allergen-specific IgE are potentially more expensive and less 
sensitive than SPT methods but may be preferred for safety reasons in patients with 
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extreme sensitivity (Sicherer and Sampson, 2010; Taylor and Hefle, 2006b). In vitro 
methods include the radioallergosorbent test (RAST), the ImmunoCAP® test (Thermo 
Fisher Scientific), and the enzyme-linked immunosorbent assay (ELISA). The most 
common test used is the ImmunoCAP®, in which the patient’s blood serum reacts with 
the allergen of interest, covalently coupled to the solid phase matrix. Fluorescent enzyme-
labeled anti-IgE is used to detect the degree of binding by allergen-specific IgE (Thermo-
Fisher-Scientific, 2011). 
Oral food challenges are the best method to establish or rule out an adverse 
reaction to foods (Bindslev-Jensen et al., 2004). Challenges can be conducted in an open, 
single-blind, or double-blind procedures. Double-blind, placebo-controlled food 
challenges (DBPCFCs) are considered the gold standard for diagnosing IgE mediated 
food allergy. A DBPCFC is reliable, consistent, and indisputably associates the ingestion 
of a specific food to a set of food allergic symptoms (Taylor and Hefle, 2006b). In case of 
a severe reaction, DBPCFCs should be performed in a clinical setting that has access to 
emergency care. However, severe reactions are rare in low-dose protocols (<1 mg 
protein) that have been found to provoke only mild objective symptoms in sensitive 
subjects, regardless of prior reaction history. Objective symptoms are discernible to 
clinical observers e.g. vomiting, urticaria, rash, angioedema, etc. Dosing protocols should 
stop at the observation of objective symptoms during challenge and follow a doubling or 
semi-logarithmic scheme to mitigate the chance of a severe reaction. In addition to 
allergy diagnosis, oral food challenges with objective endpoints can provide risk 
assessors and regulators with valuable data regarding the thresholds and minimal eliciting 
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doses of food allergic individuals and populations (Bindslev-Jensen et al., 2004; Taylor et 
al., 2004; Taylor et al., 2010).  
Treatment of Food Allergy 
The most basic and successful treatment of a food allergy is avoiding the 
offending food(s) (Taylor et al., 1986a). Avoidance diets are be successful but significant 
responsibility is placed on the patient and complete avoidance is not always possible due 
to cross-contamination of allergens in cafeterias, restaurants, packaged foods, and other 
settings (Sicherer and Sampson, 2010; Taylor et al., 1986a; Taylor and Hefle, 2006b). 
The onus for the implementation of a safe and effective avoidance diet falls upon the 
consumer causing stress and a diminution of their quality of life (Dunn-Galvin et al., 
2008). The patient should consult with an expert allergist and dietician when developing 
a proper avoidance diet as proper diagnosis and a limited the number of avoided foods 
helps ensure compliance and a nutritionally complete diet (Taylor et al., 1986a). 
Education of others is key to a successful avoidance diet. An estimated 50% of reactions 
in infants followed through preschool were to foods provided by individuals other than 
the parent, including relatives and teachers (Fleischer et al., 2012). In addition to the 
avoidance diet, pharmacologic treatments exist to help manage food allergies in case of 
accidental exposures. Pharmacologic methods such as antihistamines can block the 
histamine receptors in tissues and relieve symptoms of itching and inflammation from 
oral allergy syndrome and IgE-mediated skin reactions (Sicherer and Sampson, 2010; 
Taylor and Hefle, 2006b). Antihistamines only block one inflammatory mediator 
associated with allergic reactions and are not fully effective in treating more severe 
allergic reactions. Epinephrine (adrenaline) is a powerful drug that can resolve many 
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severe anaphylactic reactions to foods. Individuals with a food allergy are advised to 
carry an EpiPen® (epinephrine auto-injector) with them at all times as past reaction 
symptoms are not an indicator for the severity of future reactions (Taylor and Hefle, 
2006b).  
Hypoallergenic foods are available for use by food allergic infants (Kleinman et 
al., 1991). But, a few other categories of food including highly refined peanut oil and fish 
gelatin also are known to contain insufficient amounts of allergenic protein to provoke 
reactions (Hansen et al., 2004; Hourihane et al., 1997). This is especially important for 
infant formulas as milk-allergic infants cannot substitute a wide variety of foods in their 
diet and maintain adequate nutrition. To be labeled hypoallergenic, these formulas must 
not provoke reactions in 90% of infants or children with confirmed cow’s milk allergy 
with 95% confidence (American Academy of Pediatrics et al., 2000; Kleinman et al., 
1991). Milk-allergic infants have multiple hypoallergenic formulas available, including 
soybean, rice, and protein hydrolysate-based products. Elemental amino acid-based 
formulas are an option if all other hypoallergenic formulas are rejected. Practical 
experience has shown that a small number of milk-allergic infants do react to ingestion of 
hypoallergenic formula based on extensively hydrolyzed casein (Ellis et al., 1991; Saylor 
and Bahna, 1991). This observation is not surprising since testing assures only that more 
than 90% of infants will tolerate the formula.  
At present, a clinically proven treatment or cure of food allergies does not exist. 
However, multiple approaches are being studied as a means to treat food allergy 
including anti-IgE injections, Chinese herbal remedies, probiotics, modified protein 
vaccines, and immunotherapy via the oral, sublingual, and epicutaneous routes. Oral 
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immunotherapy has undergone the most clinical research and involves the daily feeding 
and gradual increase of doses of specific allergenic foods to an allergic-individual over 
the period of months to years. Once a maintenance dose is reached, the individual is 
protected from accidental consumptions of the offending food (Sicherer and Sampson, 
2010). One key question that remains about oral immunotherapy is the development of 
true long-term oral tolerance versus short-term desensitization (Jones et al., 2010; 
Sicherer and Sampson, 2010; Varshney et al., 2009). If tolerance is not achieved, it is 
unclear how long desensitization will continue if the maintenance dose is discontinued. 
Desensitization is temporary and would require a constant, possibly daily, maintenance 
dose. Tolerance is a complete lack of reactivity and could take years to achieve. 
However, desensitized individuals are provided with an increased level of safety that 
allows them to remove a large stress from their daily life. Preliminary studies in the U.S. 
with peanut, milk, or egg and a multitude of studies in Europe indicate that oral 
immunotherapy could be beneficial for the majority of food allergic individuals 
(Blumchen et al., 2010; Caminiti et al., 2009; Clark et al., 2009; Hofmann et al., 2009; 
Jones et al., 2010; Morisset et al., 2007; Skripak et al., 2008; Varshney et al., 2009). 
Legume Allergy 
The term legume refers to a leguminous plant, with seeds in pods, or directly to 
the seed, pod, or other edible part a leguminous plant. Common legumes include peanuts, 
soybeans, peas, lentils, lupin, chickpeas, and dry edible beans. Legumes are a staple food 
category in the human diet and have been cultivated for over 10,000 years (Graham and 
Vance, 2003). They are grown on 15% of the Earth’s arable surface, account for 27% of 
the world’s primary crop production, and contribute 33% or more of the dietary protein 
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nitrogen (N) needed by humans. Soybean and peanut account for more than 33% of the 
world’s processed vegetable oil (Graham and Vance, 2003). Legumes are extremely 
versatile and can be popped like popcorn, candied, or utilized in a number of products as 
a flour (bread, tortillas, chips, spreads, and extruded snacks), in liquid form (milks, 
yogurt, and infant formula), and as a modified protein concentrate or isolate to add 
protein and functional properties to a product (Egbert, 2004; Genta et al., 2002; Graham 
and Vance, 2003; Keshun, 1997; Popenoe et al., 1989). Industrial uses are just as diverse 
with legumes in biodegradable plastics, gums, dyes, pharmaceuticals, pesticides, 
phytochemicals, and inks (Morris, 1997). Soybean oil, and products from other legumes, 
are utilized as biodiesels and alternative fuels, but more research is needed in this area to 
commercially produce a fuel with an overall positive energy output compared to required 
inputs (Graham and Vance, 2003; Pimentel and Patzek, 2005; Scott et al., 2008). 
Legumes are also a primary source of cheap dietary protein and nutrients for industrial 
farm animal production (Barać et al., 2004; Graham and Vance, 2003). 
Nitrogen is required to biosynthesize basic building blocks of life and is the 
primary nutrient limiting plant production in most natural ecosystems (Emsley, 2011; 
Lawlor et al., 2001). Nitrogen fixation, or the conversion of nitrogen from its stable gas 
form (N2) to a usable form such as ammonia (NH3), is essential for agriculture (Lawlor et 
al., 2001). Legumes achieve nitrogen fixation through a symbiotic relationship with 
rhizobia, and other diazotrophs, and play an important role in colonizing disturbed 
ecosystems (Graham and Vance, 2003). The use of legumes in pastures and for soil 
improvement dates back to the Romans, who noted their benefit to future crops (Graham 
and Vance, 2003). Proper crop rotation and till conditions can increase the levels of 
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nitrogen in the soil, increase crop yields, and/or reduce the amount of fertilizer required 
to optimize crop yields (Havlin et al., 1990; López-Bellido et al., 1996; Smil, 1999). 
Annually, up to 60 million metric tons N2 are fixed by legumes and modest crop rotation 
could save U.S. farmers at least $300 million in fertilizer costs (Peterson and Russelle, 
1991; Smil, 1999).  
For centuries, legumes have been used in folk medicine (Kindscher, 1992). 
Recently, legumes have been shown to impart a number of health benefits on consumers. 
Elevated intake levels of soy protein have been shown to lower total cholesterol levels 
and low-density lipoprotein (LDL) cholesterol levels in serum (Weggemans and 
Trautwein, 2003). In 1999, the FDA concluded that soy protein included in a diet low in 
saturated fat and cholesterol may reduce the risk of coronary heart disease (CHD) by 
lowering blood cholesterol levels (FDA, 1999). Legumes, in part with a low-Glycemic 
Index diet, improved glycemic control and reduced the risk of CHD in individuals with 
type 2 diabetes (Jenkins Da and et al., 2012). Legume consumption, including lentils, 
peas, chickpeas, and beans, is inversely associated with serum concentrations of adhesion 
molecules and biomarkers of systemic inflammation (Esmaillzadeh and Azadbakht, 
2012). Consumption of dry beans, peas, and peanuts significantly reduced the risk of 
CHD and cardiovascular disease (CVD) (Bazzano et al., 2001). Increased consumption of 
peanut butter is correlated with a reduction in risk of death from CVD and CHD 
(Blomhoff et al., 2006). Soy isoflavones, genistein in particular, have been reported to 
prevent the growth of prostate cancer cells in vitro and in rodents (Prezioso et al., 2007). 
Japanese men (high consumers of soy foods) rarely die from prostate cancer while 
frequently being diagnosed with small tumors in the prostate (Pisani et al., 1999). Due to 
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the early results in human studies, the American Cancer Society includes eating soybeans 
as one of the seven steps to reduce the risk of developing prostate cancer (Liu, 2004a). 
Soy saponins are important regulators of the promotional stages of cancer formation (Liu, 
2004a). Lunasin, a 43-amino acid peptide found in soy, barley, wheat, and other plants, 
has been shown to prevent skin cancer in a mouse model and shown to be a strong tumor 
suppressor in vitro (Galvez et al., 2001). While legumes have a high nutritional value, 
they contain relatively low quantities of the essential amino acid methionine, and 
supplements or protein sources other than legumes must be consumed to obtain adequate 
methionine intake (Hove et al., 1978).  
Legumes, especially peanut, are some of the most prevalent and potent allergenic 
foods. Allergenic responses to legume proteins can provoke a spectrum of symptoms, 
from mild to life-threatening (Sicherer and Sampson, 2010). Proteins associated with 
plant food allergens, including legumes, can be mostly classified into four protein 
families and superfamilies: prolamins, cupins, profilins, and the Bet v 1 superfamily. The 
majority of allergenic proteins come from the seed storage proteins, albumins and 
globulins, within the prolamin and cupin superfamilies (Breiteneder and Radauer, 2004; 
Radauer and Breiteneder, 2007). Legume seed storage proteins are often found in high 
abundance and are resistant to thermal and proteolytic denaturation (Burks et al., 1992; 
Lehmann et al., 2006; Sen et al., 2002). Additionally, the four superfamilies include 
allergens that are defense proteins such as pathogenesis-related proteins, proteases, and 
protease inhibitors (Breiteneder and Radauer, 2004; Radauer and Breiteneder, 2007). 
Cross-reactive allergenic proteins, between legumes as well as other food groups, are 
found in all four superfamilies.  
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IgE from legume-allergic individuals have shown high cross-reactivity between 
the proteins of peanut, soybean, lima bean, pea, garbanzo bean, and green beans, but only 
5% of the study population was clinically reactive to more than one legume (Bernhisel-
Broadbent et al., 1989). Individuals with persistent peanut allergy have higher risk of 
cross-reactivity to other legumes than most legume-allergic subjects. In the U.S., the 
prevalence of peanut allergy is estimated at 0.6 – 1.0%, with up to 6.4% of peanut-
allergic individuals having clinical reactivity to soy, 2.4% to pea, and less than 1% to 
lentil, chickpea, and green bean. Of peanut-allergic individuals with clinical cross-
reactivity, 8% were cross-reactive to multiple legumes (Neuman-Sunshine et al., 2012; 
Sicherer and Sampson, 2010). European peanut-allergic individuals are more inclined to 
have cross-reactivity to lupin (up to 44%) (Fiocchi et al., 2009; Moneret-Vautrin et al., 
1999; Shaw et al., 2008). Lupin proteins, β-conglutin and the pathogenesis-related protein 
PR-10, have homologs in peanut, Ara h 1 and Ara h 8, respectively. Soybean β-
conglycinin is also homologous with lupin β-conglutin, but less clinical cross-reactivity 
between soy and lupin has been reported (Goggin et al., 2008; Guarneri et al., 2005). 
Legume cross-allergic symptoms in mice were milder than the primary allergic 
responses, but human fatalities have been reported in severe peanut-allergic individuals 
when exposed to soy (Sicherer et al., 2001; Vinje et al., 2012). Spanish populations 
demonstrate a significantly higher prevalence of clinical reactivity to multiple legumes 
(82%) including lentil, chickpea, pea and peanut with, with 69% allergic to lentil and 
chickpea (Ibáñez et al., 2003; Martinez San Ireneo et al., 2008). The prevalence of 
reactivity to multiple legumes is estimated to be higher than the reported 12% cross-
reactivity in tree nuts (Fleischer et al., 2005). 
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Soy proteins and allergens 
Soybeans are a staple food in many cultures and play a large role in the diet of 
food-producing animals (Barać et al., 2004; Friedman and Brandon, 2001). In 2009, 
farmers planted a record breaking 77.5 million acres of soybean varieties and the U.S. led 
the world in soybean exports (USDA, 2010). Soybean meal is added to animal feeds and 
processed foods as a cheap source of protein (Barać et al., 2004). Soy has high nutritional 
value, but is deficient in the essential amino acid, methionine (Friedman and Brandon, 
2001). A typical dry soybean is composed of 40% protein, 20% oil, 35% carbohydrates, 
and 5% ash (Liu, 2004b). Different varieties of soy can be grown to contain up to 48% 
protein, but the easiest way to obtain higher protein levels is to process the bean into 
defatted soy flour, soy protein concentrate (SPC), or soy protein isolate (SPI). Most soy 
flours are made by grinding dehulled and defatted soy flakes, containing at least 50% 
protein (dry basis), and are traditionally used as an ingredient in the baking industry. Soy 
protein concentrates are made by removing the soluble sugars from the defatted flake 
with an aqueous alcohol extraction. They contain at least 65% protein, and are used to 
bind water while adding protein, texture, and body to many different products. Soy 
protein isolates have the soluble and insoluble carbohydrates removed from the defatted 
flake, contain at least 90% protein, and are used for gelation, emulsification, water 
binding, viscosity, foaming, and whipping (Egbert, 2004).  
Soy flours, SPC, and SPI are used in everything from protein shakes to soups, 
baked products, meats, and cheeses. Soy products can be used for protein fortification, 
but other applications include improving texture, gelation, emulsification, water binding, 
viscosity, foaming, and whipping. Soy sauce and hydrolyzed vegetable protein are used 
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for flavor enhancement. The traditional methods to modify the functional properties of 
soy products include adjusting the protein content, heat denaturation, full or partial 
protein hydrolysis, and pH adjustment. Newer methods include jet-cooking/flash cooling, 
high pressure treatment, and different solvent extractions (Egbert, 2004). Due to the 
widespread use of soy, it is necessary to understand the effects that these treatments have 
on the different proteins found in soybeans, including the allergens.  
Mature soybeans contain a mixture of seed storage and bioactive proteins. Storage 
proteins include α-,β-, and γ-conglycinins, glycinin, and other globular proteins that range 
in molecular weight from 140 to 300 kDa. Bioactive proteins include β-amylase, 
cytochrome c, lectin, lipoxygenase, lunasin, urease, Kunitz trypsin inhibitor (SKTI), and 
Bowman-Birk chymotrypsin/trypsin inhibitor (BBI). The major seed storage proteins of 
glycinin and β-conglycinin affect the properties of any soy flour, SPC, or SPI. The food 
industry is able to achieve a wide range of desired functional properties for soy products 
by varying the composition, structure, and modification of major seed storage proteins 
such as glycinin and β-conglycinin. Health promoting, bioactive compounds found in soy 
include, but are not limited to lecithin, isoflavones, saponins, phytosterols, phytate, and 
lunasin. Antinutritional factors of SKTI, BBI, and lectins are detrimental at high levels 
but have been shown to provide anti-cancer benefits at low levels (Barać et al., 2004; 
Friedman and Brandon, 2001; Liu, 2004b; Mikić et al., 2009). Due to the commercial 
nature of soybeans, many varieties of the plant have been developed that express custom 
protein profiles. Certain proteins can be expressed at high levels and others can be 
removed all together (Mikić et al., 2009). Soybean has become one of the most versatile 
foods in the industry and can be added to products for a number of different purposes. 
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Asthma and food allergy to soy have been reported since 1934 (Duke, 1934). Soy 
is listed among the most common allergenic foods on a worldwide basis and is on the 
priority allergenic foods list in the USA, the EU, and Australia among others (Gendel, 
2012). However, soy is not listed as a priority allergen in Japan where soy is commonly 
consumed and the 7
th
 most common cause of food allergen anaphylaxis (Gendel, 2012; 
Imamura et al., 2008). While considered a major allergenic food, the data for soy used by 
the Codex Alimentarius Commission in 1999 were fragmentary and mostly focused on 
comparative prevalence in populations of food-allergic infants (Sampson and McCaskill, 
1985). Subsequently, the prevalence of soy allergy appears to be lower than that of most 
other commonly allergenic foods. In unpublished data from the large EuroPrevall study 
just completed in the EU, the prevalence of soy allergy was very low and below that of 
several foods not currently on allergen priority lists. However, an emergence of soy 
allergies to certain brands of soy milks and soy nutritional drinks has occurred in several 
EU countries (Mittag et al., 2004). Recent unpublished clinical observations from a 
Dutch clinic indicate that many of these patients can tolerate soy flour and confirm the 
previous observations that reactivity is associated with certain specific types of soy 
products. Clearly, this aspect deserves further evaluation. 
The clinical manifestations of soy allergy are broad, and include atopic dermatitis 
and eczema, asthma, severe enterocolitis of infancy, and immediate IgE-mediated 
reactions. Unlike peanut, soy is not a believed to be common cause of severe or fatal 
allergic reactions (Sicherer et al., 2001). However, anaphylaxis and exercise-induced 
anaphylaxis to soy have been reported (Adachi et al., 2009; Pumphrey and Stanworth, 
1996; Sicherer et al., 2001). Additionally, fatalities to soy have been reported in 
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individuals with asthma and severe peanut allergy (Foucard and Yman, 1999; Yunginger 
et al., 1991). Serum IgE binding to at least 16 soy proteins has been shown in soy-
sensitive individuals with atopic dermatitis (Ogawa et al., 1991). There are six proteins in 
soy recognized as allergens by the International Union of Immunological Societies (IUIS) 
including two soy hull proteins (Gly m 1 and Gly m 2), profilin (Gly m 3), a stress 
induced, pathogenesis-related starvation associated message protein (Gly m 4), β-
conglycinin (Gly m 5), and glycinin (Gly m 6). In addition to the official IUIS allergens, 
there are multiple other proteins not recognized by the IUIS that have been shown to 
cause reactions or bind IgE from soy allergic individuals. These proteins include the 
vacuolar protein P34 (Gly m Bd 30 K), Gly m Bd 28 K, the Kunitz trypsin inhibitor, and 
lectin. 
 The soy hull proteins, Gly m 1 and Gly m 2, are inhalation allergens associated 
with environmental or occupational exposure to dust from soy hulls. Gly m 1 has 2 
isoforms, both hydrophobic proteins from soybean hulls (Accession No. AAB34755 and 
AAB34756) (Gonzalez et al., 1995). Gly m 1A is 42 amino acids (AA) long and 7.5 kDa 
while Gly m 1B is missing the amino-terminal ALI tripeptide sequence, leaving it 39 AA 
in length and 7.0 kDa (Gonzalez et al., 1995). Gly m 2, or soybean defensin, is an 8 kDa 
hull protein (Accession No. A57106) (Codina et al., 1997). Collectively these 3 proteins 
were responsible for several asthma outbreaks during the 1980s in the Spanish cities of 
Barcelona and Cartagena after soy dust spread through the cities during unloading and 
transport of soybeans from the seaports (Codina et al., 1997; Gonzalez et al., 1995). 
Additionally, bakers working with soy flour have had occupational asthma to Gly m 1 
and 2, but the bakers with asthma and IgE mediated food allergy to soy were also 
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sensitized to higher molecular weight proteins in soybean (Quirce et al., 2000). Thus, Gly 
m 1 and 2 are determined to be respiratory allergens and not significant food allergens in 
IgE mediated soy allergy. 
Gly m 3, or soybean profilin, is a 14 kDa hydrophilic, heat-labile protein. Gly m 3 
is present in the seed at levels of 0.6 – 0.8% of total soluble protein (Accession No. 
CAA11755) (Amnuaycheewa and Gonzalez de Mejia, 2010). A recombinant form of this 
protein (rGly m 3) was shown to bind IgE from sera of 9 of 13 (69%) food-allergic 
subjects who had positive IgE binding to soy proteins by ImmunoCAP® tests (Rihs et al., 
1999). IgE binding to rGly m 3 depends on the availability of the full length protein in its 
original conformational structure as no IgE binding was observed to profilin fragments 
(Rihs et al., 1999). The rGly m 3 was cross-reactive with Bet v 2, birch pollen profilin, 
and Bet v 2 binding was inhibited by rGly m 3 (Mittag et al., 2004; Rihs et al., 1999). 
Multiple soy milk reactive individuals display sensitization to rGly m 3 but not rGly m 4, 
the major birch pollen cross-reactive protein in soy, suggesting Gly m 3 is also involved 
in cross-reactions between birch pollen and soy (Mittag et al., 2004). Soy milk is a 
potentially dangerous product to Gly m 3 sensitive individuals as the food matrix of soy 
milk affects profilin’s thermal stability. Pasteurization does not alter the conformational 
structure of Gly m 3 and boiling is necessary to reduce conformational epitopes 
(Amnuaycheewa and Gonzalez de Mejia, 2010). While a concern in less processed foods, 
Gly m 3 is not considered a major allergen in boiled or highly processed soy products.  
Gly m 4 is a 17 kDa stress induced, pathogenesis-related starvation associated 
message protein (SAM22) (Accession No. P26987). Gly m 4 is found in the roots and 
leaves of maturing plants and can be induced by wounding or stressing young leaves 
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(Crowell et al., 1992). Published and unpublished data estimate Gly m 4 at 0.01 – 0.1% 
of total soy protein (Mittag et al., 2004). While most soy allergic individuals must avoid 
all forms of soy, Kleine-Tebbe et al. (2002) reported certain consumers characterized by 
an existing allergy to birch pollen who experienced severe reactions to a specific SPI in a 
specific brand of soy-based nutritional drink. These reactions occurred on the first time 
that these consumers ingested this particular SPI. The soy allergen Gly m 4 was identified 
as a cross-reactive protein with Bet v 1, a major birch pollen allergen (Kleine-Tebbe et 
al., 2002). After the initial study, soy allergy to Gly m 4 and this particular SPI was 
confirmed in 16 adults with birch pollen allergy by DBPCFC (Mittag et al., 2004). 
Allergic reactions in children to soy milk made from filtered whole soybeans have been 
attributed to Gly m 4 sensitization (Kosma et al., 2011). In this case, the reactions 
occurred to the ingestion of soy during pollen season. More recent, unpublished evidence 
suggests that the number of consumers with allergic reactions to certain types of soy milk 
is increasing in some European countries and is possibly surpassing the prevalence of 
more typical soy allergy. 
The prevalence of birch pollen allergy can be estimated at 2 – 20% in North, 
Central, and Eastern Europe (D’Amato et al., 2007). It is reported that 10% of highly 
sensitized birch pollen patients have soy allergy and cross-reactivity correlated with IgE 
reactivity to one of the major birch pollen allergens (Geroldinger-Simic et al., 2011; 
Mittag et al., 2004). It is believed that individuals are first sensitized to Bet v 1 in its 
native form through inhalation of birch pollen and then experience reactions on repeated 
exposure to birch pollen and Bet v 1 homologs in food (Jenkins et al., 2005). Allergic 
reactions against pollen lead to clinical syndromes like hay fever, asthma, and dermatitis 
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while cross-reactive foods can produce symptoms including oral allergy syndrome, 
itching and swelling of the lips, tongue, and throat, hives, and anaphylaxis (Kleine-Tebbe 
et al., 2002; Neudecker et al., 2003).  
Gly m 4 and Bet v 1 share 47% sequence homology and demonstrate a conserved 
conformational structure including multiple IgE binding epitopes (Jenkins et al., 2005). 
Gly m 4 content is increased during the ripening and storage of soybeans, but its levels 
can be reduced by cooking or other processing methods. Highly fermented foods or 
roasted soybeans had no detectable Gly m 4, tofu and soy flakes had levels near 10 ppm, 
and the SPI implicated by Kleine-Tebbe et al. (2002) had 140 ppm Gly m 4 (Mittag et al., 
2004). Strong heating reduced antibody binding to Gly m 4, as detection was reduced 
after 30 minutes of cooking and eliminated after 4 hours of cooking (Mittag et al., 2004). 
The level of Gly m 4 in the soy milk made from filtered whole soybeans was not 
determined (Kosma et al., 2011). Due to the versatility of soy protein, a wide variety of 
production processes are used to obtain soy protein concentrates and isolates with 
different functional properties. The SPI product involved in these cases of European soy 
nutritional drink allergy is minimally processed compared to traditional SPIs (Egbert, 
2004; Kleine-Tebbe et al., 2002). Additionally, these soy allergic patients have reported 
reactions to raw soybean sprouts, tofu, soy milk, and a soy pudding but many could 
tolerate cooked or highly processed soy products (Mittag et al., 2004). Additionally, 
recent data from Japan identifies birch pollen sensitivity and Gly m 4 sensitivity in an 
area lacking atmospheric birch pollen (Fukutomi et al., 2012; Yamagiwa et al., 2002). 
Alder pollen (Aln g 1) was been identified as the sensitizing agent and as another Gly m 
4 cross-reactive protein (Fukutomi et al., 2012). Twenty-one Japanese soy-allergic adults, 
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some with anaphylactic reactions, were more likely to be sensitized to Gly m 4, alder, and 
birch pollen (100%) than to Gly m 5 or 6 (5%), providing more evidence that Gly m 4 is 
of clinical significance (Fukutomi et al., 2012). 
Gly m 5, or β-conglycinin, makes up 30% of the total seed proteins and is densely 
packed into trimers composed of three glycosylated subunits, α (67 kDa), α’ (71 kDa), 
and β (50 kDa) (Accession No. CAA35691, AAB01374, and AAB23463) (Holzhauser et 
al., 2009; Maruyama et al., 1998). European and Japanese IgE binding studies 
respectively found 43% and 100% recognition of Gly m 5 by soy allergic sera 
(Holzhauser et al., 2009; Ito et al., 2011). Early studies found IgE reactivity to the α but 
not the α’ or β subunits of Gly m 5 (Ogawa et al., 1995). Recent studies have shown 
sensitivity and IgE reactivity to all 3 subunits of Gly m 5 through immunoblotting 
(Holzhauser et al., 2009; Krishnan et al., 2009; Zheng et al., 2012), ImmunoCAP® (Ito et 
al., 2011), and basophil histamine release (Zheng et al., 2012). All purified subunits 
induced dose-dependent histamine release in basophils from soy-allergic patients (Zheng 
et al., 2012). Purified or recombinant α, α′, and β subunits of β-conglycinin retained 
allergenic activity and could be used for in vitro and in vivo component resolved 
diagnosis of soy allergy (Holzhauser et al., 2009; Krishnan et al., 2009; Zheng et al., 
2012). Deglycosylation of the β-subunit, by glycosidases or recombinant protein 
expression in E. coli, did not abolish IgE reactivity to the β-subunit (Krishnan et al., 
2009). Gly m 5 has been implicated in a case of exercise-induced anaphylaxis after 
consumption of tofu. Alterations in the resistance of Gly m 5 to pepsin occurred after tofu 
processing. Gly m 5 in soy milk was digested and IgE reactivity abolished after 20 
minutes of exposure to pepsin. Gly m 5 from tofu was intact after 120 minutes or more of 
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pepsin digestion and IgE reactivity remained up to 240 minutes into digestion (Adachi et 
al., 2009). 
Gly m 6, or glycinin, makes up 40% of the total seed protein, is a hexameric 
protein, and each subunit (G1, G2, G3, G4, and G5) has at least one basic and acidic 
subunit linked by a disulfide bond (Holzhauser et al., 2009; Prak et al., 2005). In a recent 
study, Gly m 6 was recognized by 36% of soy-allergic individuals subjects (Holzhauser 
et al., 2009). Five major subunits have been identified from soybean: G1 (A1aB1b, 53.6 
kDa), G2 (A2B1a, 52.4 kDa), G3 (A1bB2, 52.2 kDa), G4 (A3B4, 61.2 kDa), and G5 
(A5A4B3, 55.4 kDa) (Accession No. CAA26723, CAA26575, CAA33217, CAA37044, 
and AAA33964) (Adachi et al., 2003). Glycinin is not glycosylated and each subunit is 
composed of acidic (A1a, A1b, A2, A3, A4, A5) and basic (B1a, B1b, B2, B3, B4) chains 
linked by a disulfide bond (Maruyama et al., 2003). IgE binding studies respectively 
found 36% and 100% recognition of Gly m 6 by soy allergic sera (Holzhauser et al., 
2009; Ito et al., 2011). All five subunits are known to react with IgE (Holzhauser et al., 
2009). One study found IgE reactivity in all acidic subunits, but not in the basic subunits 
(Pedersen and Djurtoft, 1989). Conversely, another study found IgE reactivity in all five 
basic chains, but none of the acidic chains (Helm et al., 2000a). The acidic chain of G1 
(A1a) was found to have a single IgE-binding fragment of approximately 15 kDa 
corresponding to AA residues 192 to 306. Binding to A1a was stronger than to A2, the 
acidic chain of G2 (Zeece et al., 1999). Eleven linear IgE binding epitopes (4 immuno-
dominant), were found distributed asymmetrically on the surface of G2 trimers (Helm et 
al., 2000b). These epitopes were predicted to be distributed asymmetrically on the surface 
of G2 trimers. Subunits of Gly m 6 have high sequence similarity with peanut Ara h 3. 
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The Gly m 6 acidic chains of A1a and A2 shares IgE binding epitope regions with Ara h 
3 (Beardslee et al., 2000; Rabjohn et al., 1999; Xiang et al., 2002). These shared epitopes 
could in part explain the cross-reactivity found between peanut and soy in some allergic 
individuals.  
Both Gly m 5 and 6 can bind IgE through linear and conformational epitopes 
(Helm et al., 2000b; Ogawa et al., 1995; Zeece et al., 1999). Gly m 5 and 6 are stable 
proteins and potent allergens due to the combination of linear and conformational 
epitopes and their structural resistance to denaturation from tight packing and disulfide 
bonds. Significantly higher levels of soybean specific IgE was found in individuals with 
severe reactions when compared to mild reactors. Severe reactors had higher levels of 
IgE binding to Gly m 5 and Gly m 6 when compared to individuals sensitized to soybean 
without clinical allergy symptoms (Ito et al., 2011). Similarly, Holzhauser et al. (2009) 
found that 86% of subjects with anaphylaxis to soy and 55% with moderate reactions had 
IgE to Gly m 5 or 6. However, only 33% of mild reactors had IgE to Gly m 5 or 6 and 
92% of mild reactors had IgE specific to Gly m 4. Their sample size was extremely small 
so drawing any concrete conclusions is impossible, but allergy to Gly m 5 and 6 should 
translate worldwide and not be heavily influenced by regional differences of birch or 
alder pollen levels.  
Soy Kunitz trypsin inhibitor (SKTI), consists of 181 amino acids (AA), has a 
molecular weight of 20 kDa, an isoelectric point of 4.5, and represents 4-7% of the total 
extractable protein in soy. The protein is tightly packed, not glycosylated, and trypsin 
inhibition is achieved through reversible binding of SKTI to the trypsin enzyme (Barać et 
al., 2004; Friedman and Brandon, 2001; Kunitz, 1947; Mikić et al., 2009). SKTI is an 
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inhalation allergen associated with occupational exposure to flour dust in bakers (Baur et 
al., 1996; Quirce et al., 2006). There are three major isoforms of SKTI, A,B, and C, with 
only one AA difference between A and C and eight AA differences between A and B 
(Accession No. P01070, P01071, TISYC) (Kim et al., 1985). There are two disulfide 
bonds in SKTI between Cys39-Cys86 and Cys138-Cys145, both of which are critical for 
trypsin inhibition and resistance to denaturation (Sessa and Ghantous, 1987). While dry 
heat does not have an effect on trypsin inhibition, wet heat has been shown to reduce 
trypsin inhibition. Cooking parameters of 30 minutes at 100°C or 143°C for 62 seconds 
have been shown to achieve a 90% reduction in inhibitor activity (Keshun, 1997; Kwok 
et al., 2002). Proper rapid cooling methods must be followed to insure deactivation as 
slow cooling rates after heating allow nearly all of the SKTI to refold and remain intact 
(Roychaudhuri et al., 2004). High pressure processing has been tested for use in a soy 
milk system where extensive heating would ruin the sensory qualities of the milk. van der 
Ven et al. (2005) found 600 MPa at 60°C for one minute reduced inhibitor activity 40%. 
Although higher temperature, pressure, and slightly longer times would be required to 
reach 90% inactivation, it is predicted there would not be an effect on sensory qualities. 
As an allergen, SKTI primarily affects bakers exposed to large amounts of inhaled soy 
flour. The manifestation of baker’s asthma has led to individuals with IgE binding 
patterns specific for SKTI, positive SPT for SKTI, and reactions during a specific 
inhalation challenge with purified SKTI (Baur et al., 1996; Quirce et al., 2006). The 
incidence of inhaled SKTI related allergic reactions is very low. Ingestion of SKTI has 
only been confirmed to cause an allergic reaction in one individual, although symptoms 
were severe in their case (Moroz and Yang, 1980).  
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Gly m Bd 30K, also known as soybean vacuolar protein P34, is an oil body 
protein with IgE binding characteristics (Accession No. ABC56139) (Helm et al., 1998a; 
Ogawa et al., 1993). Gly m Bd 30K is a monomeric glycoprotein with thiol protease 
activity in the papain family. It has been shown to react with 65% of soy-sensitive 
patients with atopic dermitits (Helm et al., 1998a; Ogawa et al., 1993; Wilson et al., 
2005). Gly m Bd 30K is accumulated during seed maturation and is present at 5% of total 
protein levels in seed cotyledons, which become the leaves of the plant embryo. Initially 
the protein is present as a molecular mass 34 kDa polypeptide and is processed to a 
molecular mass of 32 kDa with the onset of oil mobilization, the fourth through sixth 
days of seedling growth (Herman et al., 1990; Ogawa et al., 1993). B cell epitope 
mapping with overlapping 15-mer peptides found 10 regions with IgE binding, 10–mer 
peptides revealed 16 distinct linear epitopes. Individual patient serum identified 5 
immunodominant epitopes (Helm et al., 1998b). Due to the complex structure and the 
number of epitopes in Gly m Bd 30K, heat does not significantly denature the protein or 
reduce IgE binding. Additionally, soybeans exposed to superheated steam during the 
autoclave process demonstrated increased binding to Gly m Bd 30K (Yamanishi et al., 
1995). While resistant to a number of denaturation treatments, Gly m Bd 30k may be 
coded by a single gene and represents 2% to 3% of the total protein content (Wilson et 
al., 2005). Transgene-induced gene silencing had been successfully used to prevent the 
accumulation of Gly m Bd 30 K protein in soybean seeds. The Gly m Bd 30 K-silenced 
plants were equivalent to control plants with no compositional, developmental, structural, 
or ultrastructural phenotypic differences during comparison (Herman et al., 2003). 
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Although other allergenic proteins would still be present, these results demonstrate an 
opportunity for cultivators to grow soybeans without one of the major allergens. 
Gly m Bd 28 K is a 26 kDa Asn-linked glycoprotein that has been shown to bind 
IgE from 25% of soy allergic subjects (Accession No. BAB21619) (Hiemori et al., 2000; 
Ogawa et al., 2000; Tsuji et al., 1997). Purification of Gly m Bd 28K led to a number of 
proteins with different isoelectric points but identical N-terminal AA sequences, 
suggesting that the protein is unstable (Tsuji et al., 1997). High levels of Gly m Bd 28K 
were detected in tofu, yuba (tofu skin), abura-age (fried tofu), SPI and soy milk. 
However, Gly m Bd 28K seems to be digested during fermentation as detection was not 
found in natto and soy sauce (Tsuji et al., 1997). Both Gly m Bd 30K and Gly m Bd 28K 
are N-linked glycoproteins with respective sugar chain binding to the Asn170 and Asn20 
residues (Bando et al., 1996; Hiemori et al., 2000). The sugar moiety of Gly m Bd 30K 
was shown to consist of mannose, N-acetylglucosamine, fucose, and xylose at a molar 
ratio of 3:2:1:1 (Bando et al., 1996). The glycan moiety on Gly m Bd 28K is composed of 
the same sugar ratios as the chain on Gly m Bd 30K (Ogawa et al., 2000; Tsuji et al., 
1997). The glycopeptide of Gly m Bd 28K reacted with the sera of soybean-sensitive 
patients, but did not show IgE reactivity in its deglycosylated form. Additionally, a 23 
kDa C terminal fragment of Gly m Bd 28K has been shown to have the same IgE 
reactivity as the 26 kDa form (Hiemori et al., 2000; Hiemori et al., 2004). IgE antibodies 
recognized epitopes on the protein peptide sequences of Gly m Bd 30K at a ratio of 1:4 to 
those recognizing the glycan moiety, meaning that 80% of Gly m Bd 30K IgE antibodies 
are carbohydrate-determinant specific. Similar glycan moieties could react with soy-
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sensitive IgE as a CCD but the clinical relevance of the CCD-directed IgE in soy-
sensitive individuals is not fully known (Ogawa, 2006). 
Food allergen labeling and thresholds 
Food allergen risk assessment and proper labeling is an important process for 
members of the food industry, regulatory agencies, and food allergic consumers. Allergic 
consumers have no choice but to adhere to a strict avoidance diet and carefully read the 
ingredient labels of the food they eat (Hefle et al., 2007; Pieretti et al., 2009; Taylor et al., 
1986a; Yu et al., 2006). The presence of allergens in mislabeled or unlabeled packaged 
products has led to allergic reactions in consumers relying on clear and accurate 
ingredient statements (Kemp and Lockey, 1996; Yu et al., 2006).  
The Food Allergen Labeling and Consumer Protection Act (FALCPA) was passed 
in 2004 by the U.S. Congress to protect allergic individuals from unclear or unlabeled 
products and became effective January 1, 2006 (FDA, 2006). For public health 
authorities, the primary strategies have been to develop lists of priority allergenic foods 
and enact regulations to assure that any ingredients derived from these foods are declared 
on the labels of packaged foods (Gendel, 2012). Allergen labeling laws (i.e. FALCPA in 
the U.S., EU directive 2003/89/EC, Australian Food Standards 1.2.3 and 1.2.4) were 
implemented to address the issue of hidden allergens in food (EU, 2003a; FDA, 2006; 
FSANZ, 2002). A company is required to declare when an ingredient is derived from the 
Big 8 food allergens plus a few others depending on the country (Gendel, 2012). Industry 
compliance helps consumers identify allergens hidden in hard to identify mixtures, such 
as spices and minor flavorings in processed food but these labeling laws essentially create 
a zero tolerance for unlabeled food allergens. With a de facto zero tolerance, the 
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legislation requires labeling of allergens even if present at levels that will likely not pose 
any allergic risk to the allergic consumer. Safe consumption of these foods declaring the 
presence of an allergen could mislead allergic consumers to believe their allergy has 
resolved, relax their avoidance diet, and increase their risk of an allergic reaction 
(Noimark et al., 2009; Taylor and Hefle, 2006a).  
Importance of Thresholds 
Threshold-based risk approaches have long been used for the management of 
chemical and microbial hazards in food (EU, 2003b; Kroes et al., 2000; Lammerding and 
Fazil, 2000; Larsen, 2006; Notermans et al., 1995). More recently, the importance of food 
allergy as a public health and food safety issue has placed pressure on the food industry 
and regulatory agencies to implement threshold-based strategies to protect the food 
allergic consumer. Food allergen thresholds can have different meanings to different 
stakeholders. To the food allergic consumer, their personal threshold or Minimal Eliciting 
Dose (MED) is the amount of food required to cause an allergic reaction. The population 
threshold could be the amount of food required to cause a reaction in the most sensitive 
individual or in a determined percentage of the food allergic population. To the food 
industry and regulatory bodies, the term threshold could determine how much allergen 
would trigger a product recall if unlabeled or when to place an advisory statement on the 
label if allergens are possibly present due to cross-contamination. Two countries have 
attempted to establish action levels for undeclared allergens. Switzerland has defined an 
action limit of 1,000 ppm for allergens. This limit states that if unavoidable, 
contamination above 1,000 ppm (0.1%) must be declared as an ingredient, but 
contamination below 1,000 ppm may be declared if desired (Kerbach et al., 2009). Levels 
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of 1000 ppm may provide enough protein (low mg doses) to cause reactions at moderate 
consumption levels in multiple foods (Taylor et al., 2004). Japan has taken a stricter 
approach and limited undeclared allergens to 10 ppm (0.001%) in foods (Kerbach et al., 
2009). At the present time, the U.S. has not adopted legislation or regulations regarding 
regulatory thresholds for food allergens and there is no regulatory guidance for trace 
levels of allergens due to cross-contact. In the absence of guidance from public health 
authorities regarding thresholds, the food industry has implemented the widespread use of 
various forms of voluntary advisory or precautionary “may contain” labeling in an 
attempt to manage the risk and protect food-allergic consumers. As a result, the quality-
of-life of food-allergic consumers has decreased and some are ignoring these advisory 
statements (Hefle et al., 2007; Hourihane et al., 2011). Additionally, the widespread use 
of advisory labeling has led to varying advice within the medical community on whether 
patients should avoid all foods with advisory labeling (Koplin et al., 2010; Vierk et al., 
2007). Regulatory establishment of thresholds could benefit allergic consumers but they 
should never be advised to ignore advisory statements on package labels (Taylor and 
Hefle, 2006a). All stakeholders (regulators, food industry, clinical researchers and 
patients) agreed it is essential to address the current lack of action levels and thresholds 
for food allergen labeling, but it is difficult to define and quantify a level of tolerable risk 
(Madsen et al., 2012). There is an obvious need for research and scientific advancement 
in the area of food allergen thresholds. 
 The FDA Threshold Working Group examined four approaches to allergen risk 
assessment and the establishment of thresholds (analytical methods-based, statutorily 
derived, safety assessment-based, and risk assessment-based) but came to the conclusion 
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that a quantitative risk assessment-based approach provides the strongest, most 
transparent scientific analyses to establish thresholds for the major food allergens 
(Gendel et al., 2008). Others have agreed that the use of allergic population threshold 
distributions and probabilistic risk assessment is the best approach to establish thresholds 
and determine the risk from food allergens (Madsen et al., 2009; Spanjersberg et al., 
2007). However, the probabilistic approach has only recently been applied to food 
allergens (Kruizinga et al., 2008; Rimbaud et al., 2010; Spanjersberg et al., 2010; 
Spanjersberg et al., 2007). The FDA Threshold Working Group stated that data available 
in 2006 were not sufficient to meet the requirements of the quantitative approach and that 
a research program should be initiated to develop applicable risk assessment tools and to 
acquire and evaluate the clinical and epidemiological data needed to support the 
quantitative risk assessment-based approach (Gendel et al., 2008). 
 After the declarations of the FDA Threshold Group, the Food Allergy Research 
and Resource Program (FARRP) at the University of Nebraska began gathering data on 
published low dose DBPCFCs for peanut (Taylor et al., 2009). The DBPCFC can be used 
do deduce an individual’s MED for a specific food. FARRP gathered additional data 
from an allergy clinic in Nancy, France and accumulated a total of 450 individual allergic 
thresholds from DBPCFCs (Taylor et al., 2010). It was reported that the MED for peanut-
allergic individuals in clinical trials spans 5 orders of magnitude – 0.4 mg up to 30,000 
mg of whole peanut (Taylor et al., 2009; Taylor et al., 2010). Additionally, a single 
individual’s allergic threshold can range over time but usually not in a significant fashion 
(Crevel et al., 2010). Small particulates of less than 1.0 mg peanut can cause a reaction 
and are displayed in Figure 4.  
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Figure 4 – Individually weighed particulate peanut samples up to ½ of a peanut. The lowest MED 
found in DBPCFC trials is labeled. (Photo credit: Barbara Ballmer-Weber) 
 
Clinicians have confirmed the existence of safe doses, or No Observed Adverse 
Effect Level (NOAEL), during low dose DBPCFC for all foods (Bindslev-Jensen et al., 
2004; Taylor et al., 2004; Taylor et al., 2010). The DBPCFC trials can be used to derive 
the NOAEL and Lowest Observed Adverse Effect Level (LOAEL) for each allergic 
individual. In clinical challenges, there is no significant correlation between the severity 
of a reaction and individual LOAELs (Taylor et al., 2010). As stated before, physicians 
recommend a complete avoidance of peanut but every allergic individual is able to 
tolerate a dose of peanut below their personal MED. The population threshold dose for 
peanut has been determined based on individual DBPCFC of 450 peanut-allergic 
individuals based on elicitation of objective symptoms (Taylor et al., 2009; Taylor et al., 
2010). Criteria for inclusion in the dataset are described in Table 1. Clinical literature on 
provoking doses from DBPCFC now exists for other major food allergens. Similar 
methods were used for 12 other allergenic foods (milk, egg, hazelnut, soybean, wheat, 
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cashew, mustard, lupin, sesame, shrimp, celery, and fish) to characterize the risk of each 
food (Australian Allergen Bureau, 2011; Taylor et al., 2013 (In prep)). 
Table 1 - Criteria for inclusion in peanut threshold dataset 
Published study  
Supplemented with unpublished results 
Peanut allergic by history or other factors 
Double-blind, placebo-controlled food challenges (DBPCFC) for peanut 
Open challenge allowed if patient is under 3 years old 
Description of NOAEL and/or LOAEL (if dosing regimen provided, then can determine NOAEL from LOAEL) 
Data on individual patients 
Objective symptoms @ doses 
 
Interval-Censoring Survival Analysis 
The NOAELs and LOAELs from each individual were used as part of an Interval-
Censoring Survival Analysis (ICSA) approach to generate a population threshold for 
peanut (Collett, 1993). The ICSA method is appropriate as the exact dose that provokes a 
reaction in an individual is not known but it is known to fall into a particular interval 
dependent on the dosing scheme used in the challenge (Taylor et al., 2009). As shown in 
Figure 5, left -censoring occurs when an individual experiences an objective reaction at 
the first dose in a challenge trial. If left-censored, the individual NOAEL is set to zero 
(left blank in the ICSA program) with the LOAEL set as that first dose. An individual is 
interval-censored when they experience a reaction to one of the doses in the middle of a 
dosing scheme and that individual threshold dose is bounded by the NOAEL and 
LOAEL. Right-censoring occurs if an individual does not experience an objective 
reaction after the largest challenge dose. In such cases, the NOAEL is set to that largest 
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challenge dose. An individual is considered as right-censored if they experience a 
subjective reaction to the largest dose or if a challenge was stopped early due to persistent 
subjective symptoms. The individual LOAEL is then set to infinity (left blank in the 
ICSA program) for right-censored subjects. The LIFEREG procedure (SAS v9.2) was 
used to fit cumulative probability function models to the interval-censored data. Multiple 
distributions are evaluated and the Log-Normal and Log-Logistic models were 
determined to best fit the peanut dataset at the lower end of the dose distribution. The 
models were used as shown in Figure 6 to estimate the ED10, the dose predicted to 
provoke reactions in 10% of the peanut-allergic population (Taylor et al., 2009; Taylor et 
al., 2010). Similar methods can be applied to other food allergens where sufficient 
DBPCFC data exist. 
 
Figure 5 – Diagram of the Interval Censoring Survival Analysis and how it assigns censoring values. 
Sample dosing scheme progresses from 10 mg – 50 mg – 150 mg – 500 mg. 
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Figure 6 – Log-Normal fit for the peanut population threshold from 450 DBPCFCs with objective 
symptoms in peanut allergic individuals (Taylor et al., 2010). 
 
The Log-Normal ED10 and ED05 were 12.3 mg and 5.2 mg whole peanut, 
respectively (Table 2) (Taylor et al., 2010), while the Log-Logistic ED10 and ED05 were 
12.6 mg and 4.5 mg whole peanut, respectively. The mathematical model chosen begins 
to heavily influence the predicted ED01 values when less experimental data are available, 
especially from subjects with low individual thresholds. The established Log-Normal or 
Log-Logistic threshold curve could be used in quantitative risk assessment models to set 
regulatory and food industry action levels for peanut. 
Table 2 – Eliciting doses (ED) from 450 peanut-allergic individuals as assessed by three statistical 
probability distribution functions (Taylor et al., 2010). 
Distribution ED1 95% CI ED5 95% CI ED10 95% CI ED50 95% CI 
Log-Normal 1.0 0.6, 1.6 5.2 3.6, 7.4 12.3 9.0, 16.8 260 207, 328 
Log-Logistic 0.5 0.3, 0.8 4.5 3.0, 6.7 12.6 8.9, 17.7 264 209, 333 
Weibull 0.04 0.02, 0.1 1.4 0.8, 2.6 6.6 4.1, 10.6 358 282, 455 
All values reported in mg Whole Peanut 
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Advisory labeling of food allergens in processed foods 
History of Use 
As previously stated, physicians recommend complete avoidance of the allergenic 
food(s) and avoidance of the allergenic food is the only treatment option (Taylor et al., 
1986a). Advisory “may contain” labeling is placed on products by food companies that 
cannot guarantee the absence of allergens due to incidental cross-contact during 
processing (Taylor and Baumert, 2010). With no guidance on food allergen thresholds 
from public health authorities, the food industry has placed voluntary advisory labeling 
on an ever-increasing number of packaged food products in efforts to alert food-allergic 
consumers to the possible presence of residues of the allergenic food with no 
consideration of the magnitude of any risk. While this situation assures to the maximum 
extent possible the safety and well-being of the food-allergic consumer, it serves to 
seriously limit food choices. Consequently evidence exists that some food-allergic 
consumers are ignoring precautionary allergen statements on labels, the exact opposite of 
the intent (Hefle et al., 2007; Sheth et al., 2012). Food-allergic individuals must try to 
interpret a variety of advisory labels causing confusion. Because of the proliferation of 
different forms of the wording of these voluntary advisory statements, some food-allergic 
consumers have the false impression that some foods with specific advisory statements 
(e.g. manufactured in a shared facility) are safer than foods with other statements (e.g. 
may contain) (Hefle et al., 2007). Despite the variety of statements that are used, all such 
statements are meant by the food industry to alert food-allergic consumers to foods 
possibly containing allergen residues so that they may avoid those foods. However, 
analytical surveys have documented, for products with advisory labels for peanut, that 
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only a small percentage contain detectable peanut residues and that some products 
without advisory labels possess similar allergen residue levels (Hefle et al., 2007; Pele et 
al., 2007; Pieretti et al., 2009). 
Regulatory Guidance 
Advisory labeling for allergens is voluntarily used by the food industry and not 
directly regulated or addressed by FALCPA (Gendel, 2012). With the exception of Japan, 
international allergen labeling regulations do not address advisory labeling (Gendel, 
2012; Japan Consumer Affairs Agency, 2011). Japan states that “Possibility Labeling” is 
not allowed as it would allow manufacturers an easy way to escape the Product Liability 
Act and narrows options for allergic patients (Japan Consumer Affairs Agency, 2011). 
The U.S. Food, Drug, and Cosmetics Act requires that label statements be “truthful and 
not misleading” (Chapter II, Sec. 201) but the broad statement allows for a wide variety 
of advisory statements to appear on labels. Food allergic individuals are left to interpret 
advisory labels which can cause confusion and lead to weighted opinions of differing 
label styles. In a report by the U.S. Food and Drug Administration (FDA), both allergic 
and non-allergic consumers indicate that shorter “may contain” advisory labels were 
more likely to contain peanuts or other listed allergens. Additionally, both allergic and 
non-allergic consumers were more likely to serve a product with a longer statement such 
as “shared facility” or “shared equipment” to an allergic individual than a product with a 
shorter “may contain” statement (FDA, 2006). Additional studies show that allergic 
consumers avoid products that state they “May contain” or were “Manufactured on the 
same/shared equipment” more so than products that were “Manufactured in a facility that 
also processes/uses”. Health Canada and the UK Food Standards Agency have provided 
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guidance on the wording of advisory labels to address this issue but no further direction is 
available (Gendel, 2012).  
 The Voluntary Incidental Trace Allergen Labeling (VITAL) program in Australia 
was the first food allergen management tool developed to assist the food industry with the 
use of advisory labeling and declaration of the possible presence of allergens in products 
(Australian Allergen Bureau, 2009). VITAL’s goal is to limit the use of advisory labeling 
through rigorous investigation of cross contact allergen presence in products before their 
release to the public. Initial risk management action levels were established for VITAL 
through the use of lowest reported individual threshold doses of protein from allergenic 
foods for subjective and objective allergic responses as cited by Gendel et al. (2008) in 
the 2006 U.S. Food & Drug Administration (FDA) Threshold Working Group 
(Australian Allergen Bureau, 2009). In 2011, a scientific panel was established to review 
the recommended reference doses for advisory labeling in VITAL as new data had 
become available. Between the panel and allergic consumer groups, it was decided that a 
protection level of 99% (the ED01) is ideal. FARRP and TNO, in the Netherlands, 
reviewed allergic individuals with objective symptoms reported in blinded oral 
challenges from published literature and unpublished clinical data for the VITAL 
database. The collection of data revealed that the ED01, a protection level of 99%, could 
be applied to several allergens. When the ED01 was not a viable option due to limited 
data, the lower 95% confidence interval of the ED05 was used to likely protect 97 – 99% 
of the allergic population. These general guidelines are available for companies to use 
when evaluating existing control measures and making decisions about the necessity of 
advisory labeling on their individual products. In using the VITAL reference dose, a 
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company must still assess their own internal control measures and their ability to 
consistently have allergen levels under the reference dose (Taylor et al., 2013 (In prep)). 
Previous Examples/Studies 
Products tested that contain advisory labels have been shown to have allergens 
present at low and high levels for all three major advisory labeling forms (“May contain,” 
“Shared Equipment,” and “Shared Facility”) (Ford et al., 2010; Hefle et al., 2007; Pele et 
al., 2007; Pieretti et al., 2009). A U.S. supermarket survey found 17% of products contain 
an advisory label statement for food allergens. The wording of such statements was split 
evenly among products as 38% had “May contain”, 33% had “Same/shared equipment”, 
and 29% had “Shared facility” labels. Certain categories, such as chocolate candy, 
cookies, and baking mixes, had the highest prevalence of advisory statement usage with 
40-54% of the products having an advisory label (Pieretti et al., 2009). While the use of 
advisory labeling is high, Hefle et al. (2007) found in a 2005 survey that only 7.3% of 
products with peanut advisory statements tested had detectable levels of peanut. 
Conversely, a similar study with products containing milk advisory statements found 
detectable levels of milk in 42% of products (Crotty and Taylor, 2010). Detectable levels 
of milk were found in 78% of dark chocolates with advisory labeling for milk (Crotty and 
Taylor, 2010). Ford et al. (2010) found detectable levels of allergen in 1.8% of products 
with egg advisory statements, 10.2% of products with milk advisory statements, and 
4.5% of products with peanut advisory statements. Products with milk advisory labels 
were more likely to contain detectable levels of milk if they were made by small 
companies in contrast to large food companies (Crotty and Taylor, 2010; Ford et al., 
2010). A higher prevalence of detectable allergen was found in European products with 
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advisory labeling for peanut (25% of cookies, 43% of chocolates) and hazelnut (36% of 
cookies, 79% of chocolates) (Pele et al., 2007). The absence of advisory labeling does not 
protect allergic consumers as a survey found detectable levels of peanut (11% of cookies, 
25% of chocolates) and hazelnut (25% of cookies, 53% of chocolates) in foods with no 
reference to the two allergens (Pele et al., 2007). Among U.S. products with no allergen 
declarations, only 1.9% contained detectable levels of peanut, milk, and egg products 
(Ford et al., 2010). Consumer avoidance of advisory labeled products has decreased and 
the prevalence of detectable allergen is low, but a risk of an allergic reaction still exists 
when consuming advisory labeled products. 
Commodity contamination within the food supply 
History of Use 
Due to the nature of agricultural production supply chains, raw agricultural 
commodities can become contaminated with other agricultural commodities during 
harvest, transport, and storage with shared equipment and facilities. Although direct 
ingredients derived from commonly allergenic sources must be labeled in clear terms 
when added to food, raw agricultural commodities are exempt from FALCPA (FDA, 
2006).  
Regulatory Guidance 
The U.S. Department of Agriculture (USDA) Grain Inspection Handbook allows 
up to 10% of other grains with established standards to be present in wheat (USDA, 
2004). The 10% level equates to 100,000 parts per million (ppm) or 100,000 mg/kg 
(µg/g) of other grains and would cause visual contamination within containers of wheat. 
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Other grains with established standards include barley, canola, corn, flaxseed, oats, rye, 
sorghum, soybeans, sunflower seed, and triticale (USDA, 2004). 
Before the removal of dockage (all matter other than the desired grain that can be 
removed), up to 25% of other grains are allowed in oats and barley, 20% in flaxseed, and 
10% in corn, canola, soy, sorghum, rye, sunflower seed, and triticale (USDA Grain 
Inspection Handbook). CODEX international grain standards allow 1.5% or 15,000 ppm 
(mg/kg) other grains in wheat and corn (CODEX Standard 199-1995; CODEX Standard 
153-1985). CODEX standards serve as guidance for all countries around the world. 
While Japan and Switzerland have established regulatory threshold levels, neither 
country is known to have applied these levels to commodity grains. Commodity grain 
shipments may exceed the Japanese limit. The economics of buying and selling 
commodity grains have kept comingling below these allowed limits as food processors 
demand a cleaner, higher grade of wheat and other grains. However, the extent of the risk 
from commodity comingling to allergic consumers has not been extensively investigated.  
Previous Examples/Studies 
The issue of soy in other grains has become an issue for food safety inspection as 
highlighted by numerous food alerts within the European Union Rapid Alert System for 
Food and Feed (RASFF) and the Canadian Food Inspection Agency (CFIA). The Food 
Safety Authority of Ireland has issued multiple food alerts for the presence of soy in 
wheat and corn based products (white bread flour, flour and corn tortillas, corn chips, and 
a batter mix) (RASFF Reference 2011.0015; 2011.0019; 2011.0022; 2011.0023; 
2011.0215). The CFIA also issued a food recall of a wheat-based cereal due to 
undeclared soy (Reference Number: 6848). Despite the lack of consumer complaints 
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associated with this cereal, products were recalled. In all likelihood, this cereal product 
has been produced for years with similar levels of soy. While levels of soy and other 
grains are known to occur in grain-based products, few studies have reported the levels of 
allergenic contaminants in agricultural commodities or finished products manufactured 
from these commodities. One exception is gluten, in large part due to “gluten-free” 
labeling, with North American levels of gluten contamination in other grains reported by 
multiple studies. Thompson et al. (2010) reported gluten contamination in 9 of 22 (41%) 
inherently gluten-free grain samples with levels up to 2925 ppm gluten. In a study by 
Health Canada, Koerner et al. (2011) reported 117 of 133 (88%) retail oat products 
contained levels up to 3784 ppm gluten. However, only one oat variety with a “gluten-
free” label was tested and it was consistently below the limit of quantitation for gluten. 
Recent IgE-mediated allergic reactions due to commodity contamination of wheat in 
infant foods have led the CFIA to encourage manufacturers and importers of grain-based 
products to inform consumers and transition towards the inclusion of precautionary 
labeling (a 'may contain wheat' statement) on their products containing cereal grains, such 
as oats or barley, to indicate the potential presence of wheat at low levels (CFIA, 2011). 
While the actual levels of co-mingling are much lower than the 10% and 1.5% allowed 
by the USDA Handbook and CODEX, allergic individuals could still be at risk by 
consuming these products.  
Food Allergen Risk Analysis 
Risk analysis is a three part, interactive process that consists of a scientific risk 
assessment, a risk management strategy, and an exchange of information through risk 
communication (Figure 7)(FAO/WHO, 2008). All manner of risks are evaluated using 
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this same process. Risk analysis for food allergens does not, in concept, differ from other 
risks associated with foods. 
 
Figure 7 - Diagram of the interactive processes involved in proper risk analysis. 
 
As previously stated, the prevalence of food allergies is increasing and 
recognition of the importance of food allergy as a public health and food safety issue has 
improved (Sicherer and Sampson, 2010). The occasional severity of food allergic 
reactions is evidenced by the number of annual emergency room visits and fatalities, 
which have served to heighten awareness even further (Bock et al., 2001; Clark et al., 
2011). As a consequence, public health authorities and the food industry have developed 
and implemented strategies to protect the food allergic consumer.  
For the food industry, the awareness of food allergies has led to the development 
and implementation of allergen control plans for manufacturing facilities, improved 
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labeling approaches as mandated by government authorities, and a proliferation of 
voluntary advisory statements (e.g. ‘may contain’ and many others) on packages. 
However, the zero-tolerance policy for allergens used by public health authorities creates 
practical problems for the food industry and the food allergic consumer because it is 
impossible to prove that absolutely no allergen residues are present. From an industrial 
cost-efficiency perspective, the same manufacturing facility has to be used to process 
multiple products. Shared production facilities and manufacturing equipment for multiple 
products creates an opportunity for trace residues of an allergenic food to come in contact 
with another food. Careful production schedules and meticulous cleaning are required 
when products of similar nature with differing allergen profiles are produced on shared 
equipment (i.e. ice creams or chocolates) (Taylor and Baumert, 2010; Taylor et al., 
2002). When companies are not able to guarantee complete avoidance of cross-contact, 
an advisory “may contain” statement might be placed on the product label.  
The development of better risk assessment approaches for allergenic foods could 
maintain the safety of foods for food-allergic consumers while expanding food choices. 
Overall impacts on labeling would be dependent on adoption of these approaches by the 
food industry and public health authorities. The improved approach is predicated on the 
existence of safe threshold doses for allergenic foods. Reported clinical observations of 
confirmed peanut-allergic individuals show that doses of peanut do exist below the 
exposures at which they will have a reaction (Taylor et al., 2002). The past decade has 
witnessed an influx of allergen threshold data that has allowed risk assessors to 
quantitatively adapt the traditional risk analysis approach for use with food allergens. As 
previously stated, threshold-based risk approaches are viewed favorably by public health 
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authorities and have been endorsed in consensus conferences (Gendel et al., 2008; 
Madsen et al., 2009). Similar approaches have long been used for the management of 
chemical and microbial hazards in food (FDA, 1994, 1995, 2000; Rasekh et al., 2005). A 
regulatory threshold for peanut and other allergens would reduce the proliferation of 
advisory labeling. Additionally, regulation would help allergic consumers separate the 
truly risky products from the products they are safe to consume. While the risk of 
allergenic foods has been widely recognized, the analysis of the risks (including 
assessment, management, and communication) has mostly been rudimentary and based 
upon identification and avoidance.  
Risk Assessment 
Risk Assessment is the scientific evaluation of known or potential adverse health 
effects resulting from human exposure to foodborne hazards. The process consists of four 
steps: hazard identification, hazard characterization, exposure assessment, and risk 
characterization (FAO/WHO, 2008).  
Hazard Identification  
Hazard identification is the recognition of a particular agent in foods with known 
or potential associated health effects (FAO/WHO, 2008). In food allergy, the hazard is a 
protein (or perhaps carbohydrate) moiety from a specific food that can cause sensitization 
and allergic reactions on subsequent exposures. Sensitization can occur to multiple 
proteins within a single food and any of them can be the cause of an allergic reaction 
(Taylor and Hefle, 2006b). A single protein such as Bet v 1, the major allergen in birch 
pollen, can cross react with proteins in foods from a number of categories including fresh 
fruits, vegetables, and legumes (Geroldinger-Simic et al., 2011). Sensitivity to a single 
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cross-reactive carbohydrate determinant (CCD) can lead to reactions after consumption 
of multiple foods (i.e. alpha-gal in beef, pork or lamb) (Commins and Platts-Mills, 2009). 
Clinically, food allergy has been recognized for a long period of time and the first reports 
of specific oral sensitization to egg appeared 100 years ago (Schloss, 1912; Schofield, 
1908). Exposure to the major food allergens are not a risk to the majority of the 
population, but the food-allergic population must take their avoidance diets seriously as 
the risk of consumption is potentially life-threatening.  
Hazard Characterization 
Hazard characterization is the qualitative and/or quantitative evaluation of the 
nature of the adverse effects. If data are obtainable, a dose-response assessment should be 
performed (FAO/WHO, 2008). As previously detailed, food-allergic individuals can 
experience a range of symptoms on exposure to the offending food. Not all allergic 
reactions are life-threatening, and some food-allergic individuals will never experience a 
severe reaction. Food allergy symptoms range from very mild, such as itching and flush, 
to a severe drop in blood pressure and bronchospasm. The severity of an allergic reaction 
also depends upon the dose of exposure. The MED, or threshold, varies widely across the 
entire population of individuals allergic to any specific food (Crevel et al., 2010). As 
detailed in the Interval-Censoring Survival Analysis section, individual food allergen 
thresholds can be quantitatively ascertained through clinical food challenges, preferably a 
DBPCFC with objective symptoms as the endpoint. Risk assessors then use the results of 
these challenges to determine the dose-response curve and population threshold for a 
particular allergen. Data exist for a number of allergens to conduct quantitative, dose-
response based risk assessments of food allergens. 
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Exposure Assessment  
Exposure assessment is the qualitative and/or quantitative evaluation of the likely 
intake via food and other sources if relevant (FAO/WHO, 2008). For a quantitative risk 
assessment, two main variables shape the exposure patterns. First, the probability of an 
allergic consumer purchasing a particular product will determine if there is any exposure. 
Second, the amount eaten by the individual will influence the outcome of the risk 
assessment. There is no consumption database available solely for food-allergic 
consumers. Risk assessors must assume that allergic and non-allergic individuals 
consume a product at the same rate and their reasons for non-consumption are the same. 
It is well known that allergic consumers are very brand loyal and shared experiences can 
lead to avoidance of perceived “risky” products and product categories. However, it has 
been shown that some allergic consumers will purchase products that have allergen 
advisory statements (Hefle et al., 2007). While uncertainty exists regarding the 
consumption patterns of allergic consumers, the only option is to use the consumption 
patterns of the overall population as a suitable surrogate until dietary surveys are 
designed specifically for the allergic individual. However, the assumptions involved in 
that approach must be stated and understood. 
There are many ways to estimate consumption patterns and a risk assessor can 
rely on internal company sales data or population-based dietary intake surveys to estimate 
the probability of a specific product being purchased. Depending on the company, sales 
data could include total market size for a product and the market share for the specific 
product from that company, the average number of packages sold during each 
transaction, and the estimated time until consumption once the product is in a home. 
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These data can be useful in a potential recall situation when calculating how many units 
are in the marketplace for purchase by allergic consumers and how many have already 
been consumed. Additionally, serving sizes and the likelihood of consuming more or less 
than a serving can be used to estimate the amount of exposure to a product.  
In addition to the internal company data, population based dietary surveys can 
provide useful information on the consumption patterns of products. The amount of 
information available will vary depending on the product and country where it is sold. 
Currently, there are a number of countries with dietary surveys that can help guide risk 
assessors. For example, the U.S. conducts 2-day, 24-hour dietary recall interviews as part 
of the National Health and Nutrition Examination Survey (NHANES) and releases the 
data in 2-year sections. The NHANES interview, like others population surveys, includes 
demographic, socioeconomic, dietary, and health-related questions. From this data, it is 
possible to extract consumption data based on product category, age, sex, and a number 
of other categories if desired. A combination of the 2003-04, 2005-06, and 2007-08 
surveys provides over 24,000 individuals with complete dietary recall interviews and 
more than 750,000 consumption recordings of specific product codes (CDC, 2004, 2006, 
2008). During a 24-hour recall, individuals may consume the same product over multiple 
eating occasions. The risk assessor must choose how to handle repeat exposures in the 
period of 24 hours and clearly state how consumption was estimated in their final reports.  
Risk characterization 
Risk characterization is the integration of hazard identification, hazard 
characterization and exposure assessment into a qualitative and/or quantitative estimation 
of the adverse effects likely to occur in a given population, with the attendant 
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uncertainties (FAO/WHO, 2008). There are many options when choosing how to 
characterize the risk of a food allergen in a product but the three discussed in this chapter 
will be the NOAEL-based safety assessment method, benchmark dose method, and 
probabilistic risk assessment.  
NOAEL-based safety assessment method 
The NOAEL-based safety assessment approach has been widely used in the past 
for food additives and chemical contaminants. The safety assessment uses NOAELs and 
LOAELs from animal or human studies, applies an uncertainty factor to set a regulatory 
level, and compares the product in question to the set level. The standard safety factors 
used could include 10-fold factors for interspecies differences, intraspecies differences, 
population bias, and estimation of the NOAEL if only LOAEL data are available 
(Madsen et al., 2009). Interspecies differences do not apply to food allergies as controlled 
clinical studies are done in humans. Population bias could occur with small sample 
populations, but are unlikely in a large dataset from unselected clinical populations. For 
example, a study combined 750 peanut-allergic individuals from specific European 
clinics that tested everyone suspected of having a peanut allergy, including those with 
histories of severe reactions. The peanut thresholds have remained stable with the 
addition of new populations (Taylor et al., 2013 (In prep); Taylor et al., 2010). Based on 
objective symptoms, NOAELs are available for the most sensitive individuals for a 
number of allergens so a safety factor is not required to transition from the LOAEL. The 
only possible applicable safety factor is the 10-fold difference for intraspecies variation, 
although it could be argued that intraspecies variation is already taken into account by 
using an unselected group of individuals with suspected peanut allergy and the reliance 
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on mild objective symptoms as the endpoint of oral challenges. The lowest NOAEL out 
of 450 individual thresholds with objective symptoms is 0.1 mg (100 μg) of whole peanut 
(Taylor et al., 2010). After the 10-fold uncertainty, the potential regulatory level would 
be 10 μg of whole peanut. A 10 μg regulatory level would equate to 0.2 ppm whole 
peanut in a 50 g serving. The proposed level could not be consistently attained by the 
food industry or reliably measured by current testing methods and likely lead to a drastic 
proliferation of advisory peanut labeling. 
The NOAEL-based safety assessment method has been applied for development 
of hypoallergenic infant formula according to AAP guidelines for a hypoallergenic infant 
formula study. If no reactions occur in challenges of 29 milk allergic infants there is 95% 
certainty that 90% of milk-allergic infants will tolerate the formula (essentially the 95% 
lower confidence interval of the ED10) (American Academy of Pediatrics et al., 2000; 
Kleinman et al., 1991). Previous food challenge studies have attempted to use similar 
NOAEL-based approaches to establish safe levels of consumption for allergic consumers. 
In a study with 30 soy-allergic individuals, Ballmer-Weber et al. (2007) reported a 
cumulative NOAEL for subjective symptoms of 2 mg soy flour (1.1 mg soy protein) and 
a NOAEL of 158 mg soy flour (83.7 mg soy protein) for objective symptoms. Thus, there 
is 95% certainty that 90% of soy-allergic individuals will not have objective reactions to 
158 mg soy flour. After application of a 10-fold safety factor, the regulatory level for soy 
flour would allow 15.8 mg soy flour in a 50 g serving which equates to 316 ppm soy 
flour. Hefle et al. (2003) used spray-dried whole egg (SDWE) to determine the threshold 
dose in 39 egg-allergic individuals. The objective NOAEL was 330 µg SDWE (150 µg 
egg protein). However, subsequent challenges in a similar manner determined a LOAEL 
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for one individual who reacted to the first dose of 30 µg SDWE (14 µg egg protein). As 
the individual reacted at the first dose, no NOAEL is available and an additional 10-fold 
safety factor would be used to estimate the NOAEL from the LOAEL. A 0.3 µg SDWE 
regulatory level would equate to 0.006 ppm SDWE in a 50 g serving (0.0028 ppm egg 
protein). The NOAEL-based method in these instances might be argued to endanger a 
number of soy allergic individuals, while regulatory levels for egg could not be measured 
by current testing methods. Furthermore, this approach has been used in testing of several 
food ingredients derived from commonly allergenic food sources. In the case of highly 
refined peanut oil, 58 peanut-allergic subjects were challenged with no reactions 
providing 95% confidence that 95% of peanut-allergic individuals would tolerate highly 
refined peanut oil (Hourihane et al., 1997). Fish gelatin derived from codfish skin has 
also been tested in cod-allergic subjects and 0 of 29 individuals reacted to ingestion of 
3.64 g cumulative dose of fish gelatin (Hansen et al., 2004).  
Although this approach has been used in some circumstances with a degree of 
success, there are many drawbacks to using the NOAEL-based safety assessment 
approach. The main arguments against the safety assessment approach are that it uses one 
point from one study and would set regulatory action levels too low to be helpful in some 
real world applications, e.g. egg. The NOAEL-based safety assessment approach would 
not benefit the food-allergic consumer, the food industry, or the public health authorities 
so another method must be used. 
Benchmark Dose method 
The Benchmark Dose (BD) was developed as a way to fit mathematical models to 
experimental data for chemicals and carcinogens and as a general improvement over the 
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NOAEL-based safety assessment (Crump, 1984). The BD is a low but measurable level, 
usually derived from the lower confidence interval of the statistical distribution. As stated 
by Crump (1984), “the method can be applied to either “quantal” data in which only the 
presence or absence of an effect is recorded, or “continuous” data in which the severity of 
the effect is also noted.” In chemical risk assessment, a dose that will produced a 
response in 10% of the population is the standard BD level and uncertainty factors can 
then be applied if necessary. The BD should be within the range of doses observed in the 
study to avoid extrapolation below the experimental findings and limit strong dependence 
on a particular mathematical model (Crump, 1984). In the case of food allergy, quantal 
data from clinical challenges with objective symptoms are analyzed using the Interval-
Censoring Survival Analysis technique, as previously described, to obtain a dose-
response curve. In food allergy, a BD that would place 10% (BD10) of the food-allergic 
population at risk is too high and safety factors would likely be applied. Peanut has the 
most robust allergen dataset available and a BD05 or BD01 could be used, but this level of 
analysis is not available for all food allergen population thresholds due to the lack of data 
(Australian Allergen Bureau, 2011; Taylor et al., 2013 (In prep)). Risk management 
decisions could be made on a level of acceptable risk but first a uniform method for 
evaluating BD levels and relevant safety factors, if any, must be developed. Once BD 
levels are set, a Margin of Exposure (MoE) could be evaluated (Madsen et al., 2009). The 
MoE calculation would utilize the exposure assessment for a particular food, potential 
allergen contamination levels, and the BD levels for an allergen to try and characterize 
the risk of a product. However, the risk is still not quantitatively described and multiple 
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regulatory decisions would be required regarding the appropriate exposure levels to use 
and the desired MoE.  
Quantitative Risk Assessment 
Quantitative risk assessment (QRA) was first applied to food allergens in a case 
study with hazelnut contamination found in nominally hazelnut-free chocolate spreads 
(Spanjersberg et al., 2007). A second QRA study examined large amounts of milk protein 
in multiple brands of dark chocolate products and led to a widespread change in labeling 
practices (Spanjersberg et al., 2010). Although relatively new to food allergens, QRA has 
been used by microbial and chemical risk assessors for years (EU, 2003b; Kroes et al., 
2000; Lammerding and Fazil, 2000; Larsen, 2006; Notermans et al., 1995). As previously 
stated, consensus has been reached that statistically-based quantitative methodology is 
the most promising approach for food allergen risk assessment (Gendel et al., 2008; 
Madsen et al., 2009). Prior to 2009, allergen dose-distribution modeling had been 
explored but no robust threshold datasets were available for IgE-mediated allergic 
reactions to any food (Bindslev-Jensen et al., 2002; Crevel et al., 2007). Substantial work 
has led to large datasets for a number of food allergens including peanut, milk, egg, and 
hazelnut. Datasets for soy, wheat, cashew, and other allergens have been constructed as 
well. However, a gap does exist between the number of available subjects in the top four 
datasets and the rest of the allergens (Australian Allergen Bureau, 2011; Taylor et al., 
2013 (In prep)). Kruizinga et al. (2008) noted that a shift in the dose-response curve will 
have a considerable effect on the results of the QRA. Datasets with a small number of 
subjects are significantly affected by the addition of individuals at the low or high end of 
the curve. However, this drawback is not limited to QRA alone as the BD also uses a 
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dose-response curve and the NOAEL-based method only uses a single point. Additional 
data at the low end of the dose-response curve could significantly affect the results of all 
three methods.  
Quantitative risk assessments require the most data of any risk characterization, 
but very little additional data are required to step from a BD approach to a QRA. The 
main data needed to conduct a QRA include the prevalence of food allergy, allergen 
dose-response curve, and the allergen intake curve, which consists of consumption data 
and data on the level of allergen residues present (Figure 8).  
 
Figure 8 – Probabilistic risk assessment model for food allergens in the U.S., figure adapted from 
Spanjersberg et al. (2007). 
 
The true prevalence of food allergy is unknown. In a QRA, the prevalence of a 
specific food allergy is estimated by using published literature as a reference. Once the 
prevalence of allergy is set, the distribution of allergy in the population is binomial and 
the simulation will choose if every individual is allergic or non-allergic. If the individual 
is allergic, a minimal eliciting dose (MED) will be chosen from the statistically fit dose-
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response distribution. As stated in the exposure assessment section, population-based 
dietary intake surveys or internal company data on consumption can be used for an 
individual product. If no data are available, a determined serving size can be substituted 
with the likelihood that more than one serving could be consumed. In a QRA, the 
consumption of a product is binomial, meaning the simulation chooses if purchase and 
consumption of the product occurs or it does not. The rate of purchase is determined from 
the relevant population surveys and market share data available to a company. If the 
product is purchased, the reported individual consumption amounts can be directly 
sampled from dietary intake surveys to create the consumption input or sampled from a 
representative statistical distribution. The part per million (ppm or μg/g) level of allergen 
present is determined by laboratory analysis of individual products or through product 
formulation calculations. Ideally, the risk assessment would be started on a worst-case 
product formulation scenario and adjusted after laboratory analysis has been completed. 
The presence of an allergen is a binomial distribution. The simulation will choose based 
on the percentage of positive samples to determine if the product being consumed has the 
allergen present or not. If the scenario is worst case or all samples are positive, the 
presence of allergen will be set to 100%. The ppm levels of allergen present are either 
directly sampled from the laboratory analysis or chosen from a representative statistical 
distribution. 
The QRA is a Monte Carlo simulation that will randomly sample from each 
distribution during every run and iteration, match if the individual is allergic, a consumer 
of the product in question, and if the product contains the allergen to determine if there is 
a possibility of an allergic reaction. An individual will have a predicted allergic reaction 
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if the predicted consumed amount and concentration of allergen lead to a dose over the 
predicted allergen threshold. Risk assessments can use a modified Monte Carlo approach, 
incorporating the mean and standard error associated with each input variable into a 
Bayesian framework. Briefly, the Bayesian context of a simulation with 50 runs of 
10,000 iterations will be explained using a Log-Normal dose-response curve. As the true 
population threshold and dose-response curve of each allergen are unknown, the 
Bayesian analysis will use statistical inference to generate the parameters of the Log-
Normal distribution to reflect uncertainty in the true location of each parameter. The 
confidence intervals around the curve will shrink as more individuals become available 
for the dose-response curve, thus demonstrating the importance of robust datasets. The 
end result is that every run will have a new Log-Normal distribution associated with the 
dose-response curve. The Bayesian framework will create 50 dose-distribution curves 
that fall within the confidence intervals of the predicted distribution from the interval-
censoring procedure. This same process can also be used for the distribution representing 
consumption amounts and the ppm levels of allergens present.  
Additional Bayesian methods can be applied to the binomial prevalence 
distributions estimating allergic prevalence, presence of allergen in a product, and 
consumption/purchase of the specific product. Rimbaud et al. (2010) describe the process 
for fitting a Binomial distribution with a non-informative prior Beta(1,1) distribution. 
Using the Beta probability density function, the posterior binomial distribution 
probability can be solved as follows: p ~ Beta(1+x, 1+n1-x) with x representing a positive 
response and n1 representing the total number of people in the study. Thus, a new 
binomial probability is chosen for every run of the simulation based on the number of 
67 
 
individuals collected for each input. The probabilities will shift less with each run when 
more data are available for each input. 
When the simulation is run, the stepwise process shown in Figure 9 is done for 
every iteration to predict if an allergic reaction will occur. The results of the finished 
simulation can be expressed in multiple ways, but this chapter will discuss the allergic 
user risk, risk to the allergic population, and risk to the overall population. Please note 
that the three risk values represent the same number of predicted reactions expressed 
three different ways. The allergic user risk bears the least number of uncertainties and 
assumes every individual in the simulation is allergic and consumes the product in 
question. The allergic population risk assumes every individual is allergic to the allergen 
in question but only a certain percent of the population consumes the product category. 
The overall population risk includes every individual, including non-allergic and non-
consuming individuals. The three risk values are the same because a non-allergic 
consumer is never at risk for an allergic reaction. This is different than chemical 
carcinogen risk assessment where all populations are susceptible but certain groups are 
more at risk than others. It is critical to understand the risk outputs and present them 
appropriately to avoid confusion. Quantitative risk assessment is a flexible tool that 
utilizes the food allergen threshold curves to investigate a wide range of allergen issues. 
Quantitative methods can be used to determine when to apply advisory labeling, assist 
with product release or conversely with product recall, and validate clean-in-place 
measures. 
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Figure 9 – Quantitative risk assessment step-by-step decision tree during a simulation. Arrows 
indicate where the allergic user risk, allergic population risk, and overall population risk are 
calculated from in the simulation. 
Risk management  
Risk management is defined as the process, distinct from risk assessment, of 
weighing policy alternatives in consultation with all interested parties. Risk management 
includes considering risk assessment and other factors relevant for the health protection 
of consumers and, if needed, selecting appropriate prevention and control options 
(FAO/WHO, 2008). Risk management decisions should be separate from the risk 
assessment process to ensure the scientific integrity of the risk assessment and reduce any 
conflicts of interest. However, interaction between the risk assessors and the risk 
managers is essential for practical application of any risk management options 
(FAO/WHO, 2008). Cooperation and collaboration is key when dealing with food 
allergies as a uniform risk assessment policy would benefit regulatory bodies, academics, 
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and consulting firms when presenting the results to the risk assessors and risk managers 
in the food industry. Proper risk management will integrate preliminary risk management 
activities, evaluation of risk management options, implementation of the risk 
management decision, and monitoring and review of the process based on the risk 
assessment (FAO/WHO, 2008). 
Preliminary risk management activities  
Preliminary risk management activities establish a risk profile to facilitate context 
and may commission a risk assessment to guide further action. When a risk assessment is 
needed, the policy should be established by risk managers in advance of risk assessment. 
Efforts to consult with risk assessors and regulatory bodies before the assessment is done 
help ensure a complete, unbiased and transparent risk assessment (FAO/WHO, 2008). 
The risk assessment should include all assumptions and uncertainties. The responsibility 
for resolving the impact of uncertainty on the risk management decision lies with the risk 
manager, not the risk assessors (FAO/WHO, 2008). For food allergens, the form of risk 
presented (i.e. allergic user risk, allergic population, and overall population) and 
alternative forms (i.e. predicted reactions from a product) should be clearly defined 
within the risk assessment. The risk estimate should be reported in a form that is readily 
understood by risk managers, defensible to regulatory bodies, and easily communicated 
to the food allergic community 
Evaluation of risk management options  
Evaluation of risk management options is an overarching process that weighs 
available options for managing a food safety issue. Decisive factors include available 
scientific information, a decision on an appropriate level of consumer protection, the 
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effectiveness of control measures, and a cost-benefit analysis (FAO/WHO, 2008). 
Currently, there are no national risk management programs for food allergens. A 
company is presented with limited options for allergen labeling. When an allergen is in 
the product formulation, it must be labeled in the ingredient statement and possibly a 
“contains” statement. If cross-contamination is possible then a risk assessment should be 
done and a decision must be made between “may contain” advisory labeling or not 
referencing the allergen on the label. As previously stated, the VITAL expert panel 
selected a level of 99% consumer protection as the action level for advisory labeling 
(Australian Allergen Bureau, 2011). When using the VITAL approach, an individual 
company must use the provided reference dose as a guideline with the evaluation process 
of their allergen control practices and scrutinize the use of advisory labeling on their 
products.  
Implementation of the risk management decision  
Implementation of the risk management decision will involve the application and 
verification of food safety measures. A HACCP plan is usually included and flexibility is 
desired, as long as the overall program can be objectively shown to achieve the stated 
goals (FAO/WHO, 2008). Foods may encounter cross-contamination at any point of the 
food chain. Shared equipment and storage facilities during the harvesting and 
transportation of agricultural commodities is a source of contamination for some 
commonly allergenic foods and is generally exempt from labeling (FDA, 2006; USDA, 
2004). Another source of cross-contamination for the food industry is within the 
processing facility, especially the use of shared equipment when making packaged foods. 
Supplier auditing is key as there are many levels of suppliers before a food reaches the 
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end processor and undeclared allergens could enter the food at any location. It is 
important for a company to have the best information available for the ingredients 
entering its facility to address any risk of cross-contamination appropriately (Taylor and 
Baumert, 2010). 
Dedicated facilities, processing lines, or specific equipment are not feasible in 
many commercial situations so proper management of shared equipment and facilities is 
essential to an allergen control plan (Taylor and Baumert, 2010). The physical separation 
of allergenic formulations from non-allergen products during manufacturing and the 
creative use of product scheduling strategies can help reduce the risk of cross-
contamination. Effective sanitation of equipment is key when changing back from 
allergenic to non-allergen products (Taylor and Baumert, 2010). Wet-cleaning methods 
are effective, but not allowed in many situations. Bakeries and chocolate manufactures 
must use dry-cleaning methods and have an especially hard time ensuring that all 
allergens are removed. Analytical tests, like the ELISA method, can be used on site or at 
an independent laboratory to verify the effectiveness of cleaning procedures. In situations 
with hard to clean pieces of equipment, it is recommended to test the corners and weld 
positions for any potential buildup of allergen compared to the smooth surfaces. If an 
allergen cannot be consistently controlled, advisory labeling may be implemented (Taylor 
and Baumert, 2010).  
Monitoring and review  
Monitoring and review is the gathering and analyzing of data to give an overview 
of food safety and consumer health. If goals are not being achieved, redesign of food 
safety measures will be needed (FAO/WHO, 2008). Risk management is a continuous 
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process for a food manufacturer. Monitoring cleaning processes is critical for a company 
and can be done with easy to use ELISA-based tests (Taylor and Baumert, 2010). In 
accordance with the U.S. FDA Food Safety Modernization Act (FSMA), a company must 
“evaluate the hazards (including allergens) that could affect food manufactured, 
processed, packed, or held by such facility, identify and implement preventive controls to 
significantly minimize or prevent the occurrence of such hazards and provide assurances 
that such food is not adulterated, monitor the performance of those controls, and maintain 
records of this monitoring as a matter of routine practice” (FDA, 2011). As an industry, 
significant updates will be necessary to document and validate allergen control plans to 
comply with the regulations outlined by FSMA. However, details on specific validation 
practices and approved methods are not clearly outlined within the law and companies 
will need further interpretation from the FDA to ensure compliance. To guarantee the 
highest levels of protection for the food allergic consumer, new allergen testing methods 
should be continually evaluated, new scientific knowledge should be reviewed regularly, 
and reference doses for allergen labeling should be updated as necessary when more data 
on clinical threshold trials becomes available.  
Risk Communication  
Risk communication is an interactive process exchanging information and opinion 
on risk among risk assessors, risk managers, consumers, industry, the academic 
community and other interested parties (FAO/WHO, 2008). Communication is essential 
and should continue through the entire risk analysis process. One goal of risk 
communication is to foster public understanding of the process and to enhance trust and 
confidence in the safety of the food supply (FAO/WHO, 2008). Thus, dissemination of 
73 
 
information must be done in a way that presents the food allergic consumer with a clear 
and simple understanding of the process. The main form of risk communication between 
a food producer and an allergic consumer is the product package/label. Current food 
allergen regulations mandate labeling of allergenic ingredients to clearly state when an 
allergenic risk is present to the consumer (Gendel, 2012). A second, less effective form of 
risk communication is advisory labeling for allergens. While well intended, proliferation 
of advisory labeling has led to risk taking activities within the food allergic community 
(FDA, 2006; Hefle et al., 2007). Advisory labeling must be clear, concise, and uniform 
across the food industry and only adopted when cross-contamination is likely in order to 
avoid consumer confusion.  
Summary 
 Food allergies affect a small percentage of the population. The prevalence and 
awareness of IgE-mediated food allergies appear to be increasing in developed countries. 
Symptoms of a food allergy vary from mild to severe anaphylaxis and death. Avoidance 
of the allergenic food is the only treatment option but complete success of an avoidance 
diet is unlikely. Progress has been made on aspects of identifying, characterizing, and 
detecting food allergens, and more recently on individual food allergen thresholds. 
Quantitative risk assessment is a flexible tool that utilizes food allergen threshold curves 
to investigate a wide range of allergen issues, including when to apply advisory labeling, 
assist with product release or conversely with product recall, and validate the 
effectiveness of sanitation measures. However, hurdles do remain before regulatory 
thresholds can be established for food allergens, such as regulatory and consumer 
agreement on an acceptable risk and consensus on risk communication methods to 
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demonstrate that a product has under gone a risk assessment. The main objective of this 
study was to further characterize food allergen population thresholds and develop 
quantitative risk assessment methods for food allergens in the U.S., in an effort to help 
reduce the number of severe allergic reactions caused by packaged foods. 
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Abstract 
In the absence of guidance from public health authorities regarding food allergen 
thresholds, the food industry has implemented the widespread use of various forms of 
voluntary advisory or precautionary “may contain” labeling in an attempt to manage the 
risk and protect food-allergic consumers. All stakeholders (regulators, food industry, 
clinical researchers and food-allergic consumers) agree it is essential to address the 
current lack of action levels and thresholds for food allergen labeling as the ramped use 
of advisory labeling and lack of transparency of its use limit food choices and decrease 
the quality of life of allergic individuals. This study aims to build upon initial work with 
peanut and develop a global thresholds database for all priority food allergens. Clinical 
publications and unpublished clinical data were screened for data regarding objective, 
individual challenge data for priority food allergens. Minimal eliciting doses were found 
for 13 priority allergens and include over 1800 individuals from published clinical 
literature or unpublished clinical data. The results of this study show there are sufficient 
clinical data from food allergic individuals to use for risk assessment purposes and 
developing regulatory thresholds for several allergenic foods. Allergic populations did 
not vary when analyzed by age, geographic region, or gender and only slightly varied by 
study population and challenge material. Expert judgment must be used when developing 
regulatory thresholds or action levels (reference doses) and evaluating the clinical 
challenge methods that provide data on relevant food allergic-individuals. In order to 
benefit all stakeholders, clinical food challenge studies are recommended to start below 1 
mg protein from the allergenic food and proceed at a log or semi-log scale dose increases, 
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depending on the comfort of the physician, until a final discrete dose of 4 – 5 grams of 
protein is reached.  
1. Introduction 
Food allergies are a worldwide health concern as they affect an estimated 5 – 10% 
of children and 3 – 4% of adults in westernized countries (1-3). Food allergen risk 
assessment and proper labeling are important processes for the food industry, regulatory 
agencies, and food allergic consumers. Allergic consumers have no choice but to adhere 
to a strict avoidance diet and carefully read the ingredient labels of the food they eat (4-
7). Many developed countries require labeling of the most common allergenic foods 
(peanuts, milk, eggs, tree nuts, soy, wheat (or cereal grains containing gluten), fish, and 
crustacean shellfish) and ingredients derived from these foods (8).  
Threshold-based risk approaches have long been used for the management of 
chemical and microbial hazards in food but have not been widely adopted by regulatory 
agencies in the management of food allergens (9-13). Food allergen thresholds have 
different meanings to different stakeholders. To the food allergic consumer, their 
personal threshold or Minimal Eliciting Dose (MED) is the amount of food required to 
cause an allergic reaction. The population threshold could be the amount of food required 
to cause a reaction in the most sensitive individual or in a determined percentage of the 
food allergic population. To the food industry and regulatory bodies, the term threshold 
could determine how much allergen would trigger a product recall if unlabeled or when 
to place an advisory statement on the label if allergens are possibly present due to cross-
contact. Two countries have attempted to establish regulatory action levels for undeclared 
allergens in foods. Switzerland has defined an action limit of 1,000 ppm (mg/kg) for 
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allergens. This limit states that if unavoidable, contamination above 1,000 ppm (0.1%) 
must be declared as an ingredient, but contamination below 1,000 ppm may be declared if 
desired (14). Levels of 1000 ppm may provide enough protein (low mg doses) to cause 
reactions at moderate consumption levels in multiple foods (15). Japan has taken a 
stricter approach and limited undeclared allergens to 10 ppm protein from the allergenic 
sources (0.001%) in foods (14). At the present time, the U.S. has not adopted legislation 
or regulations regarding regulatory thresholds for food allergens and there is no 
regulatory guidance for trace levels of allergens due to cross-contact. The importance of 
food allergy as a public health and food safety issue has placed pressure on the food 
industry and regulatory agencies to implement threshold-based strategies to protect the 
food allergic consumer.  
In the absence of guidance from public health authorities regarding thresholds, the 
food industry has implemented the widespread use of various forms of voluntary advisory 
or precautionary “may contain” labeling in an attempt to manage the risk and protect 
food-allergic consumers. As a result, the quality-of-life of food-allergic consumers has 
decreased due to the ever decreasing number of food choices available and some are 
ignoring these advisory statements (5, 16). Additionally, the widespread use of advisory 
labeling has led to varying advice within the medical community on whether patients 
should avoid all foods with advisory labeling (17, 18). Regulatory establishment of 
thresholds could benefit allergic consumers as there would be more transparency in the 
use of advisory labeling by food industry but they should never be advised to ignore 
advisory statements on package labels (19). All stakeholders (regulators, food industry, 
clinical researchers and food-allergic consumers) agreed it is essential to address the 
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current lack of action levels and thresholds for food allergen labeling, but it is difficult to 
define and quantify a level of tolerable or accepted risk (20). There is an obvious need for 
research and scientific advancement in the area of food allergen thresholds. 
 The FDA Threshold Working Group and others have agreed that allergic 
population thresholds and a quantitative risk assessment-based approach provides the 
strongest, most transparent scientific analyses to establish thresholds for the major food 
allergens (21-23). However, the quantitative (probabilistic) approach has only recently 
been applied to food allergens (23-26). The FDA Threshold Working Group stated that 
data available in 2006 were not sufficient to meet the requirements of the quantitative 
approach and that a research program should be initiated to develop applicable risk 
assessment tools and to acquire and evaluate the clinical and epidemiological data needed 
to support the quantitative risk assessment-based approach (21). Recent work by the Food 
Allergy Research and Resource Program (FARRP) at the University of Nebraska utilized 
published low dose double-blind, placebo-controlled oral food challenges (DBPCFC) for 
peanut and additional data from an allergy clinic in Nancy, France to accumulate a total 
of 450 individual allergic thresholds from DBPCFCs and form a stable population 
threshold distribution for peanut-allergic individuals (27, 28). This study aims to build 
upon FARRP’s initial work with peanut and develop a global thresholds database for all 
priority food allergens. Additionally, variations in challenge protocols and the number of 
subjects used in food allergen threshold studies were examined in order to produce more 
useful data for all stakeholders. The threshold work conducted by FARRP and TNO in 
the Netherlands is now being utilized by the Australian Allergen Bureau in the Voluntary 
Incidental Trace Allergen Labelling (VITAL) program, in which reference dose values 
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for priority allergens have been developed to aid in risk assessment and precautionary 
labeling decisions as discussed in more detail in the Regulatory Thresholds and 
Uncertainty Factors section of this chapter. 
2. Materials and Methods 
Food allergen thresholds 
The Food Allergen Labeling and Consumer Protection Act (FALCPA) was passed 
in 2004 by the U.S. Congress to protect allergic individuals from the ‘major’ food 
allergens of milk, egg, fish (e.g., bass, flounder, or cod), crustacean shellfish (e.g., crab, 
lobster, or shrimp), tree nuts (e.g., almonds, pecans, or walnuts), wheat, peanuts, and 
soybeans by requiring declaration of these allergens on the packaged food label in plain 
English terms (29). Additional priority allergenic foods within global regulatory 
frameworks include, but are not limited to: sesame seed, molluscan shellfish, mustard, 
celery, and lupin (8). Clinical publications were screened for data concerning DBPCFC 
thresholds for priority food allergens within the global framework. This method was 
previously described in detail by Taylor et al. (28). Briefly, study inclusion criteria were 
as follow: allergic by history or other factors, double or single blind PCFC for allergen of 
interest (open challenge allowed if patient < 3 years of age (30)), data on individual 
patients, description of a no observed adverse effect level (NOAEL) and/or a lowest 
observed adverse effect level (LOAEL) (if dosing regimen was provided, the NOAEL 
could be determined from LOAEL), and objective symptoms at time of reaction. 
Published studies were supplemented with unpublished clinical data of equal quality, 
when available. The symptoms at the LOAEL, age, and geographic location of each 
patient were recorded when possible. Additionally, the challenge material (e.g. whole 
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peanut, peanut flour, peanut butter, etc) and dosing protocol were recorded for each 
study. Challenge materials were converted to mg protein to normalize reported doses 
across studies (Table 1). Multiple centers had slightly different protein contents for a food 
(e.g. raw whole egg, liquid milk, etc.), in which case a representative, conservative 
protein value was chosen and listed with its source.  
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Table 1. Conversion factors used to normalize the threshold challenge material.  
Allergen Conversion to: 
Protein 
Content 
mg 
Protein 
mg 
Food 
Reference 
 
Peanut Whole Peanut 25.0% 1 4.0 
Taylor et al. (31) 
assumptions  
  
Peanut Defatted Peanut Flour 50.0% 1 2.0 
Taylor et al. (31) 
assumptions 
 
Milk Liquid Milk 3.3% 1 30.3 USDA - 2% Milk  
Milk NFDM 35.1% 1 2.8 
USDA - Instant 
NFDM 
 
Egg Raw Whole Egg 12.6% 1 8.0 USDA  
Egg Raw Egg White 10.5% 1 9.5 NEVO  
Egg Cooked Whole Egg 12.6% 1 7.9 USDA  
Egg Cooked Egg White 10.5% 1 9.5 NEVO  
Egg Dried Whole Egg 46.0% 1 2.2 NEVO  
Egg Dried Egg White 81.1% 1 1.2 USDA  
Hazelnut Hazelnut Flour 15.7% 1 6.4 In Wensing et al. (32)  
Soy Whole Soybean 40.0% 1 2.5 
Assumptions made by 
working group 
 
Soy Soy Flour 53.0% 1 1.9 
In Ballmer-Weber  
et al. (33) 
 
Soy Soy Milk 3.6% 1 27.8 provided by UMCU  
Wheat 
Raw or Cooked Wheat 
Flour 
10.0% 1 10.0 NEVO and USDA 
 
Cashew Cashew Flour 19.0% 1 5.3 NEVO  
Mustard Mustard Seed 26.1% 1 3.8 USDA - S. alba seed  
Lupin Lupin Flour 36.2% 1 2.8 USDA  
Lupin Yellow Lupin Flour 40.0% 1 2.5 In Shaw et al. (34)  
Sesame Crushed Sesame Seeds 17.0% 1 5.9 USDA - Roasted Seed  
Sesame Sesame Seed Flour 30.8% 1 3.2 
USDA - High Fat 
Flour 
 
Shrimp Whole Cooked Shrimp 22.8% 1 4.4 
USDA - 
Steamed/Boiled 
 
Celery Raw Celery Root 2.0% 1 50.0 NEVO  
Fish Snapper 26.3% 1 3.8 USDA  
Fish Cooked Codfish 23.0% 1 4.3 NEVO  
Fish Raw Codfish 18.3% 1 5.5 NEVO  
Fish Catfish 18.4% 1 5.4 USDA  
Fish Halibut 19.4% 1 5.2 NEVO  
Fish Tuna 23.7% 1 4.2 provided by UMCU   
Fish Tilapia 17.8% 1 5.6 provided by UMCU   
USDA, USDA National Nutrient Database; NEVO, The Dutch Food Composition Table; 
UMCU, University Medical Center Utrecht. 
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Data obtained through the literature search were merged with existing food 
allergen threshold datasets from TNO in order to maximize the number of subjects 
available for analysis. Datasets were scrutinized on an individual patient basis, with any 
disparities or duplicates being thoroughly examined. The NOAELs and LOAELs from 
each individual were modeled using a dose distribution approach as described by Crevel 
et al. (35). Allergen population threshold curves were generated using an Interval-
Censoring Survival Analysis (ICSA) approach (36) and the LIFEREG procedure (SAS 
v9.2). The ICSA method is appropriate as the exact dose that provokes a reaction in an 
individual is not known but it is known to fall into a particular interval dependent on the 
dosing scheme used in the challenge (28). Additionally, ICSA utilizes individuals that 
react to the first dose (left-censored observations) or those that do not react at all, but 
whose allergy is nonetheless proven by past history of reaction (right-censored 
observations). For left-censored individuals, ICSA assigns the NOAEL value as zero and 
the LOAEL value as the first dose in the oral challenge. For right-censored individuals, 
the last dose in the oral challenge series is considered the NOAEL value while the 
LOAEL is considered infinity. No biological evidence exists for the uses of one statistical 
model over another, so discrete doses (dose given immediately prior to the reaction) and 
cumulative doses (cumulative of all doses given up to that point) were fit using log-
normal, log-logistic, and Weibull distributions for each allergen (35). The ED01, ED05, 
ED10, and ED50 or doses predicted to provoke a reaction in 1%, 5%, 10%, and 50% of 
the allergic population, respectively, were extracted from each distribution. Results were 
analyzed and compared with potential methods available to derive reference doses or 
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perhaps future regulatory thresholds in an effort to determine how best to utilize food 
allergen threshold data for food allergen risk assessment.  
Where possible, populations (study population, geographic region, age, gender, 
challenge material) were analyzed non-parametrically using the Generalized Log-Rank 
Test for interval censored data (37, 38) through the ICSTEST macro (SAS v9.2) (39, 40) 
to determine if the populations were significantly different. Additionally, the same ICSA 
data were analyzed after parametric distribution fitting by a second method comparing 
non-overlapping 84% confidence intervals of modeled distributions as a measure of 
significance (41). Briefly, 84% confidence intervals of large-sample datasets from the 
same population have a probability of overlap of 0.95, where 95% confidence intervals 
have a probability of overlap of 0.995 and are overly conservative. Therefore, 84% 
confidence intervals that do not overlap are significantly different at α = 0.05. 
Methods to improve clinical food challenges 
Ideal number of subjects in a study 
 Subjects were randomly selected 1000 times in groups of 10, 20, 30, 50, 100, and 
200 from the known peanut threshold database of 450 individuals (27) and analyzed 
using the LIFEREG procedure. Generated ICSA dose distributions were analyzed using 
the Generalized Log-Rank Test for interval censored data and by comparing non-
overlapping 84% confidence intervals of modeled log-normal distributions as a measure 
of significance.  
Food challenge dose scheme comparisons 
Clinical literature was scanned for commonly used food challenge dosing 
schemes. Representative clinical dose schemes were created for a simulation comparing 
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individual schemes to the overall known allergen population thresholds. The population 
thresholds for egg, peanut, and soy flour were used as model allergens due to their 
respective shifts in population sensitivity. Individual allergen thresholds were generated 
for 30 or 50 subjects based on the parameters of the egg, peanut, or soy flour threshold 
curves. Generated thresholds were fit to a selected dose scheme’s respective NOAEL and 
LOAEL values and analyzed using the LIFEREG procedure. Again, Generated ICSA 
dose distributions were analyzed in nonparametric fashion using the Generalized Log-
Rank Test for interval censored data and by comparing non-overlapping 84% confidence 
intervals as a measure of significance.  
3. Results and Discussion 
Population thresholds 
Minimal eliciting doses were found for 13 priority allergens and over 1800 
individuals from published clinical literature or unpublished clinical data. Published and 
unpublished clinical threshold data are summarized in Tables 2-14. Peanut, milk, egg, 
and hazelnut have substantially more data available than the other allergens: soybean, 
wheat, cashew, mustard, lupin, sesame seed, shrimp, celery and fish. Modeling could not 
be done for celery and fish due to an insufficient number of subjects in the datasets. No 
threshold data were found for molluscan shellfish or for the priority tree nuts other than 
hazelnut and cashew (children only).  
Peanut 
Individual peanut thresholds were obtained for 750 subjects including 489 
individuals from published studies and another 261 subjects from unpublished clinical 
records (Table 2). A clinical trial from Peeters et al. (42) was conducted at a Dutch clinic 
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and data were included in the previous analysis by Taylor et al. (28). However, the clinic 
was used to gather subsequent unpublished data, and it was impossible to distinguish 
between the Peeters et al. (42) subjects and unpublished individuals. Therefore the 
Peeters’ subjects were removed from the published dataset to avoid duplication. The 
peanut dataset includes 584 children, 99 adults, and 67 individuals of undetermined age 
(impossible to discern from publication). Of the 750 subjects, 30 were left-censored and 
132 were right-censored. The peanut dataset is the strongest of the 11 available allergen 
datasets due to its number of observations, distribution of thresholds across the dosing 
spectrum, and acquisition of data from multiple clinical centers. Estimates obtained for 
both discrete and cumulative doses were considered because they matched closely (data 
not shown). All three statistical models fit the cumulative data well. The Weibull model 
provided the most conservative ED estimates but the Weibull model deviated from the 
actual data and over-estimated the population sensitivity at the lower doses in the 
distribution. Therefore, in the case of peanut, the log-normal and log-logistic distributions 
should be used in reference dose determinations (Figure 1A). Within each statistical 
distribution, 95% confidence intervals of the ED01, ED05, and ED10 do not overlap, 
illustrating the quality of data in the peanut dataset (Figure 1B). Sufficient threshold data 
exist for peanut to use the ED01 value from the population threshold to determine a 
suitable reference dose that can be used for future food allergen risk assessments.  
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Figure 1. (A) Log-logistic, log-normal, and Weibull probability distribution models of individual 
peanut thresholds (expressed as mg peanut protein). (B) Log-logistic, log-normal, and Weibull ED 
estimates and corresponding 95% confidence intervals (expressed as mg peanut protein) from the 
peanut probability distribution models. The most sensitive individual in the dataset and the VITAL 
reference dose are marked and labeled. 
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Previously, 185 peanut-allergic individual thresholds were gleaned from clinical 
literature by Taylor et al. (28). An additional 286 thresholds from a single French medical 
center in Nancy were added to the dataset in 2010 (27) with no significant differences 
observed in the ED05 and ED10 by comparison to the previously published dataset. The 
threshold curves for peanut are stable as demonstrated when Taylor et al. (58) added 300 
peanut-allergic individuals to the threshold distribution reported by Taylor et al. (27). No 
significant differences were found in the ED01, ED05, and ED10 values of distributions 
based on 750 peanut-allergic individuals versus distributions based on 450 individuals 
(Figure 2).  
 
Figure 2. Log-normal probability distribution models of peanut from 3 dataset expansions points 
(expressed as mg peanut protein). First, 185 individual thresholds were gleaned from clinical 
literature by Taylor et al. (28). An additional 286 thresholds from a single French medical center 
were added to the dataset in 2010 (27). Most recently, 300 thresholds were gleaned from newly 
published clinical literature and medical centers in the Netherlands and combined with the previous 
datasets (58).  
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Milk 
Individual milk thresholds were obtained for 351 individuals including 222 
individuals from published studies and another 129 subjects from unpublished clinical 
records (Table 3). The milk dataset includes 323 children, 25 adults and 3 individuals of 
undetermined age. Due to the natural history of milk allergy (approximately 85% of 
children outgrow their milk allergen by school age (59)), milk-allergic adults are rarely 
encountered. Of the 351 subjects, 59 were left-censored and 19 were right-censored. Like 
peanut, the milk dataset was considered to be representative due to a large allergic 
population, a good distribution of thresholds, and data from multiple clinical centers. One 
weakness in the milk dataset is the limited number of milk-allergic adults, but the data 
likely reflect the true age distribution of the milk allergic population. Estimates obtained 
for both discrete and cumulative doses were considered because they matched closely 
(data not shown). All three statistical models fit the cumulative data reasonably well but 
again the Weibull model was not the best fit at the lower doses in the distribution which 
is important for establishment of reference doses or potential regulatory threshold values 
that protect the vast majority of food allergic individuals (Figure 3A). Therefore, in the 
case of milk, the log-normal and log-logistic distributions should be used to determine 
population thresholds. Within each statistical distribution, 95% confidence intervals of 
the ED01, ED05, and ED10 do not overlap, in large part due to the quality of data and 
large number of subjects in the milk dataset (Figure 3B). Sufficient threshold data exist 
for milk to use the ED01 value from the population threshold to determine a suitable 
reference dose that can be used for future food allergen risk assessments.  
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Figure 3. (A) Log-logistic, log-normal, and Weibull probability distribution models of individual milk 
thresholds (expressed as mg milk protein). (B) Log-logistic, log-normal, and Weibull ED estimates 
and corresponding 95% confidence intervals (expressed as mg milk protein) from the milk 
probability distribution models. The most sensitive individual in the dataset and the VITAL 
reference dose are marked and labeled.  
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Egg 
Individual egg thresholds were obtained for 206 individuals including 110 
individuals from published studies and another 96 subjects from unpublished clinical 
records (Table 4). The egg dataset includes 174 children, 12 adults, and 20 individuals of 
undetermined age. Again, egg-allergic adults were less prevalent due to the natural 
history of egg allergy. Of the 206 subjects, 24 were left-censored and 33 were right-
censored. The egg dataset was considered to be representative due to the large number of 
subjects, data from multiple regions, and a good data distribution across the dosing 
scheme. However, the absence of sufficient data on individual egg thresholds among 
adults is considered as a small data gap. Estimates obtained for both discrete and 
cumulative doses were considered (data not shown) and all three statistical models fit the 
cumulative data reasonably well (Figure 4A). The Weibull model provided the best fit 
and the most conservative estimates. Therefore, in the case of egg, all three distributions 
should be considered with an emphasis on the Weibull distribution when developing a 
reference dose value for use in food allergen risk assessment. For egg, 206 subjects are 
perhaps marginally sufficient for use of the ED01 for establishment of a reference dose 
value. The uncertainty in the ED estimates is slightly higher as demonstrated by the 
overlap of the 95% confidence intervals of the ED05 and ED10 estimates for all 
distributions (Figure 4B). It is recommended that the ED01 and 95% lower confidence 
interval of the ED05 values be used in the determination of suitable reference dose values 
for food allergen risk assessment purposes.  
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Figure 4. (A) Log-logistic, log-normal, and Weibull probability distribution models of individual egg 
thresholds (expressed as mg egg protein). (B) Log-logistic, log-normal, and Weibull ED estimates and 
corresponding 95% confidence intervals (expressed as mg egg protein) from the egg probability 
distribution models. The most sensitive individual in the dataset and the VITAL reference dose are 
marked and labeled.  
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Hazelnut 
Individual hazelnut thresholds were obtained for 202 subjects although only 29 
individuals were from published studies while the other 173 subjects were from 
unpublished clinical records (Table 5). The hazelnut dataset includes 61 children and 141 
adults. Of the 202 subjects, 4 were left-censored and 67 were right-censored. Overall, the 
hazelnut dataset was considered to be good, based on the large number of subjects, good 
distribution of data across the dosing scheme, and multiple clinics providing data. 
However, the overwhelming majority of data was from the Netherlands and the regional 
bias could be considered a slight weakness in the dataset. Discrete and cumulative doses 
were considered because they matched closely (data not shown) and all three 
distributions should be considered when developing a reference dose value for use in 
food allergen risk assessment (Figure 5A). For hazelnut, 202 subjects are perhaps 
marginally sufficient for use of the ED01 as a reference dose for food allergen risk 
assessment. The uncertainty in the ED estimates is slightly higher than for peanut, milk, 
and egg, as demonstrated by the overlap of the 95% confidence intervals of the ED05 and 
ED10 estimates for all distributions (Figure 5B). It is recommended that the ED01 and 
95% lower confidence interval of the ED05 values be used suitable reference dose values 
for food allergen risk assessment purposes. 
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Figure 5. (A) Log-logistic, log-normal, and Weibull probability distribution models of individual 
hazelnut thresholds (expressed as mg hazelnut protein). (B) Log-logistic, log-normal, and Weibull ED 
estimates and corresponding 95% confidence intervals (expressed as mg hazelnut protein) from the 
hazelnut probability distribution models. The most sensitive individual in the dataset and the VITAL 
reference dose are marked and labeled.  
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Soy flour 
Individual soybean thresholds were obtained for 80 subjects including 43 
individuals from published studies and 37 subjects from unpublished clinical records 
(Table 6). The soybean dataset includes 33 children, 25 adults, and 22 individuals of 
undetermined age. Of the 80 subjects, 6 were left-censored and 28 were right-censored. 
The soybean dataset was collected from multiple centers but several issues exist with the 
soybean dataset. First, additional subjects of all ages would increase the confidence of the 
eliciting dose estimates. Second, the selection of soy-allergic subjects coupled with a 
specific challenge material may have considerable influence on the estimates. In general, 
subjects with soy flour challenges have reasonably high individual soybean thresholds 
whereas subjects with allergic histories to a specific soy milk/protein isolate appear to 
have much lower individual soybean thresholds. Clearly more clinical research is needed 
to resolve this issue. However, recent unpublished clinical observations from a Dutch 
clinic indicate that many of these soy milk-allergic patients can tolerate soy flour and 
confirm the previous observations that reactivity is associated with certain specific types 
of soy products. These individuals could be part of a unique, but not unimportant 
subpopulation that needs to be further studied. Regulators must consider the form(s) of 
the allergenic ingredient of primary concern, presumably those most likely to fall under 
the labeling requirements of any future regulatory thresholds that may be established. 
With regard to cross-contact in manufacturing situations, the most likely forms of soy 
used would be soy flours, concentrates, and isolates. With that in mind, it is 
recommended that only individuals allergic to soy flour be used in the establishment of 
reference doses used for risk assessment purposes. The proposed reference doses would 
119 
 
prove protective for these soy milk-allergic individuals in relation to some forms of soy 
and they could focus on avoiding soy milk. 
Estimates obtained for both discrete and cumulative doses were considered (data 
not shown) and all three statistical models fit the cumulative data reasonably well (Figure 
6A). However, all models had large confidence intervals in which the 95% confidence 
intervals of the ED05 and ED10 overlapped (Figure 6B). Therefore, in the case of soy 
flour, all three distributions should be considered when establishing a reference dose 
value for risk assessment purposes. It is recommended that the 95% lower confidence 
interval of the ED05 values be used in the determination of reference doses as an 
insufficient number of soy flour allergic individuals were found to determine a 
statistically sound ED01 estimate. 
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Figure 6. (A) Log-logistic, log-normal, and Weibull probability distribution models of individual soy 
flour thresholds (expressed as mg soy flour protein). (B) Log-logistic, log-normal, and Weibull ED 
estimates and corresponding 95% confidence intervals (expressed as mg soy flour protein) from the 
soy flour probability distribution models. The most sensitive individual in the dataset and the VITAL 
reference dose are marked and labeled.   
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Wheat 
Individual wheat thresholds were obtained for 40 subjects (who had confirmed 
IgE-mediated allergic reactions to wheat) including 37 individuals from published studies 
and 3 subjects from unpublished clinical records (Table 7). The wheat dataset includes 28 
children and 12 adults. Of the 40 subjects, 5 were left-censored and 1 was right-censored. 
Overall, the wheat dataset benefited from data collected at multiple centers, but additional 
data on individual thresholds would strengthen the statistical analysis. Estimates obtained 
for both discrete and cumulative doses were considered (data not shown) and all three 
statistical models fit the cumulative data with little difference (Figure 7A). Due to the 
limited number of wheat-allergic subjects, all models had large confidence intervals in 
which the 95% confidence intervals of the ED05 and ED10 overlapped (Figure 7B). The 
95% lower confidence interval of the ED05 from all 3 models should be considered when 
determining a reference dose value for use in food allergy risk assessment. The Codex 
Alimentarius guideline for gluten-free is <20 ppm gluten protein and wheat-allergic 
consumers would be largely protected by gluten-free foods produced to the  
Codex specifications. 
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Figure 7. (A) Log-logistic, log-normal, and Weibull probability distribution models of individual 
wheat thresholds (expressed as mg wheat protein). (B) Log-logistic, log-normal, and Weibull ED 
estimates and corresponding 95% confidence intervals (expressed as mg wheat protein) from the 
wheat probability distribution models. The most sensitive individual in the dataset and the VITAL 
reference dose are marked and labeled.  
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Cashew 
Individual cashew thresholds were obtained for 31 subjects; all children from 
unpublished clinical records at a single Dutch clinic (Table 8). One subject was left-
censored and 16 were right-censored. Overall, the cashew dataset was considered to be 
marginally sufficient for establishment of a reference dose and additional data on adults 
and children from multiple clinical centers would strengthen the statistical analysis. 
Similar estimates were obtained for both discrete and cumulative doses (data not shown) 
and fits for all three distributions should be considered when establishing a reference 
dose value for use in food allergy risk assessment (Figure 8A). For cashew, the number 
of subjects is marginal and leads to wide 95% confidence intervals with overlap between 
the ED01, ED05, and ED10 (Figure 8B). The lower 95% confidence interval of the ED05 
is appropriate as the basis of a provisional reference dose for cashew. Another approach 
that could be considered for the purposes of risk assessment for cashew (and other tree 
nuts where threshold data is lacking) is to use the established reference dose value for 
hazelnut until more threshold data is available to strengthen the statistical analysis. This 
approach would assume that all other tree nuts would result in similar reactivity as 
hazelnut. Currently there are no published or anecdotal clinical reports to suggest that 
other tree nuts would be more potent (or severe) than hazelnut.  
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Figure 8. (A) Log-logistic, log-normal, and Weibull probability distribution models of individual 
cashew thresholds (expressed as mg cashew protein). (B) Log-logistic, log-normal, and Weibull ED 
estimates and corresponding 95% confidence intervals (expressed as mg cashew protein) from the 
cashew probability distribution models. The most sensitive individual in the dataset and the VITAL 
reference dose are marked and labeled.  
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Mustard 
Mustard is on the priority list of allergenic foods in the EU and Canada and 33 
individual mustard thresholds were obtained from published studies (Table 9). The 
mustard dataset includes 9 children, 9 adults, and 15 individuals of undetermined age. Of 
the 33 subjects, 2 were left-censored and 10 were right-censored. Similar estimates were 
obtained for both discrete and cumulative doses (data not shown). All three distributions 
should be considered when establishing a reference dose value for mustard (Figure 9A), 
although the number of subjects is adequate only for determining the lower 95% 
confidence interval of the ED05, not an ED01. The mustard dataset has data from 
multiple clinical centers but could benefit from additional data on individual thresholds to 
tighten the currently overlapping ED confidence intervals (Figure 9B). 
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Figure 9. (A) Log-logistic, log-normal, and Weibull probability distribution models of individual 
mustard thresholds (expressed as mg mustard protein). (B) Log-logistic, log-normal, and Weibull ED 
estimates and corresponding 95% confidence intervals (expressed as mg mustard protein) from the 
mustard probability distribution models. The most sensitive individual in the dataset and the VITAL 
reference dose are marked and labeled.  
C
u
m
u
la
ti
v
e
 P
e
rc
e
n
ta
g
e
 o
f 
R
e
s
p
o
n
s
e
s
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Cumulative Dose of Protein (mg)
1.00E-03 1.00E-02 1.00E-01 1.00E+00 1.00E+01 1.00E+02 1.00E+03 1.00E+04 1.00E+05 1.00E+06
Log-Normal Log-Logistic Weibull
A
Model ED01 ED05 ED10 ED50
Log-logistic 0.055 0.46 1.2 20.2
Log-normal 0.097 0.45 1.0 18.1
Weibull 0.022 0.32 1.0 21.7
*All ED values in mg protein
B
131 
 
Lupin 
Lupin is on the priority list of allergenic foods in the EU and thresholds were 
obtained for 24 subjects; 9 individuals from published studies and 15 subjects from 
unpublished clinical records (Table 10). The lupin dataset includes 9 children and 15 
adults. Of the 24 subjects, 2 were left-censored and 7 were right-censored. Overall, the 
lupin dataset has data from multiple centers, but is heavily weighted towards a single 
clinic. Additional data on individual thresholds would strengthen the lupin dataset. 
Discrete and cumulative doses were considered because they matched closely (data not 
shown). There are a limited number of individual clinical thresholds that are 
representative of the more sensitive population of lupin allergic individuals (lower end of 
the population curve) so a data gap for thresholds at lower challenge doses currently 
exists. The Weibull distribution was the most conservative, however, due to the lack of 
actual low dose data the Weibull distribution may have provided an over estimation of 
the overall sensitivity of the lupin allergic population (Figure 10A). Therefore, the 
emphasis should be placed primarily on the log-normal and log-logistic distributions 
when establishing a reference dose for lupin. Again, there are overlapping confidence 
intervals at the ED01, ED05, and ED10 (Figure 10B) and insufficient subjects to base a 
threshold on the ED01. The lower 95% confidence interval of the ED05 should be 
considered for establishing a reference dose for lupin that can be utilized for food 
allergen risk assessment purposes. 
 
  
132 
 
 
T
a
b
le
 1
0
. 
L
u
p
in
 T
h
re
sh
o
ld
 D
a
ta
 G
le
a
n
ed
 F
ro
m
 P
u
b
li
sh
ed
 a
n
d
 U
n
p
u
b
li
sh
ed
 D
B
P
C
F
C
 C
li
n
ic
a
l 
R
ec
o
rd
s.
 
A
ll
er
g
en
 
S
tu
d
y
 
T
o
ta
l 
N
o
. 
w
it
h
 
O
b
je
ct
iv
e 
S
y
m
p
to
m
s 
R
ig
h
t 
C
en
so
r
ed
 
L
ef
t 
C
en
so
r
ed
 
L
o
w
es
t 
M
E
D
†
 (
m
g
 
p
ro
te
in
) 
H
ig
h
es
t 
M
E
D
 (
m
g
 
p
ro
te
in
) 
P
o
p
u
la
ti
o
n
 
L
u
p
in
 
M
o
n
er
et
-V
au
tr
in
 e
t 
al
. 
(9
0
) 
5
 
0
 
0
 
9
5
.9
 
3
6
2
 
C
h
il
d
re
n
 
 
F
io
cc
h
i 
et
 a
l.
 (
9
1
) 
2
 
0
 
1
 
5
0
 
3
1
5
0
 
C
h
il
d
re
n
 
 
S
h
aw
 e
t 
al
. 
(3
4
) 
2
 
0
 
0
 
1
1
1
 
1
1
1
1
 
C
h
il
d
re
n
 
 
U
n
p
u
b
li
sh
ed
 D
at
a 
*
 
1
5
 
7
 
1
 
3
6
.2
 
1
5
9
3
 
A
d
u
lt
s 
  
T
o
ta
l 
2
4
 
7
 
2
 
3
6
.2
 
3
1
5
0
 
  
†
 M
E
D
, 
M
in
im
al
 E
li
ci
ti
n
g
 D
o
se
 f
o
r 
o
b
je
ct
iv
e 
sy
m
p
to
m
s 
in
 f
o
o
d
 a
ll
er
g
ic
 i
n
d
iv
id
u
al
s 
*
 U
n
iv
er
si
ty
 M
ed
ic
al
 C
en
te
r 
U
tr
ec
h
t 
 
133 
 
 
 
Figure 10. (A) Log-logistic, log-normal, and Weibull probability distribution models of individual 
lupin thresholds (expressed as mg lupin protein). (B) Log-logistic, log-normal, and Weibull ED 
estimates and corresponding 95% confidence intervals (expressed as mg lupin protein) from the 
lupin probability distribution models. The most sensitive individual in the dataset and the VITAL 
reference dose are marked and labeled.  
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Sesame seed 
Individual sesame seed thresholds were obtained for 21 subjects; all were from 
published studies (Table 11). The sesame seed dataset includes 6 children, 13 adults, and 
2 individuals of undetermined age. The sesame seed dataset was considered as marginally 
sufficient with most of the data being interval censored, with 2 left- and 1 right-censored 
individuals. However, all clinical threshold data are from multiple studies at one French 
allergy center and the addition of individuals from other clinics would strengthen the 
statistical analysis. Discrete and cumulative distributions were similar (data not shown) 
and all three models fit the cumulative data well (Figure 11A). In establishment of a 
reference dose for risk assessment purposes, all three distributions should be considered 
with a focus on the Weibull model for conservative measures. Again, there are 
overlapping confidence intervals at the ED01, ED05, and ED10 (Figure 11B) and 
insufficient subjects to base a threshold on the ED01. The lower 95% confidence interval 
of the ED05 should be considered for establishment of a reference dose for use in food 
allergen risk assessment. 
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Figure 11. (A) Log-logistic, log-normal, and Weibull probability distribution models of individual 
sesame seed thresholds (expressed as mg sesame protein). (B) Log-logistic, log-normal, and Weibull 
ED estimates and corresponding 95% confidence intervals (expressed as mg sesame protein) from 
the sesame probability distribution models. The most sensitive individual in the dataset and the 
VITAL reference dose are marked and labeled.  
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Shrimp 
The global priority lists of allergenic foods contains crustacean, but individual 
threshold data exist only for shrimp. A number of shrimp species exist and it is not 
known if species-specific differences occur for thresholds. Individual shrimp thresholds 
were obtained for 48 adults including 25 from published studies and 23 individuals from 
an unpublished shrimp threshold study (Table 12). Additionally, 54% of individuals were 
right-censored; none were left-censored. The shrimp dataset was considered as 
marginally sufficient but could benefit from additional interval-censored data for children 
and adults. Additionally, a major data gap exists as to whether a threshold dose for 
shrimp would extend to other crustacea such as crab and lobster. Both discrete and 
cumulative doses were similar (data not shown) and all three distributions had similar fits 
(Figure 12A). Again, there are overlapping confidence intervals at the ED01, ED05, and 
ED10 (Figure 12B) and insufficient subjects to base a threshold on the ED01. The lower 
95% confidence interval of the ED05 should be considered for establishment of a 
reference dose of use in food allergen risk assessment.  
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Figure 12. (A) Log-logistic, log-normal, and Weibull probability distribution models of individual 
shrimp thresholds (expressed as mg shrimp protein). (B) Log-logistic, log-normal, and Weibull ED 
estimates and corresponding 95% confidence intervals (expressed as mg shrimp protein) from the 
shrimp probability distribution models. The most sensitive individual in the dataset and the VITAL 
reference dose are marked and labeled.  
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Celery & Fish 
Celery is on the priority list of allergenic foods in the EU and thresholds were 
obtained for 39 subjects, including 12 individuals from published studies and 27 subjects 
from unpublished clinical records (Table 13). The celery dataset includes 27 adults and 
12 individuals of undetermined age. Of the 27 subjects, 15 were left-censored and 4 were 
right-censored. Due to the high number of left-censored individuals, no actual threshold 
data were collected below what would be the ED30. In its current state, the celery dataset 
is insufficient to allow an estimate of ED values that could be utilized for establishment 
of a statistically sound reference dose estimate. Cleary, the dataset will benefit from the 
addition of more celery-allergic individuals. 
Fish is listed as a generic class of allergens on most global allergen lists. Again, 
species-related differences might occur in threshold estimates, but it is not known to what 
extent that they influence them. Individual fish thresholds were obtained for 19 subjects 
including 15 individuals from published studies and 4 subjects from unpublished clinical 
records (Table 14). The fish dataset includes 18 adults and 1 child challenged to 1 of 6 
different species of fish. Of the 19 subjects, 6 were left-censored and 2 were right-
censored and no individual threshold data exists from subjects below the predicted ED30. 
In its current state, the fish dataset is insufficient to allow an estimate of ED values that 
could be utilized for establishment of a statistically sound reference dose estimate. 
Clearly, the dataset will benefit from the addition of more fish-allergic children and 
adults. 
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Potency Comparison 
Dose distribution models for the 11 available allergens were compared for significant 
differences in potency between allergens (Figure 13A). Mustard and egg are the most 
potent allergens at the low end of the dose scheme, ED01 – ED10, while soy flour and 
shrimp are the least potent allergens. The eliciting dose for allergic reactions to three 
members of the legume family showed an decreasing potency for peanut > lupin > soy 
flour. Peanut and milk have comparable potencies across the entire dose scheme. 
Similarly, hazelnut and sesame seed, as well as lupin and cashew, form comparable 
potency pairs. Potency measures should be used together with measures of prevalence 
and severity to determine whether a food should be placed on a priority allergen list. As 
expected, peanut, milk, and egg are three of the most prevalent and potent food allergens. 
However, the contrasts between potency and prevalence estimates for mustard (high 
potency/low prevalence), soy (low potency/high prevalence), and shrimp (low 
potency/high prevalence) are striking.  Figure 13B focuses on the ED10 and 95% 
confidence interval estimates of each allergen to give a measure of confidence in potency 
estimates. The broad confidence intervals expressed on cashew, lupin, sesame seed, soy 
flour, and wheat are similar for estimates of the ED01, ED05, and ED50. Additional 
clinical data from all allergens would be valuable to increase the statistical confidence in 
the potency estimates. 
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Figure 13. (A) Log-logistic, log-normal, or Weibull probability distribution models of 11 individual 
allergens (expressed as mg protein). (B) ED10 estimates from log-logistic, log-normal, and Weibull 
probability distribution models and corresponding 95% confidence intervals (expressed as mg 
protein) for 10 food allergens. Shrimp is not displayed due to an axis skewing effect from its large 
ED10 estimate and subsequent 95% confidence intervals.  
A
B
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By age 
For all allergens, individual threshold data for children and adults were combined 
to provide sufficient data for population dose distribution modeling. For this approach to 
work, it must be assumed that the allergic population thresholds for children and adults 
do not differ. Where possible, children (less than 18 years of age) and adults were 
analyzed separately and compared for population differences. Sufficient data for children 
and adults are available for peanuts and hazelnuts only (Table 15). Other allergens such 
as cows' milk and eggs, were too skewed towards children as the vast majority of subjects 
often outgrow their allergies over time leaving a limited number of allergic adults 
available for potential threshold challenge trials (99).  
Peanut-allergic children and adults have comparable ED05 estimates of 1.7 mg 
and 2.3 mg of peanut protein, respectively (Figure 14A). However, populations of 
peanut-allergic adults and children were significantly different as determined by the 
Generalized Log-Rank Test. Examination of the ED05, ED10, and ED50 estimates and 
their respective confidence intervals revealed similar ED05 and ED10 estimates but a 
significantly different ED50 in the two populations, thus leading to a significant 
difference in the overall curves. However, the significant differences at the higher end of 
the curve are of minimal impact as further risk assessments are most interested in the 
lower ED estimates to protect the maximum number of allergic individuals. 
Hazelnut-allergic children and adults have slightly varied ED05 estimates at 1.2 
mg and 4.0 mg hazelnut protein, respectively (Figure 14B). However, populations of 
hazelnut-allergic adults and children were statistically similar as determined by the 
Generalized Log-Rank Test and ED confidence interval estimates. Based on the modest 
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differences between the curves, the combination of the children and adults for each 
respective allergen seems reasonable. In order to protect the most sensitive populations, 
data should continue to be collected on adults and children for all allergens in order to 
determine if differences do exist in the population thresholds.  
 
Table 15. Estimated eliciting doses (ED) for peanut protein and hazelnut protein as affected by age 
(children were categorized as less than 18 years of age). Significant differences in ED estimates are 
denoted with different uppercase superscript letters. 
 
 
  
ED05 ED10 # of Subjects
(95% CI) (95% CI) (Rt Cen, Lt Cen)
Peanut Adults (27, 43-45, 49-51, 57) 
b
2.3 (0.6, 9.1)
A
10.5 (3.6, 30.9)
A 99 (44, 1) Weibull
Peanut Children (27, 44, 45, 47, 51, 53-56) 
a,c
1.7 (1.2, 2.3)
A
4.0 (3.0, 5.2)
A 584 (79, 25) LogNormal
Hazelnut Adults (32) 
b,e
4.0 (1.9, 8.1)
A
10.0 (5.4, 18.5)
A 153 (57, 2) LogNormal
Hazelnut Children 
a,c
1.2 (0.3, 5.8)
A
5.0 (1.2, 17.3)
A 61 (15,2) Weibull
c -UMCG – University Medical Center Gronigen, The Netherlands
d - JBZ –Joroen Bosch Hospital, The Netherlands
e - Universitätsmedizin Berlin, Germany
mg protein
Allergen Region Distribution
a - WKZ –Wilhelmina Kinderziekenhuis Children’s Hospital of the University Medical Center Utrecht , The Netherlands
b - UMCU University Medical Center Utrecht, The Netherlands
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Figure 14. Probability distribution models for individual thresholds (expressed as mg protein) based 
on the age of the allergic individual at challenge (children were categorized as less than 18 years of 
age): (A) Peanut, (B) Hazelnut. 
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By region 
For all allergens, individual thresholds from different geographical regions were 
combined to provide sufficient data for modeling. For this approach to work, it must be 
assumed that the allergic population thresholds do not differ by geographic region. Where 
possible, regions were analyzed separately and compared for population differences. The 
available data needed for a statistically sound analysis limited comparisons by region to 
the peanut and milk allergens (Table 16).  
Populations of peanut-allergic individuals from France, the Netherlands, the U.K., 
and the U.S. were significantly different as determined by the Generalized Log-Rank 
Test. Examination of the ED05, ED10, and ED50 estimates and their respective 84% 
confidence intervals revealed similar ED05 and ED10 estimates for France and the U.S. 
and the U.S. and the Netherlands, but significantly ED05 and ED10 estimates were found 
from the U.K. However, a patient selection bias towards sensitive patients may exist in 
the U.K. peanut dataset, as the majority of subjects came from threshold and 
immunotherapy studies in which a more sensitive subpopulation of peanut-allergic 
individuals may be sought for the clinical studies. Significant differences at the higher 
end of the curve are of minimal impact as further risk assessments are most interested in 
the lower ED estimates to protect the maximum number of allergic individuals. Inclusion 
of the more sensitive U.K. population in the overall dataset ensures the maximum number 
of peanut-allergic individuals are protected in subsequent risk assessments. 
Populations of milk-allergic individuals from the Netherlands, Australia, and Italy 
were significantly different as determined by the Generalized Log-Rank Test. 
Examination of the ED05, ED10, and ED50 estimates and their respective 84% 
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confidence intervals revealed similar ED05 and ED10 estimates for the Netherlands and 
Italy (near 2.0 mg milk protein) but significantly higher estimates for Australia (69.5 mg 
milk protein) (Figure 15B). The Australian data come from one study (69) where the 
initial challenges began at 66 - 300 mg of milk protein. It is important to use data from 
very low dose challenge studies in order to obtain the best estimates of ED values. 
Multiple factors including patient selection bias and clinical protocol differences can be 
mitigated by combining data from various countries and multiple clinics, thus allowing 
the best ED value to be selected.  
 
Table 16. Estimated eliciting doses (ED) for peanut and milk as affected by the geographic region 
where the clinical studies were conducted. Significant differences in ED estimates are denoted with 
different uppercase superscript letters. 
 
ED05 ED10 # of Subjects
(95% CI) (95% CI) (Rt Cen, Lt Cen)
Peanut France (27) 2.0 (1.4, 2.9)
A
4.0 (2.9, 5.4)
A 283 (10, 7) LogNormal
Peanut Netherlands (45, 47)
a,b,c
4.0 (2.5, 6.6)
B
10.5 (6.8, 16.1)
B 309 (103, 6) LogNormal
Peanut UK (44, 46, 51, 53, 54) 0.2 (0.09, 0.6)
C
0.6 (0.3, 1.4)
C 86 (10, 13) LogNormal
Peanut USA (43, 48-50) 4.0 (0.6, 27.7)
A,B
16.3 (3.5, 75.4)
A,B 41 (8, 2) Weibull
Milk Australia (69) 69.5 (38.1, 126)
A
108 (64.2, 182)
A 53 (0, 11) LogNormal
Milk Italy (63, 64, 66, 70) 2.0 (1.1, 3.6)
B
3.5 (2.1, 5.9)
B 91 (0, 14) LogNormal
Milk Netherlands (68, 72)
b,c,d
1.9 (0.7, 5.4)
B
8.3 (3.6, 19.1)
B 148 (19, 14) Weibull
c -UMCG – University Medical Center Gronigen, The Netherlands
d - JBZ –Joroen Bosch Hospital, The Netherlands
a - WKZ –Wilhelmina Kinderziekenhuis Children’s Hospital of the University Medical Center Utrecht , The Netherlands
b - UMCU University Medical Center Utrecht, The Netherlands
mg Protein
Allergen Geographic Region Distribution
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Figure 15. Probability distribution models for individual thresholds (expressed as mg protein) based 
on the geographic region during challenge: (A) Peanut, (B) Milk.  
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By challenge material 
For all allergens, individuals challenged with different dosing materials were 
combined to provide sufficient data for modeling. For this approach to work, it must be 
assumed that the allergic population thresholds do not differ by challenge material. 
However, recent studies show some egg-allergic children are more tolerant of baked egg 
than of raw egg (2, 100, 101) and other allergens could exhibit similar differences. Where 
possible, food challenge materials were analyzed separately and compared for population 
differences. The available threshold data limited comparisons by challenge materials to 
the peanut, milk, and egg allergens (Table 17).  
Populations of peanut-allergic individuals challenged with pulverized peanut and 
peanut flour were significantly different as determined by the Generalized Log-Rank 
Test. Examination of the ED05, ED10, and ED50 estimates and their respective 
confidence intervals revealed similar ED05 and ED10 estimates but a significantly 
different ED50 in the two populations (Figure 16A). While statistically significant, 
differences at the higher end of the curves are of minimal impact to risk assessments 
concerned with the most sensitive individuals in the population. Populations of milk-
allergic individuals challenged with liquid milk and non-fat dry milk were similar as 
determined by the Generalized Log-Rank Test and ED confidence interval estimates 
(Figure 16B). Populations of egg-allergic individuals challenged with raw and cooked 
whole egg were similar as determined by the Generalized Log-Rank Test and ED 
confidence interval estimates.  However, raw egg white was significantly lower than both 
raw and cooked whole egg as determined by the Generalized Log-Rank Test and ED 
confidence interval estimates (Figure 16C). Since the ED value is based upon egg 
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protein, egg white would contain a higher proportion of egg allergens by comparison to 
egg yolk or whole egg which likely explains the difference. While some egg-allergic 
patients are known to tolerate baked egg, our study did not find cooked or raw egg to be 
significantly different from each other. However, of the 88 egg-allergic patients 
challenged with cooked egg in our study, 38 were challenged with baked egg and the 
others with boiled or fried eggs. More research is needed to study the differences between 
raw, boiled or fried, and baked eggs. Additionally, raw eggs are not likely to be found in 
processed food products and any reference doses or regulatory threshold doses used for 
purposes of food allergen risk assessments for egg should consider industry standards for 
processing and the most likely form of egg to be present in cross-contact scenarios. This 
analysis also shows that normalization of data on protein basis is a reasonable approach. 
 
Table 17. Estimated eliciting doses (ED) for peanut, milk, and egg as affected by challenge dose 
material. Significant differences in ED estimates are denoted with different uppercase superscript 
letters.  
 
ED05 ED10 # of Subjects
(95% CI) (95% CI) (Rt Cen, Lt Cen)
Peanut Crushed Peanut (27, 43, 45, 55-57) 2.1 (1.5, 2.9)
A
4.3 (3.2, 5.8)
A 342 (30, 9) LogNormal
Peanut Peanut Flour (44, 47-51, 53, 54) 
a,b,c
1.4 (0.9, 2.2)
A
4.0 (2.6, 6.0)
A 408 (101, 21) LogNormal
Milk
Liquid Cow’s Milk (60-66, 69, 70, 73-
75) 
c,d 1.9 (1.1, 3.1)
A
4.6 (2.9, 7.1)
A 287 (13, 41) LogNormal
Milk Nonfat Dry Milk (67, 68, 71, 72) 2.7 (0.7, 10.4)
A
6.0 (1.9, 19.3)
A 49 (2, 17) LogNormal
Egg Cooked Whole Egg (73, 76, 80) 
b,c
4.9 (2.1, 11.5)
A
11.1 (5.3, 23.4)
A 88 (14, 13) LogNormal
Egg Raw Whole Egg (43, 60, 61, 76) 3.4 (0.6, 20.1)
A
8.6 (1.8, 41.3)
A 22 (0, 1) LogNormal
Egg Raw Egg White (62, 65) 0.2 (0.05, 0.6)
B
0.4 (0.1, 1.1)
B 35 (0, 4) LogNormal
b - UMCU University Medical Center Utrecht, The Netherlands
c -UMCG – University Medical Center Gronigen, The Netherlands
a - WKZ –Wilhelmina Kinderziekenhuis Children’s Hospital of the University Medical Center Utrecht , The Netherlands
Allergen Dose Material Distribution
mg Protein 
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Figure 16. Probability distribution models for individual thresholds (expressed as mg protein) based 
on the dose material given at challenge: (A) Peanut, (B) Milk, (C) Egg.  
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By study population 
For all allergens, individual thresholds from study patient populations were 
combined to provide sufficient data for modeling. For this approach to work, it must be 
assumed that the allergic population thresholds do not differ and no patient selection bias 
exists by study type. The quality of the resulting ED values is dependent upon the 
representativeness of the patient population. Where possible, study types (diagnostic, 
threshold, and immunotherapy) were analyzed separately and compared for population 
differences. The available threshold data limited comparisons by study type to the peanut 
and milk allergens (Table 18).  
Populations of peanut-allergic individuals from diagnostic, threshold, and 
immunotherapy trials were significantly different as determined by the Generalized Log-
Rank Test. Examination of the ED05, ED10, and ED50 estimates and their respective 
84% confidence intervals revealed similar ED05 and ED10 estimates for diagnostic and 
threshold challenges and for threshold and immunotherapy challenges. However, ED05 
and ED10 estimates for immunotherapy trials were significantly lower than those for 
diagnostic challenges (Figure 17A). This analysis indicates that a selection bias towards 
more sensitive peanut-allergic individuals for immunotherapy trials exists but a dramatic 
difference in the overall ED values was not observed. Populations of milk-allergic 
individuals from diagnostic and immunotherapy trials were significantly different as 
determined by the Generalized Log-Rank Test. Examination of the ED05, ED10, and 
ED50 estimates and their respective 84% confidence intervals revealed similar ED05 
estimates for diagnostic and immunotherapy challenges, but the difference between the 
ED10 levels of immunotherapy and diagnostic groups is more evident for milk (2.6 and 
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13.0 mg of milk protein) than it was for peanut (Figure 17B). This example shows 
inclusion of the immunotherapy subjects leads to a more conservative estimate of ED 
values for establishment of reference doses or regulatory thresholds and only serves to 
protect more milk-allergic individuals. 
 
Table 18. Estimated eliciting doses (ED) for peanut and milk as affected by study population. 
Significant differences in ED estimates are denoted with different uppercase superscript letters. 
 
ED05 ED10 # of Subjects
(95% CI) (95% CI) (Rt Cen, Lt Cen)
Peanut Diagnostic (27, 43, 54, 56) 
a,b,c
2.0 (1.5, 2.7)
A
4.6 (3.5, 6.1)
A 564 (82, 15) LogNormal
Peanut Threshold (44-47) 0.9 (0.3, 2.7)
A,B
3.0 (1.2, 7.6)
A,B 101 (41, 3) LogNormal
Peanut Immunotherapy (48-51, 53, 55, 57) 0.4 (0.1, 1.3)
B
1.2 (0.4, 3.4)
B 85 (8, 12) LogNormal
Milk Diagnostic (61, 68-74) 
b,c,d
3.6 (1.7, 7.5)
A
13.0 (7.2, 23.7)
A 232 (19, 32) Weibull
Milk Immunotherapy (60, 63-67) 1.3 (0.7, 2.6)
A
2.6 (1.5, 4.7)
B 113 (0, 24) LogNormal
a - WKZ –Wilhelmina Kinderziekenhuis Children’s Hospital of the University Medical Center Utrecht , The Netherlands
b - UMCU University Medical Center Utrecht, The Netherlands
c -UMCG – University Medical Center Gronigen, The Netherlands
d - JBZ –Joroen Bosch Hospital, The Netherlands
Allergen Type of Study Distribution
mg Protein
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Figure 17. Probability distribution models for individual thresholds (expressed as mg protein) based 
on the study population: (A) Peanut, (B) Milk.  
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By gender 
For all allergens, individual threshold data for males and females were combined 
to provide sufficient data for population dose distribution modeling. For this approach to 
work, it must be assumed that the allergic population thresholds for males and females do 
not differ. Where possible, males and females were analyzed separately and compared for 
population differences. Sufficient data for children and adults are available for peanuts 
(data not shown). Populations of peanut-allergic males and females were statistically 
similar as determined by the Generalized Log-Rank Test and ED confidence interval 
estimates. Based on the extreme similarity between the curves, the combination of the 
males and females for each respective allergen seems reasonable.  
Regulatory thresholds and uncertainty factors 
Switzerland and Japan have set regulatory limits as to the levels of undeclared 
food allergens in packaged foods but national, risk-based thresholds for food allergens 
have not been established. At the present time, there is no regulatory guidance for trace 
levels of allergens due to cross-contact which essentially establishes a zero threshold 
situation in which food industry is left with significant challenges to reach an 
unachievable level of allergenic residue. The Allergen Bureau of Australia developed the 
Voluntary Incidental Trace Allergen Labelling (VITAL) program in 2007 as a guide to 
limit advisory labeling relating to the unintended presence of allergens. Initially, VITAL 
established very conservative action levels that were expressed as concentrations (ppm 
protein from the allergenic source, mg/kg) in a 5 g serving. Recently, the VITAL 
program was updated with new, less conservative Reference Doses expressed as mg 
protein in an effort to limit advisory labeling to situations where a significant risk exists. 
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The Reference Doses were derived by an international expert panel which utilized 
quantitative risk assessment methods and the data presented previously in this chapter. 
For the most part, these data were not available at the time of establishment of the initial 
VITAL grid. Recent evidence demonstrates a lower proportion of severe reactions 
occurring at lower doses of egg, milk, wheat, or soy, but more research is needed to 
confirm these results (102). The expert panel agreed that where sufficient data were 
available, the ED01 based on objective (observable) reactions should form the basis of 
the reference dose and protect at least 99% of individuals allergic to the particular food. 
While the ED01 minimizes the probability of a severe reaction, the possibility cannot be 
excluded. When data were insufficient for ED01 estimation, the expert panel decided to 
use the lower 95% confidence interval of the ED05 which would likely protect 97 – 99% 
of the affected population. The choice of the 99% level leads to the optimal public health 
outcome in that the large majority of the allergic population is protected and the food 
industry has mg doses of residual allergenic protein that can be operationally achieved 
and also have a positive impact on the extent of, and compliance with advisory labeling. 
The expert panel derived Reference Doses for peanut, milk, egg, and hazelnut based on 
the ED01and the lower 95% confidence interval of the ED05 for soy flour, wheat, 
cashew, mustard, lupin, sesame seed, and shrimp (Table 19, top row).  
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Table 19. Comparison of potential methods for deriving a regulatory threshold for individual 
allergenic foods. Methods displayed include the safety assessment-based approach (lowest reactor), 
the benchmark approach (and accompanying uncertainty estimates), and the VITAL approach (a 
hybrid benchmark and probabilistic risk approach). All mg values are expressed in mg protein. 
 
Peanut Milk Egg Hazelnut Soy Flour
VITAL Numbers 0.2 mg protein  0.1 mg protein  0.03 mg protein  0.1 mg protein  1 mg protein VITAL Numbers
Based On
ED01 of LogNormal 
and LogLogistic 
distributions of adults 
and children, discrete 
and cumulative
ED01 of LogNormal 
and LogLogistic 
distributions of adults 
and children, discrete 
and cumulative
ED01 and 95% LCI of 
the ED05 values of the 
Weibull and other 
distributions  of 
adults and children, 
discrete and 
cumulative
ED01 and 95% LCI of 
the ED05 values of the 
LogLogistic and other 
distributions  of 
adults and children, 
discrete and 
cumulative
95% LCI of the ED05 
values of the 
LogNormal and other 
distributions  of 
adults and children, 
discrete and 
cumulative
Based On
Peanut Milk Egg Hazelnut Soy Flour
Benchmark
LogNormal 
Cumulative
LogNormal 
Cumulative
LogLogistic 
Cumulative
LogLogistic 
Cumulative
 LogLogistic Discrete Benchmark
ED01 0.28 mg  0.34 mg  0.022 mg  0.21 mg  0.27 mg ED01
U3 0.093 0.113 0.0073 0.07 0.09 U3
U5 0.056 0.068 0.0044 0.042 0.054 U5
U10 0.028 0.034 0.0022 0.021 0.027 U10
ED05 1.5  mg  1.9 mg  0.42 mg  2.5 mg  5.6 mg ED05
U3 0.5 0.63 0.14 0.83 1.87 U3
U5 0.3 0.38 0.084 0.5 1.12 U5
U10 0.15 0.19 0.042 0.25 0.56 U10
ED05 LC 1.1 mg  1.2 mg  0.18 mg  1.3 mg  1.0 mg ED05 LC
U3 0.37 0.4 0.06 0.43 0.3 U3
U5 0.22 0.24 0.036 0.26 0.2 U5
U10 0.11 0.12 0.018 0.13 0.1 U10
ED10 3.8 mg  4.8 mg  1.6 mg  7.9 mg  22.4 mg ED10
U3 1.27 1.6 0.53 2.63 7.47 U3
U5 0.76 0.96 0.32 1.58 4.48 U5
U10 0.38 0.48 0.16 0.79 2.24 U10
ED10 LC 3 mg  3.1 mg  0.79 mg  4.5 mg  5.6 mg ED10 LC
U3 1 1.03 0.263 1.5 1.87 U3
U5 0.6 0.62 0.158 0.9 1.12 U5
U10 0.3 0.31 0.079 0.45 0.56 U10
Peanut Milk Egg Hazelnut Soy Flour
Lowest Reactor Lowest Reactor
NOAEL 0.025 mg  . . 0.0017 mg  1.1 mg NOAEL
LOAEL 0.1 mg  0.2 mg  0.0138 mg  0.0187 mg  11.1 mg LOAEL
Based On NOAEL LOAEL LOAEL NOAEL NOAEL Based On
U10/100 10 100 100 10 10 U10/100
mg with U 0.0025 mg 0.002 mg 0.000138 mg 0.00017 mg  0.11 mg  mg with U
Peanut Milk Egg Hazelnut Soy Flour
ED10 → VITAL ED10 → VITAL
ED10
3.8 mg   (Log Normal 
Cumulative)
4.8 mg   (Log Normal 
Cumulative)
1.6 mg   (LogLogistic 
Cumulative)
7.9 mg   (LogLogistic 
Cumulative)
22.4 mg  (LogLogistic 
Discrete)
ED10
VITAL 0.2 mg  0.1 mg 0.03 mg  0.1 mg 1 mg VITAL
U Needed 19 48 53.3 79 22.4 U Needed
Peanut Milk Egg Hazelnut Soy Flour
ED10 → ED01 ED10 → ED01
ED10 3.8 mg  4.8 mg  1.6 mg  7.9 mg  22.4 mg ED10
ED01 0.28 mg  0.34 mg  0.022 mg  0.21 mg  0.27 mg ED01
U Needed 4 14 73 38 83 U Needed
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However, the lack of a standardized, scientific method for deriving the Reference 
Doses across all allergens is one criticism of the VITAL expert panel approach. Standard 
methods are described for deriving the dose distributions from interval censored data, but 
as there is no biological factor to discern between models, expert judgment was used 
when deciding between log-logistic, log-normal, and Weibull models that fit the actual 
clinical threshold data in similar fashion. For example, instead of selecting one model as 
Wheat Cashew Mustard Lupin Sesame Shrimp
VITAL Numbers 1 mg protein  2 mg protein  0.05 mg protein  4 mg protein  0.2 mg protein   10 mg protein  
Based On
95% LCI of the ED05 
values derived from 
all three distributions 
of adults and 
children, discrete and 
cumulative
95% LCI of the ED05 
values derived from 
all three distributions 
of children 
(provisional due to 
lack of adults), 
discrete and 
cumulative
95% lower confidence 
interval of the ED05 
values derived from 
all three distributions 
of adults and 
children, discrete and 
cumulative
95% LCI of the ED05 
values derived from 
the LogNormal and 
LogLogistic 
distributions of adults 
and children, discrete 
and cumulative
95% LCI of the ED05 
values derived from 
all three distributions 
of adults and 
children, discrete and 
cumulative
95% LCI of the ED05 
values derived from 
all three distributions 
of adults, discrete 
and cumulative
Wheat Cashew Mustard Lupin Sesame Shrimp
Benchmark
LogNormal 
Cumulative
Weibull Cumulative Weibull Cumulative
LogLogistic 
Cumulative
Weibull Cumulative
LogNormal 
Cumulative
ED01 1.1 mg  1.4 mg  0.022 mg  3.7 mg  0.1 mg   5.8 mg  
U3 0.37 0.47 0.0073 1.23 0.03 1.93
U5 0.22 0.28 0.0044 0.74 0.02 1.16
U10 0.11 0.14 0.0022 0.37 0.01 0.58
ED05 4.2 mg  8.9 mg  0.32 mg  16.1 mg  2.1 mg   73.6 mg  
U3 1.4 2.97 0.107 5.37 0.7 24.53
U5 0.84 1.78 0.064 3.22 0.42 14.72
U10 0.42 0.89 0.032 1.61 0.21 7.36
ED05 LC 1.4 mg  2.1 mg  0.052 mg  4.5 mg  0.18 mg   12.1 mg  
U3 0.47 0.7 0.0173 1.5 0.06 4.03
U5 0.28 0.42 0.0104 0.9 0.036 2.42
U10 0.14 0.21 0.0052 0.45 0.018 1.21
ED10 8.7 mg  20.6 mg  1 mg  31.3 mg  7.6 mg   284 mg  
U3 2.9 6.87 0.3 10.4 2.53 94.7
U5 1.74 4.12 0.2 6.26 1.52 56.8
U10 0.87 2.06 0.1 3.13 0.76 28.4
ED10 LC 3.4 mg  6.4 mg  0.24 mg  11 mg  1.1 mg   63.1 mg  
U3 1.13 2.13 0.08 3.7 0.37 21.03
U5 0.68 1.28 0.048 2.2 0.22 12.62
U10 0.34 0.64 0.024 1.1 0.11 6.31
Wheat Cashew Mustard Lupin Sesame Shrimp
Lowest Reactor
NOAEL . . . . . 0.253 mg  
LOAEL 2.6 mg  2.3 mg  0.2608 mg  36.2 mg  1.02 mg   2.53 mg  
Based On LOAEL LOAEL LOAEL LOAEL LOAEL NOAEL
U10/100 100 100 100 100 100 10
mg with U 0.026 mg  0.023 mg  0.002608 mg  0.362 mg  0.0102 mg   0.0253 mg  
Wheat Cashew Mustard Lupin Sesame Shrimp
ED10 → VITAL
ED10
8.7 mg   (LogNormal 
Cumulative)
20.6 mg   (Weibull 
Cumulative)
1 mg   (Weibull 
Cumulative)
31.3 mg   (LogLogistic 
Cumulative)
7.6 mg    (Weibull 
Cumulative)
284 mg   (LogNormal 
Cumulative)
VITAL 1 mg  2 mg  0.05 mg  4 mg  0.2 mg   10 mg
U Needed 8.7 10.3 20 7.825 38 28.4
Wheat Cashew Mustard Lupin Sesame Shrimp
ED10 → ED01
ED10 8.7 mg  20.6 mg  1 mg  31.3 mg  7.6 mg   284 mg  
ED01 1.1 mg  1.4 mg  0.022 mg  3.7 mg  0.1 mg   5.8 mg  
U Needed 8 15 41 8 84 49
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the best fit and basis for the reference dose, slight differences in the predicted ED values 
could lead to multiple models contributing to the final, averaged reference dose. It could 
be argued that a second panel might not reach the same conclusions. In an effort to 
standardize the selection of a reference dose, the other frameworks outlined by the US 
Food and Drug Administration (FDA) Threshold Working Group (analytical methods-
based, statutorily derived, safety assessment-based, and risk assessment-based) were 
investigated (21). The analytical methods and statutorily derived approaches are not 
applicable as they do not utilize individual food challenge data. The safety assessment-
based method determines a “safe” level using the No Observed Adverse Effect Level 
(NOAEL) from human challenge studies and applies an appropriate Uncertainty Factor 
(UF) applied to account for knowledge gaps. Typically, uncertainly factors of 10 are 
applied for differences in sensitivity between animals and human, for inter-individual 
variation among humans, and in cases where the LOAEL is used instead of the NOAEL. 
The animal-to-human UF is not relevant as all food challenge tests were done in humans. 
The most sensitive allergic individual is listed and proper UF are applied for all 11 
allergens with VITAL Reference Doses under the “Lowest Reactor” section (Table 19). 
The safety assessment approach does not consider the entire food allergic population or 
the probable health risk that would be predicted at these exposure levels. Results from 
this method of risk assessment are extremely conservative and in many cases, produce 
mg levels that would be below the limit of detection for current analytical methods for 
detection.  
The benchmark risk assessment-based approach has been used for chemical risks 
in foods and was the starting point for the VITAL expert panel’s decision making 
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process. The benchmark dose of the ED01, ED05, ED05 lower 95% confidence interval, 
ED10, and ED10 lower 95% confidence interval are presented in Table 19 with an 
accompanying UF of 3, 5, and 10. To complete this method, a statistical model must be 
chosen for each allergen by expert judgment, with consideration of simple statistical 
(AIC) and visual fits at the most sensitive end of the distributions. After UF application, 
the VITAL Reference Doses for peanut, milk, egg, and hazelnut (based on ED01) align 
closest with the UF of 5 applied to the lower 95% confidence interval of the ED05. All 
other Reference Doses (based on ED05 lower 95% confidence interval) aligned well with 
the UF of 5 applied to the lower 95% confidence interval of the ED10. However, not all 
allergen dose distribution curves have the same slope, as demonstrated by the UF needed 
to reach the VITAL reference dose from the predicted ED10. This point is further 
illustrated by the calculated UF needed to reach the ED01 from the predicted ED10 
(Table 19, bottom 2 sections). A standard UF based on a standard ED would be over 
conservative in some cases and overly risky in others. The decision on the optimal 
method to determine regulatory thresholds is not straightforward and although not an 
easy task, the resulting thresholds should be transparent and easily defensible. 
Methods to improve food challenges 
Importance of number of subjects in a study 
Subjects randomly selected from the previously published Taylor et al. (27) 
peanut threshold database of 450 individuals and generated ICSA dose distributions were 
analyzed using the Generalized Log-Rank Test for interval censored data (Table 20). The 
probability that a randomly selected population was significantly different than the 450 
population decreased as the number of random subjects increased. Similar results were 
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found when comparing the 84% confidence intervals of modeled log-normal distributions 
as an indicator of significant differences (Table 21). Both tests predict a less than 2% 
chance of 200 individuals being different than the known 450 peanut-allergic individuals. 
However, the collection of data from 200 well characterized allergic subjects would be 
quite difficult for some allergenic foods especially for single clinics. Individual clinics 
and DBPCFC studies do not have the time, money, or patient population to collect 200 
data points in rapid succession. If a clinic was able to challenge 30 individuals, it is 
predicted to have a 5 – 10% chance of finding significantly different results than the 
Taylor et al. (27) data. The two statistical tests do not mirror one another completely, as 
the 84% confidence interval test found a higher number of populations to be different 
when fewer subjects were selected. These differences should be investigated with 
additional studies. 
Table 20. Probability of the randomly selected subject population nonparametric distribution being 
significantly different than Taylor et al. (27) 450 dataset, alpha = 0.05.  
No. of random 
subjects 
 Generalized Log-Rank Test I 
(Zhao & Sun (38)) 
 Generalized Log-Rank Test II 
(Sun, Zhao & Zhao (37)) 
10 4.3% 4.2% 
20 3.2% 3.6% 
30 4.6% 4.5% 
50 3.4% 3.7% 
100 2.2% 2.3% 
200 1.6% 1.8% 
 
Table 21. Chance of the randomly selected subject log-normal distribution being significantly 
different than Taylor et al. (27) 450 dataset at selected ED values, 84% CI used (alpha = 0.05).  
No. of random subjects ED01 ED05 ED10 ED50 
10 16.2% 16.3% 16.5% 13.9% 
20 14.8% 14.4% 13.8% 10.4% 
30 10.3% 10.4% 10.0% 9.2% 
50 7.5% 7.9% 8.2% 7.0% 
100 5.5% 4.7% 5.0% 3.4% 
200 1.9% 1.5% 1.9% 1.6% 
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Figure 18 shows the predicted log-normal ED10 values of the randomly selected 
subject populations with the Taylor et al. (27) log-normal ED10 of 3.1 mg peanut protein 
indicated in red. The maximum predicted ED10 value with 10 subjects was 110 mg 
peanut protein, 35 times higher than the 450 dataset. With 30 subjects, the maximum 
ED10 was 9 times higher than the 450 dataset. By 100 and 200 subjects, the maximum 
ED10 estimates were 3 and 2 times higher, respectively, than the 450 dataset. These 
results show that a clinical population with fewer subjects is more likely to significantly 
overestimate the ED10 of an allergic population and subsequently put a higher proportion 
of allergic individuals at risk if that ED10 from an individual study alone is used in risk 
management decisions. However, the cost of clinical studies and limited size of allergic 
populations do not always allow for 100 or 200 subjects to be tested. Single center studies 
with 30 allergic individuals challenged by a recommended dosing scheme (discussed 
below) would have ~90% certainty that the ED values predicted were statistically similar 
to the true population values and the use of additional uncertainty factors could provide 
reasonable data for provisional risk assessments. 
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Figure 18. Predicted log-normal ED10 after randomly selected 10, 20, 30, 50, 100, or 200 subjects 
from the Taylor et al. (27) 450 dataset. Taylor et al. (27) found an ED10 of 3.1 mg peanut protein, 
indicated in red. 
 
Dose scheme results 
Dose schemes selected for the population simulations are displayed in Table 22. 
Populations of 30 or 50 subjects were randomly generated 1000 times from the soy flour, 
peanut, and egg distribution models and fit to 10 different dosing schemes selected from 
or based on published clinical dosing schemes.  
Table 22. Dose schemes selected to study in population simulations. Populations of 30 or 50 subjects 
were randomly generated 1000 times from the soy, peanut, and egg distribution models and fit to 10 
different dosing schemes. All doses are expressed in mg protein. 
Dose Scheme 1 Scheme 2 Scheme 3 Scheme 4 Scheme 5 Scheme 6 Scheme 7 Scheme 8 Scheme 9 Scheme 10 
#1 0.01 500 1 0.1 1 0.01 0.01 0.1 0.1 100 
#2 0.1 1000 5 1 10 0.1 1 1 1 200 
#3 1 2000 10 5 100 1 100 3 3 400 
#4 10 2000 50 10 
 
5 10000 10 10 800 
#5 100 
 
100 50 
 
10 
 
30 30 1600 
#6 1000 
 
500 100 
 
20 
 
100 100 3200 
#7 10000 
 
1000 500 
 
100 
 
300 300 
 
#8 
  
5000 1000 
 
5000 
 
1000 1000 
 
#9 
   
5000 
   
3000 3000 
 
#10 
        
5000 
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Results of the Generalized Log-Rank Tests indicate that schemes 2, 3, 4, 6, 9, and 
10 are more likely to produce populations that are significantly different than the base 
distribution models for egg, peanut, and soy flour (Table 23). Scheme 6 is particularly 
different due to its extreme dosage increase to end the challenge. Analysis of the 84% 
confidence intervals revealed that schemes 2, 5, and 10 produced significantly different 
results than the other schemes tested (data not shown). Schemes 2, 5, and 10 challenge 
doses start significantly higher or end significantly lower than other schemes tested and 
these results indicate the importance of a challenge protocol that covers the entire dose 
distribution curve. Such approaches generate fewer left- and/or right-censored 
individuals. 
167 
 
 
I
II
I
II
I
II
I
II
I
II
I
II
S
c
h
e
m
e
 1
2
.8
%
3
.4
%
S
c
h
e
m
e
 1
3
.3
%
5
.0
%
S
c
h
e
m
e
 1
1
.0
%
3
.8
%
S
c
h
e
m
e
 1
2
.4
%
0
.0
%
S
c
h
e
m
e
 1
0
.6
%
0
.9
%
S
c
h
e
m
e
 1
0
.5
%
0
.4
%
S
c
h
e
m
e
 2
0
.3
%
2
.1
%
S
c
h
e
m
e
 2
0
.0
%
1
.6
%
S
c
h
e
m
e
 2
2
.7
%
8
.2
%
S
c
h
e
m
e
 2
4
.0
%
7
.8
%
S
c
h
e
m
e
 2
1
.4
%
1
.2
%
S
c
h
e
m
e
 2
0
.8
%
0
.3
%
S
c
h
e
m
e
 3
3
.7
%
4
.9
%
S
c
h
e
m
e
 3
3
.8
%
5
.4
%
S
c
h
e
m
e
 3
5
.0
%
7
.9
%
S
c
h
e
m
e
 3
6
.2
%
9
.0
%
S
c
h
e
m
e
 3
1
.7
%
1
.5
%
S
c
h
e
m
e
 3
0
.7
%
0
.6
%
S
c
h
e
m
e
 4
3
.7
%
4
.9
%
S
c
h
e
m
e
 4
3
.8
%
5
.4
%
S
c
h
e
m
e
 4
4
.9
%
7
.7
%
S
c
h
e
m
e
 4
6
.2
%
8
.9
%
S
c
h
e
m
e
 4
1
.7
%
1
.5
%
S
c
h
e
m
e
 4
0
.7
%
0
.6
%
S
c
h
e
m
e
 5
1
.8
%
0
.9
%
S
c
h
e
m
e
 5
0
.7
%
0
.1
%
S
c
h
e
m
e
 5
1
.0
%
0
.2
%
S
c
h
e
m
e
 5
1
.8
%
0
.5
%
S
c
h
e
m
e
 5
4
.3
%
0
.0
%
S
c
h
e
m
e
 5
1
.1
%
0
.0
%
S
c
h
e
m
e
 6
0
.9
%
5
.1
%
S
c
h
e
m
e
 6
0
.5
%
4
.2
%
S
c
h
e
m
e
 6
1
1
.7
%
2
6
.7
%
S
c
h
e
m
e
 6
7
.7
%
2
1
.6
%
S
c
h
e
m
e
 6
1
.1
%
1
.5
%
S
c
h
e
m
e
 6
1
.0
%
0
.9
%
S
c
h
e
m
e
 7
0
.1
%
1
.1
%
S
c
h
e
m
e
 7
0
.0
%
0
.9
%
S
c
h
e
m
e
 7
0
.3
%
4
.5
%
S
c
h
e
m
e
 7
0
.4
%
4
.8
%
S
c
h
e
m
e
 7
0
.0
%
0
.0
%
S
c
h
e
m
e
 7
0
.0
%
0
.0
%
S
c
h
e
m
e
 8
3
.1
%
4
.0
%
S
c
h
e
m
e
 8
2
.3
%
2
.3
%
S
c
h
e
m
e
 8
2
.5
%
4
.1
%
S
c
h
e
m
e
 8
5
.1
%
6
.8
%
S
c
h
e
m
e
 8
3
.9
%
3
.6
%
S
c
h
e
m
e
 8
2
.7
%
2
.6
%
S
c
h
e
m
e
 9
3
.1
%
4
.5
%
S
c
h
e
m
e
 9
2
.4
%
2
.2
%
S
c
h
e
m
e
 9
3
.2
%
7
.1
%
S
c
h
e
m
e
 9
5
.7
%
8
.5
%
S
c
h
e
m
e
 9
0
.9
%
0
.6
%
S
c
h
e
m
e
 9
0
.1
%
0
.0
%
S
c
h
e
m
e
 1
0
2
.9
%
5
.0
%
S
c
h
e
m
e
 1
0
2
.4
%
4
.1
%
S
c
h
e
m
e
 1
0
4
.0
%
9
.9
%
S
c
h
e
m
e
 1
0
4
.3
%
8
.4
%
S
c
h
e
m
e
 1
0
2
.3
%
1
.7
%
S
c
h
e
m
e
 1
0
1
.2
%
1
.1
%
T
a
b
le
 2
3
 -
 P
ro
b
a
b
il
it
y
 o
f 
th
e
 d
o
se
 s
ch
e
m
e
 c
re
a
ti
n
g
 a
 n
o
n
p
a
ra
m
e
tr
ic
 d
o
se
 d
is
tr
ib
u
ti
o
n
 f
ro
m
 r
a
n
d
o
m
ly
 s
e
le
ct
e
d
 s
u
b
je
ct
s 
th
a
t 
is
 s
ig
n
if
ic
a
n
tl
y
 d
if
fe
re
n
t 
th
a
n
 t
h
e
 V
IT
A
L
 e
g
g
, 
p
e
a
n
u
t,
 a
n
d
 s
o
y
 f
lo
u
r 
p
o
p
u
la
ti
o
n
 m
o
d
e
ls
. 
G
e
n
e
ra
li
ze
d
 L
o
g
-R
a
n
k
 T
e
st
 I
 &
 I
I 
a
lp
h
a
 =
 0
.0
5
.
E
g
g
 3
0
E
g
g
 5
0
P
e
a
n
u
t 
3
0
P
e
a
n
u
t 
5
0
S
o
y
 3
0
S
o
y
 5
0
168 
 
Limitations in the statistical tests are demonstrated by scheme 7, which is 
recommended by both statistical methods but could cause severe reactions in a clinical 
setting with its extreme dose escalations. Additional limitations are illustrated Figure 19, 
in which all 3 examples would be considered statistically similar to the original 
population but schemes 2 and 5 do not visually fit the dose distribution. Expert judgment 
must be used to interpret all results and clinical reaction implications and to select the 
optimal dose scheme. Recommended challenge protocols would follow a log or semi-log 
scale increase in protein doses and cover the entire range of dose distributions, similar to 
schemes 1, 4, 8, or 9. 
 
Figure 19. Visual depiction of scheme fits. Selected schemes include protocols 1, 2, and 5. Due to large 
confidence intervals in schemes 2 and 5, all dose distribution curves displayed (red) are not 
statistically different than the original VITAL datasets (blue). 
 
1 2 
5 
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4. Conclusion  
 The results of this study show that sufficient clinical data from food allergic 
individuals exist to use for risk assessment purposes and perhaps to develop regulatory 
thresholds for several allergenic foods. However, data collection must continue on all 
allergens, especially the priority tree nuts such almond and walnut where little or no data 
currently exist. As noted by others, the data in this study strengthen the notion that 
statistical risk assessment methods provide the best and the most transparent approach to 
developing regulatory thresholds. Allergic populations did not vary when analyzed by 
age, geographic region, or gender and only slightly varied by study population and 
challenge material. Due to limited global data, it would serve all stakeholders to continue 
to combine and merge datasets from different studies in an effort to mitigate biases from 
an individual study and enhance the overall dataset. Different approaches exist to derive a 
reference dose for use in risk assessments and comparisons demonstrated that a 
traditional toxicological benchmark-UF approach and the VITAL approach arrive at 
essentially the same suggested reference doses. 
 Scientifically sound clinical challenge dosing protocols would benefit all 
stakeholders. The low dose log or semi-log dosing protocols, recommended by others for 
its clinical safety and efficiency, were proven to be as sound as any other dose scheme 
available. Dose schemes are recommended to start below 1 mg protein from the 
allergenic food source and proceed at a log or semi-log scale, depending on the comfort 
of the physician, until a final discrete dose of 4 – 5 grams of protein is reached. As with 
the threshold datasets, expert judgment must be used when developing a dose scheme to 
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ensure the safety of subjects involved and the usefulness of subsequent challenge data for 
risk assessors.  
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Abstract 
Foods with advisory labeling (i.e. “may contain”) continue to be prevalent and 
may be increasingly ignored by allergic consumers. We sought to determine the residual 
levels of peanut in various packaged foods bearing advisory labeling, compare similar 
data from 2005 and 2009, and determine any potential risk for peanut-allergic consumers. 
Of 186 food products bearing advisory statements regarding peanut or 16 products that 
had peanut listed as a minor ingredient (last three ingredients on statement), 16 (8.6%) 
and 6 (37.5%) contained detectable levels of peanut (>2.5 ppm whole peanut). Peanut 
was detected at similar rates and levels in 54 identical products tested in both 2005 and 
2009. Although detectable levels of peanut protein were lower among all products tested 
in 2009, peanut-allergic consumers may still be at risk by consuming these products. 
Since the nutrition bar category contained the highest levels of peanut among products 
with advisory labeling, an additional market survey was conducted with 399 products 
including 120 nutrition bars with peanut listed as an ingredient, 44 products that listed 
peanut as a minor ingredient, 15 products declared as peanut-free, 49 products with no 
mention of peanut, 159 products with advisory statements for peanuts, 7 products with 
advisory statements for nuts, and 5 products declaring peanuts as a minor ingredient and 
also bearing an advisory statement. Of 215 nutrition bars with peanuts as a minor 
ingredient and/or an advisory statement for peanuts, 53 products (24.6%) tested positive 
for peanut (3.1 – 44,000 ppm) compared to 2 of 49 (4%) products with no mention of 
peanuts on the label. Probabilistic risk assessment showed the risk of a reaction to peanut 
allergic consumers from advisory labeled nutrition bars was significant but brand-
dependent. Peanut advisory labeling may be overused on some nutrition bars but 
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prudently used on others. The probabilistic approach could provide the food industry with 
a quantitative method to assist with determining when advisory labeling is most 
appropriate. 
 
Keywords: Peanut, Allergy, Labeling, Risk assessment, Probabilistic, Quantitative 
 
1. Introduction 
Peanut is one of the most common allergenic foods with a prevalence of 0.6 – 
2.9% (Osborne et al., 2011; Rona et al., 2007; Sicherer et al., 2010; Sicherer and 
Sampson, 2010). Peanut allergies are potentially life-threatening and the most common 
cause of food-allergy fatalities in the United States (Bock et al., 2007; Keet and Wood, 
2007; Rona et al., 2007). Peanut allergic consumers must adhere to a strict avoidance diet 
and carefully examine ingredient labels (Hefle et al., 2007; Pieretti et al., 2009; Taylor et 
al., 1986; Yu et al., 2006). The presence of peanut in mislabeled or unlabeled packaged 
products has led to allergic reactions in consumers relying on clear and accurate 
ingredient statements (Kemp and Lockey, 1996; Yu et al., 2006).  
In the U.S., the Food Allergen Labeling and Consumer Protection Act (FALCPA) 
that protects allergic individuals from unclear or unlabeled products was passed in 2004 
and became effective January 1, 2006 (FDA, 2006). Similar international allergen 
labeling laws have been implemented in 18 other national regulatory frameworks to 
address the issue of improved labeling of allergens in food (Gendel, 2012). For public 
health authorities, the primary strategies have been to develop lists of priority allergenic 
foods and enact regulations to assure that any ingredients derived from these foods are 
declared on the labels of packaged foods (Gendel, 2012). FALCPA requires that 
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companies must declare ingredients derived from the major allergenic foods including 
peanuts. Labeling of peanut is required by all 19 international regulatory frameworks that 
address allergen labeling (Gendel, 2012). However, advisory labeling for allergens is 
voluntarily used by the food industry and not directly regulated or addressed by FALCPA 
or most similar international regulations. The U.S. Food, Drug, and Cosmetics Act does 
require that label statements be “truthful and not misleading” (Chapter II, Sec. 201). 
Since advisory label statements are voluntary, a variety of advisory labels are used which 
can cause confusion and lead to weighted opinions of differing label statements. In a 
report by the U.S. Food and Drug Administration (FDA), both allergic and non-allergic 
consumers indicate that shorter “may contain” advisory labels are more likely to contain 
peanuts or other listed allergens. Additionally, both allergic and non-allergic consumers 
were more likely to serve a product with a longer “shared facility” or “shared equipment” 
statement to an allergic individual than a product with a shorter “may contain” label 
(FDA, 2006). Allergic consumers are more likely to avoid products that state they “May 
contain” or were “Manufactured on the same/shared equipment” than products that state 
they were “Manufactured in a facility that also processes/uses” (Hefle et al., 2007). 
However, peanut may be present in products that contain any form of advisory label for 
peanut (Hefle et al., 2007; Pele et al., 2007).  
A U.S. supermarket survey found 17% of products contain an advisory label 
statement for food allergens. The wording of such statements was split evenly among 
products as 38% had “May contain”, 33% had “Same/shared equipment”, and 29% had 
“Shared facility” labels. Certain categories, such as chocolate candy, cookies, and baking 
mixes, had the highest prevalence of advisory statement usage with 40-54% of the 
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products having an advisory label (Pieretti et al., 2009). While the use of advisory 
labeling is high, Hefle et al. (2007) found in a 2005 survey that only 7.3% of products 
with peanut advisory statements tested had detectable levels of peanut. Consumer 
avoidance of advisory labeled products has decreased and the prevalence of detectable 
peanut is low, but a risk of an allergic reaction still exists when consuming advisory 
labeled products (Hefle et al., 2007). 
The current study surveyed package foods with an advisory label for peanut for 
the presence of peanut. Special attention was paid to the difference between foods with 
peanut advisory labeling and peanut labeled as a minor ingredient. Comparisons to a 
similar study conducted in 2005 by Hefle et al. (2007) were done and the potential risk to 
the peanut allergic consumer was determined through the use of probabilistic risk 
assessment. Monte Carlo simulations have become popular in the quantitative assessment 
of microbial and chemical risks (EU, 2003; Kroes et al., 2000; Lammerding and Fazil, 
2000; Larsen, 2006; Notermans et al., 1995) but their use with food allergens is a recent 
development. Probabilistic risk assessment of food allergens was introduced by TNO in 
the Netherlands and used to investigate the risk associated with undeclared hazelnut in 
chocolate spreads (Spanjersberg et al., 2007). Additional research conducted by the same 
group, and others in France, has shown the robust capabilities of the probabilistic models 
and expanded the concept to products with advisory labels for milk and peanut 
(Kruizinga et al., 2008; Rimbaud et al., 2010; Spanjersberg et al., 2010). To date, 
probabilistic risk assessment of food allergens based on packaged products found in the 
U.S. has not been done. This study aims to assess the risk to a peanut allergic consumer 
who intentionally purchases packaged food products with advisory labeling for peanut.  
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2. Methods and Materials 
2.1. Peanut Advisory Labeling Studies 
2.1.1. 2009 Packaged food samples 
A total of 202 packaged food products bearing advisory statements regarding 
peanut (186) or products that had peanut listed as a minor ingredient (last three 
ingredients on statement; 16) were purchased in Lincoln, Nebraska, USA. Products were 
categorized as baked goods/mixes, baking ingredients, candy/confectionery, 
cereals/cereal bars, frozen desserts, instant meals, nutritional/meal bars, or snack foods. 
Two different lot numbers of each product were obtained leading to a total of 404 
samples. Fifty-four products purchased in the 2005 study (Hefle et al., 2007) were 
available to purchase again in 2009 for comparison.  
2.1.2. Peanut analysis 
A representative sample from each package was homogenized and then analyzed 
for the presence of peanut using a commercial enzyme-linked immunosorbent assay 
(Peanut Veratox®, Neogen) with a lower limit of quantification of 2.5 parts per million 
(ppm, μg/g) whole peanut (0.63 ppm peanut protein). Samples were prepared and 
analyzed according to instructions provided with the kit.  
2.1.3. 2010 Nutrition bar market survey 
 Due to the level of peanut in nutrition bars with advisory labeling in the 2005 and 
2009 surveys, an in depth survey of nutrition bars available in Lincoln, Nebraska, USA 
was conducted. Products were categorized by the nature of the declaration of peanut on 
the labeling including contains peanut, minor ingredient, advisory statement for peanut, 
unique advisory labeling, declaration of peanut free, and no mention of peanut on the 
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label. A total of 399 nutrition bars were recorded and 279 were purchased for testing 
including 49 with minor ingredient declaration, 166 with advisory labeling statements, 15 
declared peanut free, and 49 with no mention of peanut. Products stated to contain peanut 
were not tested. A single lot number of each nutrition bar was tested in this study.  
2.2. Quantitative Approach to Risk Assessment 
The probabilistic risk assessment model for food allergens was described by 
Spanjersberg et al. (2007) and Kruizinga et al. (2008). Briefly, data inputs for prevalence 
of food allergy, allergen thresholds, consumption patterns, and product test results can be 
fit to statistical distributions for use in a Monte Carlo simulation. The Monte Carlo 
program will randomly sample from each distribution during every run and iteration, 
match if the individual is allergic, a consumer of the type of product, and if the product 
contains peanut to determine if there is a possibility of an allergic reaction. An individual 
will have a predicted allergic reaction if the predicted consumed amount and 
concentration of peanut lead to a dose over the predicted allergen threshold for that 
individual. The current risk assessment uses a modified Monte Carlo approach, 
incorporating the mean and standard error associated with each input into a Bayesian 
framework to better estimate the confidence of the risk of an allergic reaction from 
consumption of nutrition bars with advisory labeling for peanut. The simulation scheme 
can be seen in Figure 1.  
For the probabilistic risk assessment model, the prevalence of peanut allergy was 
taken from the study of Sicherer et al. (2010) that estimates peanut and tree nut allergy in 
the U.S.. This telephone survey data documents that 103 of 13,534 subjects or 0.76% 
were allergic to peanut. By nature, peanut allergy is a binomial distribution with yes/no 
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responses as individuals are either allergic or nonallergic. Using the Bayesian framework, 
Rimbaud et al. (2010) describe the process for fitting a binomial distribution with a non-
informative prior Beta(1,1) distribution. The posterior binomial distribution can be solved 
as follows: p ~ Beta(1+x, 1+n1-x) with x representing a positive response and n1 
representing the total number of people in the study. The allergic prevalence data are fit 
as follows p ~ Beta(104, 13432). The beta distribution provides a new allergic prevalence 
probability estimate for the binomial distribution for every run in the simulation. In turn, 
the binomial distribution decides if an individual is allergic or not for every iteration in 
the simulation. The probabilities estimating allergic prevalence, peanut present in the 
nutrition bar, allergic shoppers purchasing advisory labeled products, and nutrition bar 
consumption are all binomial distributions, and the method shown by Rimbaud et al. 
(2010) was used to fit these inputs with prior beta distributions throughout the study. 
The distribution of individual threshold doses from DBPCFC of 450 peanut-
allergic individuals as based on objective symptoms was taken from Taylor et al. (2010). 
The No Observed Adverse Effect Levels (NOAELs) and Lowest Observed Adverse 
Effect Levels (LOAELs) from each individual were used, as previously described (Taylor 
et al., 2009), to fit a posterior Log-Normal probability distribution function for the 
threshold dose expressed as mg whole peanut. The Bayesian context uses statistical 
inference to generate the intercept and scale parameters of the Log-Normal distribution 
and assumes a prior normal distribution for each using their respective mean and standard 
error estimates from the LIFEREG procedure in SAS. These measures help reflect 
uncertainty in the true location of each parameter and can be used similarly with 
consumption and contamination distributions.  
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Four variables shape the consumption input distributions, the probability of a 
nutrition bar containing advisory labeling for peanut, the probability of the allergic 
shopper purchasing advisory labeled products, the probability of eating nutrition bars, 
and the amount eaten. The 2010 nutrition bar survey determined the probability of 
nutrition bars containing advisory labeling for peanut. The probability was set to a non-
informative prior Beta(1,1) distribution with a binomial posterior distribution. Surveys 
conducted at the Food Allergy & Anaphylaxis Network (FAAN) patient conferences 
were used to estimate how many allergic consumers buy products with advisory labeling 
on the package (Hefle et al., 2007). The probability of allergic shoppers purchasing 
advisory labeled products was conservatively estimated at 40% (258 of 645), the number 
parents with food allergic children from the survey indicating that they would possibly 
purchase products with a “same facility” label. This probability was fit to a non-
informative prior Beta(1,1) distribution with a binomial posterior distribution.  
Consumption data for nutrition bars were extracted from the U.S. National Health 
and Nutrition Examination Survey (NHANES) using a combination of the 2003-04, 
2005-06, and 2007-08 surveys (CDC, 2004, 2006, 2008). Only individuals completing 
both of the 24 hour dietary recall interviews were included in the dataset. Within the 
NHANES data, USDA food codes specific to high protein nutrition and meal 
replacement bars, PowerBar™, and Snickers™ Marathon bars (41435110, 53541200, 
53544450, 91780010, and 91781010) were used to create the nutrition bar product 
category. Individuals were considered consumers if they ate nutrition bars during one of 
the two recall days. For individuals consuming multiple nutrition bars in a 24 hour 
period, the intakes were summed to a daily consumption level. As there is no 
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consumption database available solely for allergic consumers, the assumption was made 
that allergic and nonallergic individuals consume nutrition bars at the same rate and their 
reasons for nonconsumption are the same.  
From the NHANES survey, the probability of consuming nutrition bars was 
estimated and fit to a non-informative prior Beta(1,1) distribution with a binomial 
posterior distribution. Two simulations were run with differing consumption inputs. First, 
the simulation randomly selected a value from the individual consumption amounts in 
NHANES to represent consumption. A second, repeated simulation fit the range of 
consumption levels to a Log-Normal distribution and simulated a value expressed as the 
consumed amount. Inputs for the intercept and scale properties of the posterior Log-
Normal distribution were assumed to follow prior normal distributions. 
Nutrition bar products from all packaged food surveys conducted in 2005, 2009, 
and 2010 provided a total of 197 unique brand and flavor combinations with advisory 
labeling for peanut. As one lot number of each brand/flavor combination was tested in 
2010 and two lot numbers were testing in 2005 and 2009, each lot number was treated as 
an individual sample for a total of 270 tested products. The probability of peanut being 
present was fit to a prior Beta distribution with a binomial posterior distribution. Sample 
concentrations of the positive products were expressed two ways. The first simulation 
used a randomly selected ppm result from the laboratory analysis data. The second, 
repeat simulation fit the laboratory analysis range of ppm results to a Log-Logistic 
distribution and simulated a value expressed as ppm whole peanut. Inputs for the 
intercept and scale properties of the posterior Log-Logistic distribution were assumed to 
follow prior normal distributions. 
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2.3. Software and statistics 
All statistical tests were done in SAS (version 9.2). The χ2 test with a P value of 
less than 0.05 being significant was used to compare the frequency of positives from all 
2005 and 2009 products, products purchased in both 2005 and 2009, and nutrition bars 
against all other products with minor ingredient labeling. Fisher's Exact Test with a P 
value of less than 0.05 being significant was used to compare the frequency of positives 
between advisory labeled products and products with no mention of peanut on the label in 
the 2010 nutrition bar survey due to an expected cell count of less than 5. For 
probabilistic modeling, a Monte Carlo sampling technique was performed with 50 runs of 
100,000 iterations for each simulation. The stepwise method of the simulation can be 
seen in Figure 2.  
3. Results 
3.1. Peanut advisory labeling study 
 Peanut was detected in at least one lot in 8.6% (16/186) of products with peanut 
advisory statements and 37.5% (6/16) of products with peanut listed as a minor ingredient 
(Table 1). In the advisory labeled products, 3 of 46 products with “may contain” 
statements, 9 of 65 products with “shared equipment” statements, 2 of 69 products with 
“shared facility” statements, and 2 of 6 products with unique advisory labels had 
detectable levels of peanut in one or both lots. These results are similar to the 2005 
survey conducted by Hefle et al. (2007) that found detectable peanut in 7.3% of advisory 
labeled products from the same categories (P= 0.64). Detectable peanut was found in the 
advisory labeled nutrition/meal bars (6/24), candy/confectionary (4/32), baking 
ingredients (2/16), cereal/cereal bars (2/20), snack foods (1/25), and baked goods/mixes 
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(1/43) categories. No detectable peanut was found in the advisory labeled frozen desserts 
products (0/9) or the instant meals (0/17).  
 The 16 advisory labeled products with detectable levels of peanut had levels 
ranging from 3 to 510 ppm. Inconsistencies were seen as only 7 of 16 products had both 
lots tested positive for detectable peanut. Detectable peanut in the 6 products with minor 
ingredient labeling ranged from 5 to 69,000 ppm. Both lots tested positive for peanut in 5 
of 6 cases.  
 Of 54 products tested in both the 2005 and 2009 advisory labeling surveys, peanut 
was detected in 13.0% (7/54) and 16.7% (9/54) of similar products in 2005 and 2009, 
respectively. These percentages were not significantly different even though FALCPA 
was implemented in 2006 (P= 0.59).  
3.2. Nutrition Bar Market Survey  
 Of 399 different nutrition bars, peanut is listed on 84% of labels, 42.4% (169/399) 
contain peanut in the ingredient statement and 41.6% (166/399) have an advisory label 
for peanut. A small number of nutrition bars, 3.8% (15/399), claim to be peanut free and 
12.2% (49/399) have no declaration of peanut on the label. Detailed category breakdowns 
and ppm ranges can be found in Table 2. Among nutrition bars with minor ingredient 
labeling, 34 of 44 tested positive for peanut. Products contained up to 44,000 ppm whole 
peanut with 9 products over 1,100 ppm, 9 between 50 – 650 ppm, and 16 between 3.5 – 
11 ppm. Five nutrition bars had peanut listed both as a minor ingredient and had an 
advisory statement indicating they were processed in the same facility with peanut; all 
tested positive at a range of 17 – 49,000 ppm. Of 159 nutrition bars with advisory 
labeling, 12 contained peanut with one 26,000 ppm sample, 4 samples between 70 – 150 
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ppm, and 7 samples between 3 – 40 ppm. Seven nutrition bars were labeled “may contain 
nuts” and 2 of 7 samples tested positive for peanut at 2.8 and 16.2 ppm. No detectable 
peanut was found in 15 products with various peanut-free statements including “peanut 
free facility”, “nut free facility, peanut free”, or “nut free”. Two of 49 nutrition bars with 
no mention of peanut on the label tested positive at 13 and 1,260 ppm. No significant 
difference was found in the frequency of detectable peanut in products with advisory 
labeling for peanut (12/159) and products that had no mention of peanut on the label 
(2/49) (P= 0.20). 
3.3. Quantitative Risk Assessment 
The 2010 nutrition bar survey determined 41.6% (166/399) of nutrition bars have 
an advisory label for peanut. From the combined labeling surveys, 11.1% of nutrition 
bars with advisory labels for peanut were found to contain detectable levels of peanut 
residues at concentrations ranging from 2.5 to 26,000 ppm whole peanut. Two of the 30 
positive samples (6.7%) contained peanut at 26,000 and 4,000 ppm whole peanut. Five 
samples (16.7%) had 131 – 510 ppm whole peanut present. Four samples (13.3%) were 
between 70 – 87 ppm whole peanut and 4 more samples (13.3%) were within 27 – 39 
ppm whole peanut. The remaining 15 samples (50%) contained between 2.5 and 18 ppm 
whole peanut. From the NHANES survey, the probability of consuming nutrition bars 
was estimated to be 0.82% (201 of 24,621), including 35 individuals consuming nutrition 
bars both days. The average consumption of nutrition bars was 64 g per day, close to a 
common serving size for a single nutrition bar (Table 3). The 90
th
 percentile intake was 
130 g (2 nutrition bars). The 99
th
 percentile intake was 204 g (3 nutrition bars) and the 
maximum amount consumed was 272 g (4 nutrition bars) in one day. Probabilistic risk 
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assessment modeling allows quantification of the risk faced by peanut-allergic consumers 
from consumption of advisory labeled nutrition bars.  
The simulation input parameters and results are listed in Table 4. Simulation risk 
results are presented in three ways including the allergic user risk, the risk to the peanut 
allergic population, and the risk to the overall population. These three risk values 
represent the same number of predicted reactions expressed three different ways. The 
allergic user risk assumes every individual is allergic to peanut and consumes advisory 
labeled nutrition bars. The predicted number of reactions is 5.5 – 8.1 per 1,000 allergic 
users. To estimate the risk for the peanut allergic population, all individuals are allergic to 
peanut, 0.82% consume nutrition bars, 40% are assumed purchase advisory labeled 
nutrition bars, and 42% of nutrition bars contain advisory labeling for peanut. The 
predicted number of reactions is 0.8 – 1.1 per 100,000 peanut allergic individuals. To 
estimate the risk to the overall population, the inputs include that 0.76% of people are 
allergic to peanut, 0.82% consume nutrition bars, 40% are assumed purchase advisory 
labeled nutrition bars, and 42% of nutrition bars contain advisory labeling for peanut. The 
predicted number of reactions due to nutrition bars with advisory labeling for peanut is 
5.8 – 8.5 per 100,000,000 people in the U.S. No differences were noted between using 
simulation inputs from the log-normal consumption and concentration distributions 
versus using a random selection of actual consumption levels and concentrations taken 
from the actual data sets.  
The number of allergic reactions in peanut-allergic consumers can be predicted on 
a per day basis by utilizing the number of predicted peanut advisory labeled nutrition bars 
consumed in the U.S. per day, the prevalence of peanut allergy, and the allergic user risk. 
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The number of peanut advisory labeled nutrition bars consumed can be calculated with 
the equation below: 
# consumed 
overall per day 
= 
U.S. 
population × 
Nutrition bar 
consumption 
probability 
× 
Probability of nutrition 
bar with advisory 
labeling for peanut  
1.03 million 
nutrition bars 
= 
300 
million × 0.0082 × 0.42 
The number of nutrition bars with advisory labeling for peanut consumed is used 
to estimate the number of allergic individuals purchasing nutrition bars with advisory 
labeling for peanut on a daily basis as shown in the equation below: 
 
# consumed by allergic 
individuals 
= 
Consumed 
overall × 
Prevalence 
of peanut 
allergy 
× 
Probability of 
purchasing advisory 
labeled products 
3,131 advisory labeled 
nutrition bars consumed 
by peanut allergic per day 
= 
1.03 
million × 0.0076  × 0.40  
The number of expected allergic reactions per day can then be calculated by 
multiplying the number of peanut advisory labeled nutrition bars consumed by allergic 
individuals by the risk to the allergic user population in the equation below: 
# of reactions = 
# Consumed by 
allergic individuals × 
Allergic 
user risk 
27 predicted 
reactions per day 
= 3,131  × 0.0085  
The predicted reactions were heavily influenced by the two samples with the 
highest concentration of peanut (26,000 ppm and 4,000 ppm). These samples each 
account for 3.3% of the positive samples but are respectively responsible for ~35% and 
~22% of predicted reactions. Still, nutrition bars with lower concentrations are also a risk 
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as products with levels of less than 100 ppm whole peanut led to 15 – 25% of the 
predicted reactions. Roughly 50% of the predicted reactions occurred at consumption 
amounts of 65 g or less, a common nutrition bar serving size. Approximately 10% of the 
reactions involved predicted consumption values over 130 g or 2 or more nutrition bars 
and ~1% involved predicted consumption values were over 204 g. The simulation 
predicts that 70 – 80% of the reactions have a dose over of 10 mg whole peanut, ~85% of 
the reactions have a dose over 5 mg whole peanut, and ~99.5% of the reactions have a 
dose over the most sensitive recorded individual threshold of 0.4 mg whole peanut as 
observed in Taylor et al. (2010). These results indicate that consuming nutrition bars with 
advisory labels for peanut would present a significant health risk to the peanut allergic 
community. When the 26,000 ppm and 4,000 ppm samples are removed from the 
simulation, the number of predicted reactions was reduced by 50%, but 23% of the 
predicted reactions occurred at a dose of more than 20 mg whole peanut. The lower 
concentrations of peanut in advisory labeled nutrition bars would still present a 
significant health risk to the peanut allergic community.  
When using the Log-Normal and Log-Logistic curves, the simulation can predict 
unrealistic values for the consumption and ppm values at the extreme high and low ends 
of the curve. For instance, consumption values up to 563 g or 8 to 10 nutrition bars were 
predicted to cause a reaction in one simulation. Additionally, concentration values as low 
as 0.0000007 ppm peanut and higher than one million parts per million peanut (clearly 
impossible) were predicted by the Log-Logistic curve. However, these extreme values are 
statistically expected when repeating the simulation with a large number of iterations. A 
simulation was run using the Log-Logistic curve with the lower and upper extremes of 
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the concentration values capped at 2.5 to 26,000 ppm respectively. No significant 
changes in the results were seen when comparing the unbound simulations to the 
simulations with concentration values capped at 2.5 to 26,000 ppm whole peanut. 
4. Discussion 
Detectable levels of peanut were found in 8.6% (16/186) of packaged products 
during the 2009 advisory labeling survey. Results were not significantly different from a 
similar study conducted in 2005 before FALCPA fully went into effect. As found in the 
2005 study, nutrition/meal bars and candy/confectionary products tested in 2009 were 
most likely to contain peanut among products with advisory labels. Our results indicate 
that 25% (6/24) of advisory labeled nutrition bars contained peanut in 2009, as compared 
to 14% (4/28) in 2005. However, the expanded 2010 market survey for nutrition bars 
found peanut in only 7.5% (12/159) of advisory labeled nutrition bars. A lower 
prevalence of peanut in the 2010 survey may be attributed to testing of only one lot 
number compared to two in previous surveys. The lack of positive samples does not 
necessarily mean the labels are misleading since only one or two lot numbers and a single 
sample from each were tested. However, the criteria used for advisory labeling within the 
food industry varies and the probability of detectable peanut can range from high to 
nearly nonexistent. Advisory labeling leads to consumer frustration and confusion and 
may lead to a false sense of security. Allergic consumers are most likely to avoid 
products that state “May contain” an allergen on the label by comparison to products with 
labels stating “Manufactured on shared equipment” or “Manufactured in a facility that 
also uses/processes” allergens, but similar levels of peanut were found in all three 
advisory labels. In 2009, products with “shared equipment” labels had the highest levels 
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of detectable peanut, but such products had the lowest levels in 2005. The products with 
“shared facility” labels had the highest levels in 2005 but had the lowest prevalence of 
positive tests in 2009. Based on such inconsistencies and the presence of detectable 
peanut in 8.6% of advisory labeled products, peanut-allergic individuals should be 
advised to avoid such products regardless of the wording of the advisory statement.  
In some instances, minor ingredient declarations for peanut have been used by 
food companies as a stronger deterrent than advisory labeling. In 2005, 33% (7/21) 
products with minor ingredient statements had detectable levels of peanut. No change 
was found in 2009 with 37.5% (6/16) containing detectable peanut. Nutrition bars with 
minor ingredient labeling had a significantly higher rate of detectable peanut with 79.7% 
(47/59) positive during the combined 2005, 2009, and 2010 surveys compared to a 
combination of all other products with minor ingredient labeling with 20.3% (13/64) 
testing positive (P< 0.0001). While, these surveys comprise a small sample of all 
products with minor ingredient statements for peanut, such products demonstrate a 
significant risk to peanut allergic consumers. It is strongly recommended that peanut 
allergic consumers avoid products with peanut listed as a minor ingredient.  
It is clear that many products with advisory labeling for peanut contain over 0.4 
mg whole peanut, the individual threshold for an objective allergic reaction of the most 
sensitive peanut-allergic patients (Taylor et al., 2010), but how large of a health risk do 
they present? The ED05 and ED10, or doses predicted to provoke a reaction in 5% and 
10% of the peanut-allergic population, were 5.2 mg and 12.3 mg whole peanut 
respectively (Taylor et al., 2010). Of predicted reactions in the simulation, 70 – 80% have 
a dose over of 10 mg whole peanut and ~85% have a dose over 5 mg whole peanut. 
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Probabilistic risk assessment indicates that nutrition bars with advisory labels for peanut 
constitute a serious risk for many peanut-allergic individuals. This risk assessment 
predicts that 27 allergic reactions should be occurring in the U.S. each day from ingestion 
of nutrition bars. Removal of samples with 26,000 or 4,000 ppm from the risk assessment 
results in 13 predicted allergic reactions per day. No evidence exists to suggest that the 
prevalence of allergic reactions to nutrition bars with advisory labeling is so high. The 
simulation seems to greatly overestimate the number of reactions per day in the U.S. due 
to a number of conservative input estimates, including the number of peanut allergic 
consumers purchasing nutrition bars and more specifically advisory labeled nutrition 
bars. The current simulation does not account for consumer preference for products 
absent of advisory labeling. However unlikely, it is assumed that 40% of allergic 
individuals will purchase an advisory labeled nutrition bar at the same rate as a product 
absent of advisory labeling. Additionally, mild reactions to these products may go 
unnoticed or unreported by peanut-allergic individuals. Still, advisory labeling for peanut 
is justified on many nutrition bars. The overlap of predicted exposure doses with 
confirmed DBPCFC peanut thresholds is sufficient to create a probable risk.  
Conversely, the choice to consume products with no mention of peanut on the 
label will not remove all risk of an allergic reaction in peanut-allergic individuals. Two 
nutrition bars from the 2010 survey that contained detectable levels of peanut (12.6 and 
1260 ppm respectively) did not list peanut on the label. While two data points are not 
enough to run a probabilistic simulation, the large serving size of nutrition bars 
demonstrates that a risk does exist for peanut allergic consumers of these 2 products. 
Nutrition bars labeled as peanut free or produced in a peanut free facility did not contain 
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detectable peanut. While only 15 peanut free samples were tested, these results are 
encouraging for peanut allergic individuals and suggest a safer choice for peanut allergic 
individuals who want to consume nutrition bars.  
The only strategy to avoid an allergic reaction is avoidance of the food. Current 
food allergen regulations allow for ambiguous advisory statements to be placed on a label 
and more consumers are beginning to ignore these labels (Hefle et al., 2007). This study 
demonstrates that a risk is present to peanut-allergic consumers of nutrition bars with and 
without advisory labeling for peanut. Quantitative risk assessment gives risk assessors a 
flexible tool to help inform decisions on labeling, product release, and product recalls. A 
full quantitative risk assessment was not necessary to see the risk in nutrition bars with 
advisory labeling for peanut, but it provides justification for an advisory label beyond that 
provided by a simple deterministic approach. In cases with lower concentrations of 
peanut, such as the baking ingredient category in Table 1, quantitative risk assessment 
could detail the low risk of a product in realistic consumption scenarios and advocate the 
removal of advisory labeling from the product. The use of quantitative risk assessments 
by the food industry to make decisions about advisory labeling would help clarify the 
current situation, expand choices for allergic consumers, and reduce the potential for 
allergic reactions caused by packaged foods by making advisory labels more meaningful. 
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Tables and Figures 
 
Figure 1. Probabilistic risk assessment model for food allergens in the U.S., figure adapted from 
Spanjersberg et al. (2007). 
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Figure 2. Stepwise progression of the Monte Carlo Simulation.  
a Consumers that follow advisory labeling warnings and avoid nutrition bars with advisory labeling 
for peanut are still at risk for an allergic reaction, as nutrition bars absent of peanut on the label 
have been shown to contain detectable levels of peanut.  
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Table 1. Concentration and serving-size doses of peanut in packaged foods bearing allergy advisory 
statements for peanut (2009 survey). 
  "May contain" labeling   
"Shared equipment" 
labeling   
"Shared facility" 
labeling   Other unique labeling   Total   
 
Minor ingredient labeling 
Product 
category No.*  Conc†  Dose‡    No. Conc Dose   No.  Conc  Dose   No. Conc  Dose   No.     No. Conc  Dose 
Baked goods/ 
mixes  
14 
(0) 
- -   14 
(1) 
8 ppm,  
BLQ  
0.2 mg,  
<0.08 mg 
  15 
(0) 
- -   - - -   43 (1)   - - - 
Baking 
ingredients 
4 
(1) 
3 ppm,  
BLQ  
0.1 mg,  
<0.07 
mg 
 6 (1) 9 ppm,  
11 ppm  
0.3 mg,  
0.3 mg 
 6 (0) - -  - - -  16 (2)   - - - 
Candy/ 
confectionary  
8 
(1) 
15 ppm,  
BLQ  
0.8 mg,  
<0.1 mg 
 13 
(3) 
24 ppm,  
BLQ  
0.8 mg,  
<0.1 mg 
 10 
(0) 
- -  1 
(0) 
- -  32 (4)   2 (1) 93 ppm,  
BLQ  
1.7 mg,  
<0.05 
mg 
  - -   3 ppm,  
BLQ  
0.1 mg,  
<0.1 mg 
  - -   - -      - - 
  - -   5 ppm,  
BLQ  
0.2 mg,  
<0.1 mg 
  - -   - -      - - 
Cereal/ 
cereal bars 
5 
(0) 
- -  8 (0) - -  5 (0) - -  2 
(2) 
97 ppm,  
19 ppm  
3.4 mg, 
0.7 mg 
 20 (2)   8 (2) 11 ppm,  
27 ppm  
0.3 mg,  
0.6 mg 
  - -   - -   - -   20 ppm,  
19 ppm  
0.6 mg, 
0.5 mg 
     32 ppm,  
32ppm  
1.1 mg,  
1.1 mg 
Frozen desserts 5 
(0) 
- -  2 (0) - -  2 (0) - -  - - -  9 (0)   - - - 
Instant meals - - -  2 (0)    15 
(0) 
- -  - - -  17 (0)   - - - 
Nutrition/ 
meal bars 
7 
(1) 
4 ppm,  
BLQ  
0.2 mg,  
<0.1 mg 
 7 (3) 17 ppm,  
32 ppm  
0.7 mg,  
1.3 mg 
 9 (2) 4 ppm, 
BLQ 
0.2 mg,  
<0.1 mg 
 1 
(0) 
- -  24 (6)   3 (3) 86 ppm,  
121 ppm  
6.7 mg,  
9.4 mg 
  - -   510 ppm,  
11 ppm  
20.4 mg,  
0.4 mg 
  4 ppm, 
29 ppm  
0.2 mg,  
1.2 mg 
  - -      5 ppm,  
5 ppm  
0.3 mg,  
0.3 mg 
  - -   3 ppm,  
131 ppm  
0.1 mg,  
5.2 mg 
  - -   - -      69000 ppm,  
56000 ppm  
3795 
mg,  
3080 mg 
Snack foods 3 
(0) 
- -  13 
(1) 
3 ppm,  
BLQ  
0.1 mg,  
<0.1 mg 
 7 (0) - -  2 
(0) 
- -  25 (1)   3 (0) - - 
Total 46 
(3) 
      65 
(9) 
      69 
(2) 
      6 
(2) 
      186 
(16) 
  16 
(6) 
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Table 2. Concentration of peanut in packaged nutrition bars in 2010 market survey. 
Nutrition Bars No. 
No. 
Tested No. Positive PPM Range 
Contains Peanut 104 0 - - 
Minor Ingredient 44 44 34 3.6 - 44,000 
Advisory Label 159 159 12 3.1 - 26,000 
May Contain 50 50 1 3.1 
Shared Equipment 34 34 4 87 - 26,000 
Shared Facility 75 75 7 5.6 - 70 
Unique Label 28 13 8 2.8 – 49,000 
Contains Peanut + Advisory Statement a 16 0 - - 
Minor Ingredient + Advisory Statement 5 5 5 17.8 - 49,000 
May Contain Nuts b 7 7 2 2.8 - 16.2 
Peanut Free Label 15 15 0 - 
No Mention of Peanut 49 49 2 13 - 1,260 
Total 399 279 55  
 
a
 Not tested because they contain peanut and have an advisory label 
 
b
 "May Contain Nuts" or nut advisory label statements not specifically mentioning peanut 
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Table 4. Inputs and results of the probabilistic modeling approach to risk assessment of nutrition 
bars with advisory labeling for peanut. All nutrition bars in the simulation are assumed to contain 
advisory labeling for peanut. 
Parameter Inputs  
Average 
Value (%)  
Distribution 
Shape  Source of Data  
Prevalence of Peanut Allergy  0.76  Beta  Sicherer et al. (2010) 
Allergic Peanut Threshold  
 
Log-Normal  Taylor et al. (2010) 
Probability of purchasing advisory labeled 
products  40  Beta  Hefle et al. (2007) 
Consumption Probability  0.82  Beta  NHANES Database  
Amount Eaten  
 
Log-Normal  NHANES Database  
Presence of Peanut Probability  11.1  Beta  Labeling Surveys  
Level of Peanut Present  
 
Log-Logistic  Labeling Surveys  
Presence of Advisory Labeling for Peanut 41.6 Beta Labeling Surveys 
Simulation Results  Mean  Std. Dev.  
Reaction Probability in Allergic User Population  
5.5 – 8.1 per 
1,000 1.5 – 2.0 
Reaction Probability in Peanut Allergic Population  
0.8 – 1.1 per 
100,000  0.2 – 0.3  
Reaction Probability in Overall Population 
5.8 – 8.5 per 
100,000,000 2.0 – 2.3  
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Abstract 
In the United States, food ingredients derived from allergenic sources must be 
clearly labeled on a package. However, no requirement exists to declare the presence of 
raw agricultural commodities due to agricultural commodity comingling. Clinical reports 
of allergic reactions to undeclared soy in wheat based products are rare and uncertainty 
exists regarding the degree of risk posed by wheat based products that are comingled with 
soy. Wheat flours available at local grocery stores were surveyed for the presence of soy 
and the potential risk to soy-allergic consumers of these products is determined. Soybean 
residues were found in 22 of 35 (62.8%) samples representing all forms of wheat flour. 
Detectable soy was found in wheat flours at concentrations of 3 – 443 ppm soy flour (1.6 
– 236 ppm soy protein). Conservative probabilistic risk assessments predict a risk of 
allergic reaction among the most sensitive soy-allergic individuals of 2.8 ± 2.0 per 1,000 
soy-allergic user eating occasions of foods containing wheat flour. Given the low level of 
predicted risk and the lack of evidence for allergic reactions among soy-allergic 
consumers to wheat based products, the avoidance of wheat based products by soy-
allergic consumers does not appear to be necessary. However, diminution of this low risk 
remains a desirable goal. Accordingly, the distribution of soy residues during the wheat 
milling process was examined to determine the effect of milling on the amount of soy in 
various milling fractions. Experimental milling (6 flour streams, bran, shorts) and stream 
separation was conducted with spiked soy in wheat samples. Soy was detected in all 8 
streams; 53% of the soy is separated in the bran or shorts and 47% of the soy enters one 
of the 6 flour streams. Stream separation was not enough to produce soy-free wheat flour 
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and additional cleaning measures will be needed to remove soy before wheat milling 
begins to obtain soy-free wheat flour.  
1. Introduction 
  Recent studies estimate that 4 – 10% of children and 3 – 4% of adults are affected 
by food-induced allergic reactions (Branum and Lukacs, 2009; Osborne et al., 2011; 
Rona et al., 2007; Sicherer and Sampson, 2010). Soy is one of the most common 
allergenic foods in children, and soy allergy can be severe (Sicherer and Sampson, 2010). 
Soy-allergic consumers are advised to adhere to a strict avoidance diet and carefully read 
ingredient labels of all foods (Hefle et al., 2007; Pieretti et al., 2009; Taylor et al., 1986). 
The Food Allergen Labeling and Consumer Protection Act (FALCPA) was passed in 
2004 by the United States Congress to protect allergic individuals from unclear or 
unlabeled products and became effective January 1, 2006 (FDA, 2006). Although 
ingredients derived from commonly allergenic sources must be labeled in clear terms 
when added to food, raw agricultural commodities are exempt from FALCPA (FDA, 
2006). Due to the nature of agricultural production in the United States and worldwide, 
raw agricultural commodities are often comingled with other agricultural commodities 
during harvest, transport, and storage with shared equipment and facilities. The United 
States Department of Agriculture (USDA) Grain Inspection Handbook allows up to 10% 
of other grains with established standards to be present in wheat (USDA, 2004). Other 
grains with established standards include barley, canola, corn, flaxseed, oats, rye, 
sorghum, soybeans, sunflower seed, and triticale (USDA, 2004). The 10% level equates 
to 100,000 parts per million (ppm) or 100,000 mg/kg (µg/g) of other grains and would 
cause visual contamination within containers of wheat. The economics of buying and 
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selling wheat have kept commodity comingling well below these allowed limits as food 
processors demand a cleaner, higher grade of wheat. However, the extent of the risk from 
commodity comingling to allergic consumers has not been investigated.  
The issue of soy in other grains has become an issue for food safety inspection as 
highlighted by numerous food alerts within the European Union Rapid Alert System for 
Food and Feed (RASFF) and the Canadian Food Inspection Agency (CFIA). The Food 
Safety Authority of Ireland has issued multiple food alerts for the presence of soy in 
wheat and corn based products (white bread flour, flour and corn tortillas, corn chips, and 
a batter mix) (RASFF Reference 2011.0015; 2011.0019; 2011.0022; 2011.0023; 
2011.0215). The CFIA also issued a food recall in a wheat-based cereal due to undeclared 
soy (Reference Number: 6848). Despite the lack of consumer complaints associated with 
this cereal, products were recalled. In all likelihood, this cereal product has been 
produced for years with similar levels of soy. While levels of soy and other grains are 
known to occur in grain-based products, few studies have reported the levels of allergenic 
contaminants in agricultural commodities or finished products manufactured from these 
commodities. One exception is gluten, in large part due to “gluten-free” labeling, with 
North American levels of gluten contamination in other grains reported by multiple 
studies. Thompson et al. (2010) reported gluten contamination in 9 of 22 (41%) 
inherently gluten-free grain samples with levels up to 2,925 ppm gluten. In a study by 
Health Canada, Koerner et al. (2011) reported 117 of 133 (88%) retail oat products 
contained levels up to 3784 ppm gluten. However, only one oat variety with a “gluten-
free” label was tested and it was consistently below the limit of quantitation for gluten. 
Recent IgE-mediated allergic reactions due to commodity contamination of wheat have 
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led the CFIA to encourage manufacturers and importers of grain-based products to 
inform consumers and transition towards the inclusion of precautionary labeling (a 'may 
contain wheat' statement) on their products containing cereal grains, such as oats or 
barley, to indicate the potential presence of wheat at low levels (CFIA, 2011). 
Conversely, Health Canada has released guidance stating exposure to soy in grain-based 
foods is not likely to represent a health risk for soy-allergic individuals and advised the 
industry not to use advisory labeling for soy (Health Canada, 2013). Other countries have 
attempted to establish action levels for undeclared allergens including cross 
contamination of other grains in products and commodities. Switzerland has defined an 
action limit of 1,000 ppm for allergens. This limit states that if unavoidable, 
contamination above 1,000 ppm must be declared as an ingredient, but contamination 
below 1,000 ppm may be declared if desired (Kerbach et al., 2009). Levels of 1000 ppm 
may provide enough protein (low mg doses) to cause reactions at moderate consumption 
levels in multiple foods (Taylor et al., 2004). Japan has taken a stricter approach and 
limited undeclared allergens including commodities to 10 ppm in foods (Kerbach et al., 
2009). Commodity grain shipments may be expected to exceed this Japanese limit but 
with unknown frequency. 
 While the actual levels of other grains in wheat are much lower than the 10% 
allowed by the USDA Handbook, allergic individuals could still be at risk by consuming 
these products. This study surveyed wheat flours available at local grocery stores for the 
presence of soy. The resultant potential risk to soy-allergic consumers of these products is 
determined. Additionally, experimental milling of wheat flour and subsequent stream 
analysis was done with wheat samples spiked with soy to determine the distribution of 
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soy through the milling process and into the various milling streams. The goal was to 
observe if current size separation cleaning practices could produce soy-free wheat 
through stream separation. 
2. Materials and Methods 
2.1. Wheat flour market survey 
A total of 35 wheat flour products were purchased in 2010 from grocery stores in 
Lincoln, Nebraska, USA. Products included all-purpose, whole wheat, white wheat, 
bread, and pastry flours. A representative sample from each package was homogenized 
and then analyzed for the presence of soybean using a commercial enzyme-linked 
immunosorbent assay (Neogen Veratox
®
 Soy Allergen kit) with a lower limit of 
quantification of 2.5 parts per million soy flour (ppm, μg/g). Samples were prepared and 
analyzed according to instructions provided with the kit. Results were converted to ppm 
soy protein for quantitative risk assessment by assuming that soy flour contains 53% 
protein (Ballmer-Weber et al., 2007). 
2.2. Quantitative risk assessment of soy in commercially available wheat flours 
The probabilistic risk assessment model for food allergens utilizes the Monte 
Carlo simulation to quantitatively estimate the risk of a specific product for a food 
allergic population (Kruizinga et al., 2008; Spanjersberg et al., 2007). Briefly, data inputs 
for prevalence of soy allergy, soy thresholds, consumption patterns, and the 
concentrations of soy in flour samples can be fitted to statistical distributions for use in a 
Monte Carlo simulation. Allergic reactions are predicted if the estimated consumed 
amount and concentration of soy in wheat lead to an estimated dose over the predicted 
soy threshold for that individual. The modified Monte Carlo approach for risk analysis 
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incorporates the mean and standard error associated with each input into a Bayesian 
framework to better estimate the confidence of the risk of allergic reaction as 
demonstrated by Rimbaud et al. (2010). The simulation scheme can be seen in Figure 1.  
The distribution of individual threshold doses from double-blind, placebo-
controlled food challenges (DBPCFC) of 43 soy-allergic individuals as based on 
objective symptoms was taken from Remington et al. (2013 (In prep)). The lowest-
observed-adverse-effect-levels (LOAELs) and/or no-observed-adverse-effect-levels 
(NOAELs) from each individual were used, as previously described (Taylor et al., 2009), 
to fit posterior Log-Normal, Log-Logistic, and Weibull probability distribution functions 
for the threshold dose expressed as mg soy protein. Simple fit statistics (AIC, AICC, 
BIC) and the visual fit were similar for all three distributions. No biological basis exists 
upon which to select any one of the distributions over the others; the Log-Normal 
distribution was chosen for use in all probabilistic risk assessments. The Bayesian context 
uses statistical inference to generate the intercept and scale parameters of the Log-Normal 
distribution to help reflect uncertainty in the true location of each parameter.  
 The presence of soy residues in wheat flour resulting from commodity 
comingling was used to assess the risk to soy-allergic consumers across a broad spectrum 
of wheat flour-based foods. Consumption of wheat flour was based on individuals in the 
United States and extracted from the 2003-2006 National Health and Nutrition 
Examination Surveys (NHANES) of the U.S. Department of Agriculture (USDA). 
Individuals that did not complete both days of the survey were excluded from the 
analysis. Wheat flour consumption was estimated using the Foods Analysis and Residue 
Evaluation (FARE™) program from Exponent® with an eating occasion being defined as 
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one hour of consumption. Conservatively, this study estimated that one hour of 
consumption was equal to one eating occasion. The recipes in FARE™ are based on the 
recipes provided by USDA with modifications to analyze individual components of 
foods. Consumption of wheat flour has two inputs, the probability of consuming wheat 
flour and the amount eaten in one hour. Wheat flour consumption is a binomial 
distribution with a yes/no response as individuals are consumers or non-consumers. 
Using the Bayesian framework, Rimbaud et al. (2010) describe the process for fitting a 
Binomial distribution with a non-informative prior Beta(1,1) distribution. The posterior 
Binomial distribution can be solved as follows: p ~ Beta(1+x, 1+n1-x) with x representing 
a positive response and n1 representing the total number of people in the study. The Beta 
distribution provides a new wheat flour consumption probability estimate for the 
Binomial distribution for every run in the simulation. In turn, the Binomial distribution 
determines if an individual is a wheat flour consumer or not for every iteration in the 
simulation. The amount of wheat flour consumed is fit to a Weibull distribution with 
statistical inference used to generate the scale and shape parameters as part of the 
Bayesian framework.  
 Chocolate chip cookies were used as a model food for risk assessment of a single 
food category. Consumption of chocolate chip cookies was based on the 2003-2006 
NHANES survey. Chocolate chip cookies are estimated to be 20% wheat flour by weight 
after analyzing the weights of ingredients in popular chocolate chip cookie recipes from 
the USDA National Nutrient Database. Since no consumption database exists solely for 
allergic consumers, the assumption was made that allergic and non-allergic individuals 
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consume wheat flour and chocolate chip cookies at the same rate and their reasons for 
non-consumption are the same. 
 Results from the market survey were used to estimate the prevalence and 
concentration of soy in commercially available wheat flours. The prevalence of soy in 
wheat flours is a binomial distribution. The simulated concentrations of soy were 
randomly selected from the ELISA analytical results for every consumption event. The 
dose of soy per consumption event was determined using the concentrations of soy in 
wheat flour and the amount of wheat flour consumed. 
2.3. Stream analysis during the milling process of clean wheat seed spiked with soy  
Soy-free, hard red winter wheat seed was obtained from the University of 
Nebraska-Lincoln Department of Agronomy and Horticulture courtesy of Dr. Stephen 
Baenziger. Soybeans were broken into pieces of soy smaller than ½ of a soybean using a 
coffee grinder. The smaller pieces represented soy likely to pass through physical screens 
during the wheat cleaning/screening process and enter into the flour mill. Soybean was 
spiked into wheat seed by weight at a level of 1000 ppm (mg/kg). Ten individual spikes 
were weighed into tempering buckets for repeated milling runs (1998 g wheat with 2 g 
broken soybean). The spiked samples were tempered to a moisture content of 16% from 
an initial moisture content of 11% to prepare for milling and to reflect commercial 
conditions. 
Samples were milled on a Bühler Experimental Mill (Model MLU-202) according 
to the American Association of Cereal Chemists (AACC) International Method 26-21.02 
for hard wheat. A diagram of the experimental mill displays 3 break cycles and 3 
reduction cycles for the wheat to potentially pass through (Figure 2). Each break or 
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reduction is followed by a sifter to separate the sample into the appropriate streams. 
Screen sizes and stream allocations can be found in Table 1. Screens ranged in size from 
160 – 600 microns with particles less than 160 microns entering a finished flour stream. 
The cleanout milling method was used instead of continuous milling to reduce potential 
cross-contamination of soy into subsequent samples. Briefly, during cleaning, the mill 
was brushed and tapped down after each spiked sample to remove flour adhering to 
pieces inside the mill. After brushing, 500 g of tempered soy-free wheat was milled as a 
buffer between samples and upon completion the mill was brushed and tapped down a 
second time. All spiked samples were milled after the clean-buffer-clean cycle. All 8 
milling streams were collected, weighed for mass balance, and analyzed for the presence 
of soybean using a commercial enzyme-linked immunosorbent assay (Neogen Veratox
® 
Soy Flour kit) with a lower limit of quantification of 2.5 parts per million soy flour (ppm, 
μg/g). Results were converted to ppm soy protein for comparison to the wheat flour 
market survey assuming soy flour is 53% protein (Ballmer-Weber et al., 2007). 
2.4. Software and statistics 
All statistical tests were done in SAS (version 9.2). For the probabilistic 
modeling, a Monte Carlo sampling technique was performed (50 runs; 10,000 iterations). 
For every iteration during the simulation, an individual is selected and determined if 
allergic to soybean. If allergic, the simulation chooses if they consume wheat flour. If 
both allergic and consumers of wheat flour, the amount of wheat flour consumed is 
multiplied by the concentration level of soybean in the product to estimate the mg dose of 
soybean protein that was eaten. The dose produced is then matched against the predicted 
allergic threshold value for that individual to predict if an allergic reaction will occur.  
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Streams from the experimental milling procedure were analyzed as part of a 
randomized complete block design (RCBD) to determine if soy was separated into each 
stream of flour at a significantly different rate. 
3. Results 
3.1. Wheat flour market survey 
 Soybean residues were found in all forms of wheat flour with 22 of 35 (62.8%) of 
flours containing detectable soy (Table 2) at concentrations of 3 – 443 ppm soy flour (1.6 
– 236 ppm soy protein). An average serving size for wheat flour (30 g) would contain 
0.05 – 7.1 mg soy protein. Due to the small sample size for each wheat flour category, 
differences in frequency and levels of soy could not be deemed significant. 
3.2. Risk assessment of soy in commercially available wheat flours 
 On a daily basis, wheat flour is consumed by 97.1% of the total U.S. population, 
and greater than 99.3% in the population 3 years of age and up (Table 3). Average wheat 
flour consumption was 34 ± 36 g or slightly more than a suggested serving of wheat flour 
per eating occasion. Chocolate chip cookies are consumed by 11.7% of the U.S. 
population (Table 4). The average chocolate chip cookie consumption amount was 29 ± 
29 g (1 – 2) cookies per day or 5.8 ± 5.8 g wheat flour based on the amount of wheat 
flour in the chocolate chip cookie recipe. 
Simulation risk results are presented as the allergic user risk (Table 5). The 
allergic user risk assumes every individual is allergic to soybean and consumes wheat 
flour or chocolate chip cookies. Two simulations were run for wheat flour, first using the 
range of soy concentrations detected in wheat flour and second with the maximum 
amount of 10% soy allowed in wheat by the USDA Grain Inspection Handbook (USDA, 
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2004). The predicted number of reactions is 2.8 ± 2.0 per 1,000 soy-allergic user eating 
occasions for concentrations of soy found during the wheat flour survey. If the maximum 
amount of soy allowed was milled into wheat flour, the predicted number of reactions 
would be 23.4 ± 4.9 per 100 soy-allergic user eating occasions. The predicted number of 
allergic reactions from chocolate chip cookies is 6.6 ± 6.9 per 10,000 soy-allergic user 
eating occasions. 
The number of allergic reactions in soy-allergic consumers can be predicted on a 
per day basis if it is assumed that a soy-allergic individual consumes wheat flour only 
once per day. The number of eating occasions is found by multiplying the total 
population, the probability of wheat flour consumption, and the probability of a soy-
allergic individual. In the U.S., the prevalence of soy allergy is estimated at 0.35% 
(Sicherer and Sampson, 2010). The minimum number of eating occasions per day is 
predicted below: 
Minimum eating 
occasions per day 
= 
U.S. 
population × 
Wheat 
consumption 
probability 
× 
Prevalence of 
soy allergy 
1.02 million wheat 
flour consumption 
occasions 
= 
300 
million × 0.971 × 0.0035 
  The number of eating occasions is multiplied by the soy-allergic user risk to 
predict the number of allergic reactions per day. The number of predicted reactions can 
be calculated with the equation below: 
Predicted reactions per day 
from soy in wheat 
= 
Minimum eating 
occasions per day × 
Soy-allergic 
user risk  
2,850 objective reactions 
per day 
= 
1.02 million wheat 
flour consumptions × 0.0028 
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 None of the reactions were predicted to occur at doses of soy greater than 88 mg 
soy protein, the lowest LOAEL found in the 43 DBPCFCs for soy (Magnolfi et al., 
1996). The Log-Normal ED05, or dose predicted to provoke a reaction in 5% of the soy-
allergic population is 24.5 mg soy protein, with a lower 95% confidence interval of 5.5 
mg soy protein (Remington et al., 2013 (In prep)); 41% of predicted reactions had doses 
greater than 5.5 mg soy protein. The suggested Reference Dose to guide advisory 
labeling for soy flour is 1.0 mg protein in the VITAL program from the Allergy Bureau 
of Australia (Taylor et al., 2013 (In prep)); 83% of predicted reactions had doses greater 
than 1.0 mg soy protein (Figure 3A). The same methods can be used to calculate 81 
predicted allergic reactions per day due to chocolate chip cookie consumption. No 
reactions were predicted to occur at doses over 88 mg soy protein, 1.5% of predicted 
reactions occurred at doses greater than 5.5 mg soy protein, and 34% of predicted 
reactions occurred at doses greater than 1.0 mg soy protein (Figure 3B).  
3.3. Stream analysis during the milling process of clean wheat seed spiked with soy  
An average mass recovery of 96.2 ± 0.5% was achieved after milling. An average 
soy recovery of 130 ± 20% was observed with the Veratox
®
 Soy Flour ELISA kit. 
Streams were separated into 3 break flours, 3 reduction flours, the bran, and the shorts 
with soy being detected in all samples (Table 6). Separate streams contained detectable 
soy at 28 – 5235 ppm soy flour (15 – 2775 ppm soy protein) with a significant difference 
in the concentration of soy within the final flour streams (P< 0.001). The 1
st
 and 2
nd
 break 
flours had significantly less soy present than other streams. Shorts had the highest 
concentration of soy, followed by 3
rd
 break and 3
rd
 reduction flours. After mass 
adjustment, separate streams of wheat contained 4 – 1097 mg soy flour (2.1 – 581 mg soy 
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protein). In mass units, shorts contained the highest levels of soy followed by 1
st
 
reduction flour, bran, and 2
nd
 reduction flour. The 1
st
 and 2
nd
 break flours contained 
significantly less soy than other streams. By weight, 53% of the soy is separated in the 
bran or shorts and 47% of the soy enters one of the 6 flour streams. 
4. Discussion 
Detectable levels of soy were found in 62.8% (22/35) of wheat flours during the 
market survey. All types of wheat flours contained detectable soy proteins. Cake and 
pastry flours are made from soft wheat due to ideal texture properties imparted by a high 
starch and low protein content. Soybeans and soft wheat share many growing regions in 
the US and it could be hypothesized that a higher soy content would be expected in soft 
wheat flours due to the proximity of soy in the production process. In this survey, the 3 
pastry flours contained low levels of soy in comparison to harder wheat flours, but these 
results could be attributed to the small number of samples. Further studies with larger 
numbers of samples could be of use to investigate the effects of regional differences on 
concentrations of soy in different wheat flours and to determine if different types of 
wheat flours have significantly different levels of detectable soy.  
Soy protein was found at concentrations up to 236 ppm in wheat flour, a dose of 
7.1 mg soy protein per 30 g serving. No published soy challenges have reported an 
objective allergic reaction from doses at or below 7.1 mg soy protein. Despite this 
observation, the quantitative risk assessment indicates that the user risk from soy 
comingling with wheat flour is rather substantial predicting 2850 reactions per day 
among soy-allergic consumers in the U.S. alone. Since no published reports exist of 
reactions that might be attributable to soy comingling with wheat flour, clinical allergists 
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are either overlooking all of these cases (unlikely if 2850 occur per day in the U.S.) or the 
quantitative risk assessment is overstating the actual risk. A thorough examination of the 
inputs to the quantitative risk assessment suggests that are several factors that could result 
in an overestimation.  
Probably owing to the comparatively low prevalence of soy allergy, the current 
investigation was only able to find published individual threshold data from DBPCFC 
soy flour challenges for 43 soy-allergic individuals (Remington et al., 2013 (In prep)). 
Peanut allergy is far more prevalent. The published dataset contains thresholds from 450 
peanut-allergic individuals (Taylor et al., 2010). Populations with a low number of 
individuals have wider confidence intervals and can be significantly affected by the 
addition of data points at the low or high end of the threshold dose distribution. 
Probabilistic risk assessment is still an option with fewer subjects, but the predicted 
threshold distribution will vary widely within the Bayesian context. Additional clinical 
data from soy challenges would be valuable to increase the statistical confidence in the 
population threshold estimates. The study populations for three of the studies used 
(Fiocchi et al., 2003; Magnolfi et al., 1996; Zeiger et al., 1999) involved infants, while 
the remaining study (Ballmer-Weber et al., 2007) assessed an older patient population 
(Remington et al., 2013 (In prep)). Supplementary data on older children and adults 
would enrich the current threshold dataset. The most sensitive objective NOAEL found in 
the clinical literature for soy challenges was 83.7 mg soy protein (Ballmer-Weber et al., 
2007), while the most sensitive objective LOAEL was 88 mg soy protein (Magnolfi et al., 
1996). The Log-Normal ED05, is 24.5 mg soy protein, with a lower 95% confidence 
interval of 5.5 mg soy protein (Remington et al., 2013 (In prep)). By comparison, a 
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NOAEL-based risk assessment would utilize a 10-fold safety factor to convert the 
LOAEL of 88 mg soy protein to a NOAEL equivalent of 8.8 mg soy protein. If a 
benchmark dose risk assessment were used, a reference dose comparable to the lower 
95% confidence interval of the ED05 would be selected from a the Log-Normal, Log-
Logistic, or Weibull distributions. Larger threshold datasets, such as peanut, will have 
general agreement between the lowest eliciting dose, ED01 and/or 95% LCI of the ED05, 
and the VITAL reference dose. A smaller dataset, such as soybean, yields a conservative 
estimate of the ED05 that varies greatly from the lowest eliciting dose.  
A NOAEL-based worst case scenario utilizing the p90 consumption of 73 g wheat 
flour with a soy protein concentration of 236 ppm contains a dose of 17.2 mg soy protein. 
The risk of an allergic reaction to the most sensitive soy-allergic individuals could not be 
ruled out. Probabilistic risk assessments have a number of measurements to eliminate the 
uncertainty found in NOAEL-based risk assessments but they still predict a risk of 
allergic reactions due to soy in wheat flour. If soy-allergic individuals consume wheat 
based products once a day, our simulation predicts an estimated 2,850 objective allergic 
reactions per day due to commodity contamination of soy in wheat. Obviously, reactions 
of this number would be reported or observed on a national scale. Additional factors also 
contribute to the overestimation of the risk to soy-allergic consumers due to soy in wheat. 
The estimated prevalence of soy allergy of 0.35% (Sicherer and Sampson, 2010) is likely 
too high. Historically, estimates of soy allergy prevalence have been based on perceived 
allergy in pediatric populations (Luccioli et al., 2008; Zuidmeer et al., 2008). Perception 
of adverse reactions to food far outnumbers the true prevalence of food allergy (Rona et 
al., 2007; Zuidmeer et al., 2008). Studies estimating the prevalence of soy allergy based 
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on the rate of sensitization to soy through skin prick tests are also based on pediatric 
populations. These studies will overestimate the prevalence of soy allergy as it is well 
known that sensitization alone does not equate to true food allergy (Sicherer and 
Sampson, 2010; Zuidmeer et al., 2008). Oral challenges found 0.7% of children up to age 
14 were allergic to soy milk (Roehr et al., 2004). However, many soy patients reactive to 
soy milk and other less processed forms of soy can tolerate further cooked or processed 
soy products (Mittag et al., 2004). Finally, an estimated 70% of children will outgrow 
their food allergies (Eggleston, 1987). All of these factors combined indicate a prevalence 
of soy allergy in the overall population is closer to 0.1%.  
The datasets for soy contamination in wheat flour and for consumption of wheat 
flour-based foods are reasonably good. However, the nature of probabilistic simulations 
predicted multiple reactions with individual consumption amounts greater than the 99
th
 
percentile estimate for intake and ranged from 150 – 240 g wheat flour (35 – 58 mg soy 
protein), 5 – 8 suggested servings of wheat flour in one sitting. More realistic 
consumption amounts of a highly contaminated wheat flour can produce doses of soy 
protein close to the lower 95% confidence interval of the ED05 from the threshold curve, 
41% of predicted reactions had doses greater than 5.5 mg soy protein. No dose was 
predicted to be above 60 mg soy protein. The probabilistic risk assessment of chocolate 
chip cookies predicts 81 soy-allergic reactions per day due to cross contamination of soy 
in wheat. The simulation estimates 29 of the 81 reactions occur after consumption of 1 
cookie (29 g), the average consumption amount in the U.S. Additionally, 34 reactions 
were predicted after consumption of 2 cookies, 8 reactions after consuming 3 cookies, 8 
reactions after consuming 4 cookies, and 2 reactions after consumption amounts greater 
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than 4 cookies. No reaction was predicted with a dose over 25 mg soy protein (105 g 
wheat flour, 18 cookies). Certainly, this predicted number of reactions to chocolate chip 
cookies have not been observed or reported among soy-allergic consumers. The predicted 
risk from chocolate chip cookies is likely an overestimate of the actual risk for the same 
reasons as outlined for overall wheat flour consumption. While the quantitative risk 
assessment predicts a level of risk from soy comingling with wheat, that level of risk is 
exceedingly small (2.8 ± 2.0 per 1,000 soy-allergic user eating occasions for consumption 
of wheat flour based upon the analysis of wheat flour in our survey) and not evident from 
reported clinical observations. In DBPCFC, experienced clinicians are recording 
relatively mild transitory objective reactions occurring at specific doses; these become 
the LOAELs. Perhaps some mild reactions are indeed occurring from the consumption of 
wheat based products by the soy-allergic population but they are so mild and short-lived 
that affected individuals do not complain. In our opinion, the vast majority of soy-allergic 
individuals should not be advised to avoid foods with wheat flour, although the 
possibility exists that a small number of highly sensitive soy-allergic consumers do exist 
who could be at risk from such exposures.  
However, the level of predicted risk (23.4 ± 4.9 per 100 soy-allergic user eating 
occasions) occurring if wheat flour contained the maximum level of soy contamination 
(10%) allowed by USDA grain standards is 100-fold higher. Perhaps consideration 
should be given to lowering these allowable levels of soy comingling to assure protection 
of soy-allergic consumers. From our survey of wheat flour, the milling industry appears 
able to achieve a much lower level of soy contamination from comingling. 
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Does the current wheat flour milling process allow production of flour streams 
with little or no soy contamination? Throughout the wheat cleaning process, size 
exclusion screening will remove mature soybeans and a number of splits. Immature 
soybeans along with smaller splits and pieces will proceed with the wheat through size 
exclusion screenings and be milled into wheat flour. In commercial milling, wheat and 
soy are broken and milled into 20-40 main streams of flour, bran and shorts. During the 
experimental mill study (6 flour streams, bran, shorts), soy was detected in all 8 streams 
produced. The experimental milling process reduced the amount of soy in flour streams, 
with 53% of the soy separated into the bran or shorts and 47% of the soy entering one of 
the 6 flour streams. The bran and shorts fractions are removed from white flour, thus 
reducing the amount of soy entering the commercial product. Whole wheat flours contain 
the bran and shorts and will include 100% of the soy that enters the milling process. 
There was a significant difference in the concentrations of soy within each stream, but no 
stream could be considered soy-free. Stream separation alone is not enough to create soy-
free wheat. Additionally, single streams are not available for purchase by consumers. 
Milled flour streams are mixed at different ratios to achieve specified protein contents, 
ash ratios, and final properties for customers of different retail products (cake flour, 
pastry flour, bread flour, all-purpose flour, quick-mixing flour, etc). Flours with different 
stream ratios have different dough qualities, baking properties, etc. Additional wheat 
cleaning methods are being explored to remove soy from wheat in the cleaning house but 
currently there are no solutions to completely remove soy from wheat once they have 
been comingled. 
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The only strategy to prevent an allergic reaction is avoidance of the food. Current 
food allergen regulations allow for commodity contamination of agricultural products to 
go unlabeled. Our conservative risk assessment shows the most sensitive soy-allergic 
individuals could have mild, objective reactions after consuming large amounts wheat 
flour or wheat based products. Clinical reports of allergic reactions attributable to soy 
contamination of wheat flour do not match with the predicted level of risk by the risk 
analysis, indicating that the risk assessment model is very conservative and that mild 
reactions, if they are actually occurring, are going unreported. Consequently, no changes 
should be considered to labeling laws regarding commodity comingling and specifically 
soy in wheat.  
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Figures and Tables 
 
Figure 1 –Probabilistic risk assessment model for food allergens in the United States, figure adapted 
from Spanjersberg et al. (2007). 
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Figure 2 – Diagram of the Bühler Experimental Mill (Model MLU-202). The “Br” break cycles are 
denoted with red lines to represent corrugated rollers. Each break or reduction is accompanied by a 
sifter. Particles < 160 microns in size entered a flour stream. 
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Table 1 – Micron screen sizes and destinations for higher flour yield with hard wheat. All particles 
smaller than screen 1 will pass through to be separated by screen 2. 
Break/Reduction Screen 1 > Screen 1 to: Screen 2 > 160 to: < 160 to: 
1st Break  600 A 2nd Break  160 D 1st Reduction 1st Break Flour 
2nd Break  475 B 3rd Break 160 1st Reduction 2nd Break Flour 
3rd Break 475 Bran 160 1st Reduction 3rd Break Flour 
1st Reduction 600 Shorts  160 E 2nd Reduction 1st Reduction Flour 
2nd Reduction  275 C Shorts  160 E 3rd Reduction 2nd Reduction Flour 
3rd Reduction    160 E Shorts 3rd Reduction Flour 
A 600 - opening of 600 microns (0.0236") 
B 475 - opening of 475 microns (0.0187") 
C 275 - opening of 275 microns (0.0108") 
D 160 - opening of 160 microns (0.0063") 
E 1st, 2nd, and 3rd reductions have two 160 micron screens present for efficient flow through 
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Table 2 – Concentration of soybean in packaged wheat flours. 
Wheat Flours No. Tested No. Positive 
PPM Soy 
Protein 
All Purpose Flour 13 10 1.6 – 236 
Bread Flour 4 2 7.3 – 152 
Pastry Flour 3 2 5.0 – 7.1 
White Wheat Flour 4 2 23 – 70  
Whole Wheat Flour 10 5 2.1 – 128  
Unique 1 1 39 
Total 35 22 (62.8%) 1.6 – 236 
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Table 3 – Consumption of wheat flour in the United States per eating occasion (defined as one hour 
time frame) as determined by the FARE™ program from Exponent®. 
Age Percent User Mean (g) Std. Dev. (g) P90 (g) Max (g) 
Total Population 97.1% 34 36 73 906 
Infants 78.8% 14 10 32 167 
Children 99.9% 28 24 60 446 
Teenagers 99.7% 42 31 87 906 
Adults 99.3% 36 44 75 701 
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Table 4 – Consumption of chocolate chip cookies per day in the United States based on the 2003-2006 
NHANES database. 
Age Percent User Mean (g) Std. Dev. (g) P90 (g) Max (g) 
Total Population 11.7% 29 29 56 510 
Infants 8.0% 14 8 30 71 
Children 16.2% 26 18 45 126 
Teenagers 16.1% 29 20 53 315 
Adults 9.0% 31 40 60 510 
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Table 5 – Simulation results 
Product Consumption Pattern Level of Soy Present (ppm) Soy-Allergic User Risk (%) SD 
Wheat Flour Total Population 1.6 - 236 ppm soy protein 0.28 0.20 
Wheat Flour Total Population 40,000 ppm soy protein 23.4 4.9 
Chocolate 
Chip Cookies 
Total Population 1.6 - 236 ppm soy protein 0.066 0.069 
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A 
 
 
B 
 
Figure 3 – Thresholds of predicted reactions expressed as mg protein with the predicted consumption 
for each reaction: (A) Soy in Wheat Simulation, (B) Chocolate Chip Cookie Simulation. Relevant 
reference doses and threshold levels are labeled. 
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Table 6 – Stream analysis of milled wheat samples in ppm soy flour with mass balance calculated in 
mg soy. Significant differences within streams or mg soy are denoted with different superscript 
letters. 
  
Total fraction 
weight (g) 
Percent total 
wheat flour 
Average PPM 
soy protein 
Percent 
total soy 
Average mg 
soy protein 
1st Break Flour 114 ± 3 g 6 ± 0% 15 ± 3 ppm
 A
 0.1 ± 0.0% 2 ± 0.4 mg
 A
 
2nd Break Flour 227 ± 8 g 11 ± 0% 63 ± 14 ppm
 A
 1 ± 0% 16 ± 4 mg
 A
 
3rd Break Flour 55 ± 1 g 3 ± 0% 1120 ± 195 ppm
 D
 6 ± 2% 88 ± 15 mg
 B
 
1st Reduction 
Flour 
727 ± 11 g 36 ± 1% 329 ± 58 ppm
 B
 17 ± 3% 247 ± 41 mg
 E
 
2nd Reduction 
Flour 
296 ± 19 g 15 ± 1% 615 ± 183 ppm
 C
 14 ± 3% 196 ± 59 mg
 D
 
3rd Reduction 
Flour 
82 ± 10 g 4 ± 0% 1240 ± 256 ppm
 D
 9 ± 3% 131 ± 27 mg
 C
 
Bran 352 ± 10 g 17 ± 1% 564 ± 244 ppm
 C
 18 ± 11% 213 ± 93 mg
 D,E
 
Shorts 186 ± 9 g 9 ± 0% 2780 ± 704 ppm
 E
 35 ± 11% 581 ± 149 mg
 F
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Abstract 
The food industry utilizes different varieties of soy flours and protein products for 
a number of purposes in a wide range of available products. The traditional methods to 
modify the functional properties of soy products include adjustment of the protein 
content, heat denaturation, full or partial protein hydrolysis, and pH adjustment. Newer 
methods include jet-cooking/flash cooling, high pressure treatment, and different solvent 
extractions. Due to the widespread use of soy, it is necessary to understand the effects 
that these treatments have on the different proteins found in soybeans, including the 
allergens, with respect to protein identification and IgE binding capabilities. In this study, 
allergens were quantified in all major forms of soy available to the food industry and IgE 
binding studies using sera from soy-allergic individuals were conducted on these same 
products. The results from this study show that LC-MS/MS is a viable method to identify 
the majority of allergenic soy proteins. Fourteen known allergens were identified in the 
soy product samples, including all subunits of Gly m 5 (β-conglycinin) and Gly m 6 
(glycinin), the Kunitz trypsin inhibitor, Gly m Bd 28K, and Gly m Bd 30K. Additional 
method refinements or different techniques might be necessary to detect low abundance 
proteins such as Gly m 3 and 4. IgE binding patterns could not be clearly correlated to 
clinical histories and symptoms as patients with similar histories could exhibit intense 
binding or no binding at all. However, when IgE binding was present, the relative amount 
of an allergen in a sample correlated positively to the intensity of IgE binding to proteins 
at the expected molecular weight. 
  
243 
 
1. Introduction 
Soybeans are a staple food in many cultures and play a large role in the diet of 
food-producing animals (Barać et al., 2004; Friedman and Brandon, 2001). Studies 
estimate that 4 – 10% of children and 3 – 4% of adults are affected by food-induced 
allergic reactions (Branum and Lukacs, 2009; Osborne et al., 2011; Rona et al., 2007; 
Sicherer and Sampson, 2010). Soy is one of the most common allergenic foods in 
children, and soy allergy can be severe (Sicherer and Sampson, 2010). Soy-allergic 
consumers are advised to adhere to a strict avoidance diet and carefully read ingredient 
labels of all foods (Hefle et al., 2007; Pieretti et al., 2009; Taylor et al., 1986).  
A typical dry soybean is composed of 40% protein, 20% oil, 35% carbohydrates, 
and 5% ash (Liu, 2004). Previous research quantified 8 soybean allergens in varieties of 
unprocessed soybeans using tandem mass spectrometry-based multiple reaction 
monitoring (MRM) (Houston et al., 2011). Gly m 3 and Gly m 4 were not detected but 
have respectively been found by others to be present at 0.6 – 0.8% and 0.01 – 0.15% of 
total soy protein (Amnuaycheewa and Gonzalez de Mejia, 2010; Houston et al., 2011; 
Julka et al., 2012; Mittag et al., 2004). Natural variability exists in allergen expression 
among soy varieties (Houston et al., 2011; Nordlee, 1995), but environmental effects 
have been shown to affect protein expression patterns with greater significance than 
breeding differences (Stevenson et al., 2012). Different varieties of soy can be grown to 
contain up to 48% protein, but the easiest way to obtain higher protein levels is to process 
the bean into defatted soy flour, soy protein concentrate (SPC), or soy protein isolate 
(SPI). Most soy flours are made by grinding dehulled and defatted soy flakes, containing 
at least 50% protein (dry basis), and are traditionally used as an ingredient in the baking 
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industry. Soy protein concentrates (SPC) are made by removing the soluble sugars from 
the defatted flake with an aqueous alcohol extraction, contain at least 65% protein, and 
are used to bind water while adding protein and textural characteristics to many different 
products. Soy protein isolates (SPI) have the soluble and insoluble carbohydrates 
removed from the defatted flake, contain at least 90% protein, and are used for gelation, 
emulsification, water binding, viscosity, foaming, and whipping (Egbert, 2004). Soy 
flours, SPC, and SPI are used in many different products ranging from protein shakes to 
soups, baked products, meats, and cheeses. Soy ingredients can be used for protein 
fortification, but other applications include improving texture, gelation, emulsification, 
water binding, viscosity, foaming, and whipping. Soy sauce and hydrolyzed vegetable 
protein are used for flavor enhancement. The traditional methods to modify the functional 
properties of soy products include adjustment of the protein content, heat denaturation, 
full or partial protein hydrolysis, and pH adjustment. Newer methods include jet-
cooking/flash cooling, high pressure treatment, and different solvent extractions (Egbert, 
2004). Due to the widespread use of soy, it is necessary to understand the effects that 
these treatments have on the different proteins found in soybeans, including the allergens, 
with respect to protein identification and IgE binding capabilities.  
Serum IgE binding to at least 16 soy proteins has been shown in soy-sensitive 
individuals with atopic dermatitis (Ogawa et al., 1991). There are six proteins in soy 
recognized as allergens by the International Union of Immunological Societies (IUIS) 
including two soy hull proteins (Gly m 1 and Gly m 2), profilin (Gly m 3), a stress 
induced, pathogenesis-related starvation associated message protein (Gly m 4), β-
conglycinin (Gly m 5), and glycinin (Gly m 6). In addition to the official IUIS allergens, 
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multiple other proteins, not recognized by the IUIS, have been shown to cause reactions 
or bind IgE from soy-allergic individuals. These proteins include the vacuolar protein 
P34 or Gly m Bd 30 K, Gly m Bd 28 K, the Kunitz trypsin inhibitor, and lectin. More 
research is needed to investigate the production processes of soy milks (SM), SPIs, and 
other soy products to help understand how processing affects the detectable protein levels 
and IgE binding characteristics of allergens present. In this study, allergens were 
quantified in all major forms of soy available to the food industry including full-fat 
flours, defatted flours, soy protein concentrates, soy protein isolates, and multiple soy 
milks and drinks. Additionally, samples associated with reactions specifically associated 
with Gly m 4-sensitive patients in the United States and Europe were analyzed to 
investigate if a difference in protein levels and IgE binding patterns is present in the final 
products.  
2. Methods and Materials 
Soy products used in study 
 Sixteen soy protein ingredients or drink products were acquired for allergen 
characterization by liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
relative protein quantification and human IgE binding studies (Table 1). Samples 
believed to be representative of the range of soy proteins used in the food industry were 
provided by a large soy protein ingredient supplier. Additional samples implicated in soy-
allergic reactions were provided by clinical allergists or purchased from local stores in 
Lincoln, Nebraska, U.S. 
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Table 1. Soy products acquired for allergen evaluation. 
 
  
Category
Product 
Name
Description Info From
Aquired 
Through
Defatted 
Soy Flour
SF1
Minimally dry heat processed and most nearly resembles 
the native defatted fraction of raw soybeans. 
Product 
information sheet
Soy protein 
supplier
SF2
Moderately dry heat treated with its greatest use in bakery 
and cereal applications.
Product 
information sheet
Soy protein 
supplier
SF3
Fully dry heat treated and used in cookies, crackers, cereals, 
beverages, calf milk replacers, and fermentation media.
Product 
information sheet
Soy protein 
supplier
Full Fat Soy 
Flour
SF4
Stone ground, not heat treated. Germ, bran and natural oils 
are fully preserved. 
Product website
Retail 
Purchase
Soy Protein 
Concentrate
SPC1
A traditional alcohol washed SPC manufactured to remove 
soluble sugars and reduce the anti-nutritional factors. 
Product 
information sheet
Soy protein 
supplier
SPC2
Manufactured by an alcohol wash with additional 
(unknown) steps and an acid precipitation. 
Product 
information sheet
Soy protein 
supplier
SPC3
A water-washed soy protein concentrate with a low flavor 
profile and high protein solubility. 
Product 
information sheet
Soy protein 
supplier
Soy Protein 
Isolate
SPI1
A SPI with a pH drop. It is a medium- to low-viscosity 
protein that is dispersible in water or other liquid systems. 
Product 
information sheet
Soy protein 
supplier
SPI2
A hydrolyzed SPI. It is specially processed for applications 
where a very low-viscosity protein is desired.
Product 
information sheet
Soy protein 
supplier
SPI3
A specially processed SPI product used for its non-water 
binding properties. It is used in the manufacture of natural 
soy cheese.
Product 
information sheet
Soy protein 
supplier
SPI4
A functional product with no modifications. It is a soluble, 
dispersible product developed for use in food systems 
where a highly functional protein is required.
Product 
information sheet
Soy protein 
supplier
Soy Milk
8
th 
Continent
Manufactured with an unknown SPI as its protein source. 
Specific production methods are unknown. Purchased for 
comparison to Alpro™ Soya.
Ingredient List
Retail 
Purchase
SILK® 
Original
Manufactured in the U.S. and made with filtered whole 
soybeans. Implicated in U.S. reactions to soy and 
purchased for comparison to Alpro™ Soya.
Ingredient List
Retail 
Purchase
Alpro™ 
Soya
Manufactured in Europe, made with filtered whole 
soybeans, and implicated in Gly m 4 related reactions.
Ingredient List
Allergist 
Provided
Other 
Products
Almased®
A SPI/cow’s milk/honey nutritional drink that has been 
implicated in Gly m 4 related reactions. It originated in 
Europe and is sold in the U.S. as well. The SPI used in 
Almased is produced through cold-pressed separation of 
the oils from the soy flakes, protein extraction at pH 8-8.5, 
neutralization, and spray drying without an acid 
precipitation of the proteins (Kleine-Tebbe et al., 2002; 
Mittag et al., 2004). There is an additional modification step, 
however, that is confidential information and not released 
by the manufacturer.
(Kleine-Tebbe et 
al., 2002; Mittag et 
al., 2004)
Retail 
Purchase
Soybean 
Powder 
(SBP)
A specially designed product for use in dairy systems. This 
product is made from de-hulled organic whole soybeans 
which are finely ground in a high-temperature aqueous 
environment and then spray dried.
Product 
information sheet
Soy protein 
supplier
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Relative Quantification of Soy Allergens using Mass Spectrometry 
Protein Digestion 
Soy product samples were dissolved and acetone precipitated before digestion. 
Briefly, 500µg of protein was precipitated by cold acetone (-20°C) added (80 µL) at four 
times the largest sample volume in a polypropylene tube. Samples were vigorously 
stirred, incubated for 60 minutes at -20°C, and centrifuged for ten minutes at 13,000 x g. 
The supernatant was decanted and the protein pellet was dried at room temperature for 30 
minutes. The protein pellet was reconstituted in 20 µL of 100 mM ammonium 
bicarbonate (AMBC) and 6M urea. Proteins were reduced with 1 µL of 15% 
dithiothreitol (w/v) in 100 mM AMBC at 25°C for 1 hour. Alkylation of proteins was 
achieved with the addition of 20 µL of 3.6% iodoacetamide in 100 mM AMBC and 
incubation for 1 hour in the dark at room temperature. Leftover alkylating agent was 
consumed by the addition of 4 µL of 15% dithiothreitol (w/v) in 100 mM AMBC and 
incubation for 45 minutes at room temperature. Urea concentrations were diluted to less 
than 1M through buffer exchange. Briefly, samples were transferred to Amicon
®
 Ultra 
3K centrifugal filter concentrators (UFC500396, Millipore, Billerica, MA) and buffer 
exchange done with 200µL of 50 mM AMBC. Samples were centrifuged for 14,000 x g 
for 10 min and the flow through buffer was discarded. The washing process was repeated 
4 times. Exchanged samples are collected into clean microfuge tubes by reverse 
centrifugation at 1,000 x g for 2 minutes. Samples were then subjected to a 2-step multi-
enzyme digestion. Sequencing grade endoproteinase Glu-C from Staphylococcus aureus 
(1µg/µL in 50 mM AMBC) (P6181, Sigma-Aldrich, St. Louis, MO) was added at a 1:50 
enzyme to protein ratio (10 µL per sample) and incubated for 3-6 hours at 25°C. 
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Sequencing grade trypsin from porcine pancreas (1µg/µL in 50 mM AMBC) (T6567, 
Sigma-Aldrich, St. Louis, MO) was added at a 1:20 enzyme to protein ratio (25 µL per 
sample) and digested overnight at 37°C. 
LC-MS/MS analysis 
 LC-MS/MS was performed with an Ultimate® 3000 Dionex MDLC system 
(Dionex Corporation, USA) integrated with a nanospray source and LCQ Fleet Ion Trap 
mass spectrometer (Thermofinnigan, USA). LC-MS/MS included on-line sample pre-
concentration and desalting using a monolithic C18 trap column (Pep Map, 300 µm I.D x 
5mm, 100Å, 5 um, Dionex). Samples were loaded onto the monolithic trap column at a 
flow rate of 40 µl/min. The desalted peptides were eluted and separated on a C18 Pep Map 
column (75 µm I.DX15 cm, 3 µm, 100Å, New Objective, USA) by applying an 
acetonitrile (ACN) gradient (ACN plus 0.1% formic acid, 90 minute gradient at a flow 
rate of 300 nl/min) and were introduced into the mass spectrometer using the nano spray 
source. The LCQ Fleet mass spectrometer was operated with the following parameters: 
nano spray voltage, 2.0 kV; heated capillary temperature, 200°C; full scan m/z range, 
400-2,000). The mass spectrometer was operated in data dependent mode with 4 MS/MS 
spectra for every full scan, 5 microscans averaged for full scans and MS/MS scans, a 3 
m/z isolation width for MS/MS isolations, and 35% collision energy for collision-induced 
dissociation.  
Database analysis  
The MS/MS spectra were searched against the Glycine max protein sequence 
database using MASCOT (Version 2.2 Matrix Science, London, UK). Database search 
criteria were as follows: enzyme: endoproteinase Glu-C/Trypsin, missed cleavages: 2; 
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mass: monoisotropic; fixed modification: carbamidomethyl (C); variable modification: 
oxidation (M); peptide tolerance: 2Da; MS/MS fragment ion tolerance: 1Da. Probability 
assessment of peptide assignments and protein identifications were accomplished by 
Scaffold (Scaffold 3.0 Proteome Software Inc., Portland, OR). Criteria for protein 
identification included detection of at least 1 unique identified peptide and a peptide and 
protein probability score of ≥90. Relative quantitation of the proteins was done based on 
the label-free method of spectral counting using the normalized spectral counts for each 
protein.  
IgE binding studies with soy sensitive subjects 
Human Sera 
Serum samples were collected from consenting individuals with a positive clinical 
food challenge to soybean or a convincing history of allergic reactions to soybean. All 
sera were collected under Institutional Review Board oversight at their respective clinical 
institutions. Sera from 31 soybean-allergic individuals and one control subject without 
soybean allergy were used in this study (Table 2). The allergic patients utilized in this 
study had soybean specific IgE level ranging from <0.35-34.8 kU/L as measured by 
ImmunoCAP
®
. Representative sera from 8 individuals were chosen to represent all 32 
sera due to their characteristic binding patterns (Table 3). The control subject used in this 
study has no reported food allergies. 
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Table 2. Sera from 31 soybean-allergic individuals and one control subject without soybean allergy 
used to investigate IgE binding patterns to a spectrum of soy ingredients and products. 
Subject Soy CAP Gly m 4 
CAP 
Food 
Challenge 
Soy Milk 
Reactor 
Soy Flour 
Reactor 
Peanut 
Allergic 
DDB 34.8  No Unknown Yes No 
ACG 3.18  No Unknown Yes No 
JENB <0.35  No Unknown Yes  Unknown 
MA <0.35  No Unknown Yes  Unknown 
HS 0.6  No Unknown Yes No 
JB <0.35  No Unknown Yes  Unknown 
JL 007 1.22  No Unknown Yes Yes 
AB 008    No Unknown Yes Yes 
SP902 0.78 17.6 Yes Yes No Yes 
SP903 1.55 0 Yes No Yes Yes 
SP904 8.96 5.11 Yes No Yes Yes 
SP905 4.55 0.44 Yes Yes No No 
SP906 1.43 0.5 Yes No Yes No 
SP907 <0.35 26.2 Yes Yes No Yes 
SP908 <0.35   Yes Yes No No 
SP909 9.23 >100 Yes Yes No Yes 
219  14.1   No Yes No  Unknown 
791     No Yes No  Unknown 
450  4.4   No Yes No  Unknown 
681 0.35 9.81 Yes Yes No No 
422 7.65 0.13 No Yes No Yes 
42 <0.35 16.2 No Yes No Yes 
48 <0.35 14.9 No Yes No No 
925 0.35 3.62 No Yes No No 
339 0.35 5.69 No Yes No Yes 
893 <0.35 5.02 No Yes No No 
668 0.9 11.4 No Yes No No 
155 0.6 20.6 No Yes No Yes 
138 <0.35 5.79 No Yes No Yes 
32 0.35 28.8 Yes Yes No No 
579 <0.35 14.6 No Yes No No 
Control 1 <0.35   No No No 
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Extraction of soy proteins 
Soluble proteins from the obtained soy samples were extracted 1:10 (w/v) in 0.01 
M phosphate buffered saline (PBS; 0.002 M NaH2PO4, 0.008 M Na2HPO4, 0.85% 
NaCl, pH 7.4) overnight with gentle rocking at room temperature. Extracts were 
centrifuged for 30 minutes at 4100 × g in a tabletop centrifuge at 10°C. The supernatant 
was aliquoted in 1 mL intervals and stored at -20°C. The protein content of the extracts 
was determined by the micro BCA protein method (Smith et al., 1985) (23252, Pierce 
Biotechnology, Inc., Rockford, IL). 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein separation by SDS-PAGE was done with a Bio-Rad Mini-Protean
®
 
Tetracell electrophoresis unit (Bio-Rad Laboratories, Hercules, CA). For non-reduced 
samples, 25 µg each respective soy sample were boiled for 5 minutes in Laemmli sample 
buffer and separated on a 12% Mini-PROTEAN
®
 TGX™ Tris-HCl precast gel (Bio-Rad 
Laboratories, Hercules, CA) at 200V (constant voltage) for 30 minutes. For reduced 
samples, 25 µg of each sample were boiled in Laemmli sample buffer containing 5.4% 
dithiothreitol (w/v) and separated on a 12% Mini-PROTEAN
®
 TGX™ Tris-HCl precast 
gel (Bio-Rad Laboratories, Hercules, CA) at 200V (constant voltage) for 30 minutes. 
Protein stained gels were fixed in a solution of 60% trichloroacetic acid and 17.5% 5-
sulfosalicylic acid (F7264-500ML, Sigma-Aldrich, St. Louis, MO), stained with 
Coomassie Brilliant Blue R-250 Staining Solution (161-0436, Bio-Rad Laboratories, 
Hercules, CA), and destained with Coomassie Brilliant Blue R-250 Destaining Solution 
(161-0438, Bio-Rad Laboratories, Hercules, CA). Gel images were captured using a 
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Kodak Gel Logic 440 Imaging System (Eastman Kodak, Rochester, NY) equipped with 
Carestream Molecular Imaging software (v5.0.2.30, Carestream Health, Rochester, NY). 
Immunoblotting procedures 
As described above, 25 µg of protein from each sample was separated by SDS-
PAGE. After electrophoresis, the proteins were transferred onto a polyvinyl difluoride 
(PVDF) membrane using the Trans-Blot
®
 Turbo™ Transfer Pack Midi format (170-4147, 
Bio-Rad Laboratories, Hercules, CA) and Trans-Blot
®
 Turbo™ Transfer System at 25V 
(limit voltage), 2.5A (constant amperage) for 10 minutes. The membrane was then 
blocked by incubation with 0.01 M PBS, pH 7.4 containing 0.05% Tween 20 (PBS-T) 
and 5% nonfat dry milk (NFDM) for 2 hours at room temperature. Individual human sera 
were diluted 1:10, in 2.5% NFDM in PBS-T, blocked for 1 hour, and then incubated with 
the blocked membrane overnight at room temperature. Unbound antibody was removed 
from the membranes by washing with PBS-T, four repetitions, 2 minutes each with 
vigorous shaking. Bound IgE was detected using monoclonal horseradish peroxidase 
(HRP) conjugated anti-human IgE (9160-05, clone B3102E8, SouthernBiotech, 
Birmingham, AL), diluted 1:1000 with 2.5% NFDM in PBS-T. Unbound secondary 
antibody was removed from the membranes by washing with PBS-T, four repetitions, 2 
minutes each with vigorous shaking. Supersignal West Dura Extended Duration substrate 
(34076, Pierce, Rockford, IL, USA) was used for detection. Membrane images were 
captured using a Kodak Gel Logic 440 Imaging System (Eastman Kodak, Rochester, NY) 
equipped with Carestream Molecular Imaging software (v5.0.2.30, Carestream Health, 
Rochester, NY). 
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3. Results and Discussion 
LC-MS/MS results 
Endoproteinase Glu-C and trypsin digested proteins were analyzed by LC-
MS/MS. A single sample of each soy product was digested and analyzed in a single 
replication. A MASCOT search of the Glycine max protein database assigned over 600 
proteins with at least 1 unique identified peptide and a peptide and protein probability 
score of ≥90. Approximately 66% of identified proteins are “putative uncharacterized 
proteins” and 33% are known proteins. Fourteen known allergens were identified in the 
soy product samples, including all subunits of Gly m 5 (β-conglycinin) and Gly m 6 
(glycinin), the Kunitz trypsin inhibitor, Gly m Bd 28K, and Gly m Bd 30K (Table 2). 
Additionally, profilin can be identified in one sample, SF3, when the peptide probability 
threshold is lowered to >0 and the protein probability score is lowered to ≥20. Gly m 4 
was not identified by relative quantification. Figure 1 shows the normalized spectral 
counts for each allergen. The subunits of seed storage proteins Gly m 5 and 6 accounted 
for the majority of the 10 most abundant proteins, allergens and non-allergens included, 
in all tested products. The G1 subunit of Gly m 6 is the most abundant protein in all 16 
product samples. The G2 subunit of Gly m 6 is the 2
nd
 most abundant protein in 13 of 16 
product samples, 3
rd
 most abundant in 1 of 16 samples, and 4
th
 most abundant in 1 of 16 
samples. The α-subunit of Gly m 5 is the 2nd most abundant protein in 2 of 16 product 
samples, 3
rd
 most abundant protein in 13 of 16 samples, and 4
th
 most abundant in 1 of 16 
samples. Eleven allergens were identified at least 13 products. However, proteins less 
frequently identified included Gly m Bd 28K and Kunitz trypsin inhibititor (KTI) B, in 6 
products and Gly m 6 subunit G3, in 9 products.  
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Table 4 – Allergenic proteins of interest in soybean during relative quantification by LC-MS/MS. 
Allergen 
 
Number of Products 
Identified In (Out of 16) 
Accession 
Number 
Gly m 3   1 3021373  
Gly m 4   0 134194  
Gly m 5 α subunit 16 Q948X9 
  α' subunit  14 Q4LER6 
  β subunit 15 P25974 
Gly m 6 G1 16 P04776 
  G2 16 18609 
  G3 9 18639 
  G4 16 Q9S9D0 
  G5 16 P93707 
Kunitz KTI A 13 18770 
Trypsin KTI B 6 P01071 
Inhibitor KTI 1 14 P25272 
Isoforms KTI 2 15 P25273 
Gly m Bd 28K   6 187766751 
Gly m Bd 30K   16 O64458 
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Figure 1 – Relative quantitation of 14 soy allergens in 16 soy ingredients and products by LC-MS/MS 
after endoproteinase Glu-C/Trypsin digestion. Criteria for protein identification included detection 
of at least 1 unique identified peptide and a peptide and protein probability score of ≥90. Relative 
quantitation of the proteins was done based on the label-free method of spectral counting using the 
normalized spectral counts for each protein.  
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Profiles of individual soy ingredients and products show slight variations in 
frequency and abundance of individual proteins identified (Figure 2). Defatting and 
varying heat treatments did not significantly affect the proteins expressed in available soy 
flours. Additionally, the processing involved in creating the soybean powder did not alter 
the protein profile from the less processed soy flours. Glycinin G3 was identified in all of 
the soy flours, soy milks, and soybean powder, but not in the 4 SPIs tested. Additionally, 
glycinin G3 was not identified in the alcohol washed SPCs 1 and 2, but was identified in 
the water washed SPC3. Gly m Bd 28K is the least abundant identified allergen. Similar 
to glycinin G3, Gly m Bd 28K was not identified in the alcohol washed SPCs but was 
identified in the water washed SPC. Gly m Bd 28K was not identified in less processed 
soy flours, SFs 1 and 4, but was identified in high heat treated samples, SFs 2 and 3.  
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Figure 2 – Relative quantitation of soy allergens grouped by individual products analyzed with LC-
MS/MS after endoproteinase Glu-C/Trypsin digestion. Criteria for protein identification included 
detection of at least 1 unique identified peptide and a peptide and protein probability score of ≥90. 
Relative quantitation of the proteins was done based on the label-free method of spectral counting 
using the normalized spectral counts for each protein.  
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IgE binding results 
Figure 3 shows the protein profile of the soy products and ingredients tested under 
non-reducing and reducing conditions. The heavy banding present from 50-75 kDa in the 
non-reduced gels represents the subunits of Gly m 5 and 6. Reduced gels still contain the 
major Gly m 5 subunits near 70 kda, but the subunits of Gly m 6 have separated into 
acidic and basic components clustered around 35 kDa. Hydrolysis has a distinct effect on 
the protein profile of select soy ingredients known to be subjected to the hydrolysis 
process (SPI 2 and 3). All soy milks have protein profiles similar to whole soy or 
minimally processed soy. Almased, a mix of specially processed SPI (50%), cow’s milk, 
and honey, has a distinct protein profile but the effects can be partially attributed to the 
dilution of soy protein due to cow’s milk and honey present in the sample. Brown rice 
was included as negative control sample. Navy bean was included as a 2
nd
 negative 
control sample and as an indicator of possible cross-reactive carbohydrate (CCD) 
epitopes bound by allergic individuals (Panda, 2012). 
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Figure 3 – SDS-PAGE gels of soy products under non-reducing (A) and reducing (B) conditions.  
Sample gels (25 µg extract protein per lane) were run under SDS-PAGE (200V, constant voltage) non-
reducing and reducing conditions, fixed, and then stained using Coomassie Brilliant Blue R-250. After 
destain, gel images were captured using a Kodak Gel Logic 440 Imaging System. 
Soy-allergic sera were divided into multiple categories for analysis of binding 
patterns. Categories included an anaphylactic history to soy, a positive food challenge to 
soy, or a clear history of mild reaction to soy. Challenge positive individuals were further 
split into soy flour and soy milk reactors. Each group had individual serum IgE that 
bound strongly to representative soy samples, while others showed weak or no binding at 
all. The majority of sera showed binding to navy bean near 35 kDa, indicative of CCD 
epitopes in soy (Panda, 2012). The 8 soybean-allergic sera in Figures 4-11 were selected 
from the 31 available soybean-allergic sera for their representative binding patterns. 
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Figure 4 – Serum 668 IgE immunoblot of soy products under non-reducing (A) and reducing (B) 
conditions. Sample gels (25 µg extract protein per lane) were run under SDS-PAGE non-reducing and 
reducing conditions and transferred to PVDF membranes. Membranes were blocked in PBS-T with 5% 
NFDM followed by incubation with serum diluted 1:10. Bound IgE was detected using monoclonal HRP 
conjugated anti-human IgE diluted 1:1000 in 2.5% NFDM in PBS-T. Chemiluminescent substrate was used 
for detection and membrane images were captured using a Kodak Gel Logic 440 Imaging System. 
 Patients 668 and 422 had a history of clear allergic reactions to soy milk and 
provided sera 668 and 422 (Figure 4 and 5). Serum 668, which had a history of 
anaphylaxis to soy milk, had low CAP and ISAC scores to Gly m 5 and 6 but had 
moderate responses to Gly m 4. Low CAP scores for Gly m 5 and 6 correlated to light 
binding to a number of high and low molecular weight proteins in non-reduced IgE 
immunoblots (Figure 4). Reducing conditions induced small changes to the binding 
profile, such as reduction in binding to high molecular weight proteins and an intensified 
binding to a 12-14 kDa protein. Binding of serum 668 intensified to the 12-14 kDa 
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protein in both navy bean and brown rice on reduced gels. There is a distinct lack of 
binding to the 12-14 kDa protein in 4 hydrolyzed and/or highly heat processed soy 
ingredients (SF3, SPC1, SPIs 2 and 3). One serum (SP905) shared the binding profile of  
patient 668 to this protein in soy, brown rice, and navy bean. Five sera (DDB, SP902, 
SP909, 138, 925) bound to a ~15 kDa protein in soy products but not brown rice or navy 
bean. One serum (SP906) bound strongly to this protein in soy products and brown rice, 
but not in navy bean. Three sera (ACG, 42, 579) bound to this protein in soy and navy 
bean, but not brown rice. Four sera (JL 007, 32, 48, SP904) bound to the ~15 kDa protein 
in rice and/or navy bean, but not soy products. Gly m 3 (14 kDa) has known analogs in 
rice (Accession No. Q5VMJ3) and navy bean (Accession No. P49231) with high 
sequence conservation and secondary structure prediction between the 3 proteins 
(PRALINE multiple sequence alignment, data not shown). Additionally, Gly m 4 (17 
kDa) has analogs in rice (Accession No. NP_001049857) and navy bean (Accession No. 
CAA65727) with moderate sequence conservation but high similarity in secondary 
structure prediction (PRALINE multiple sequence alignment, data not shown). It is 
impossible to distinguish between Gly m 3 and 4 based on the data available in the 
current results. Additional 1-D inhibition binding studies, 2-D binding studies, or 
basophil histamine release studies could help distinguish if the binding near 15 kDa is to 
Gly m 3 or 4 and if the binding is clinically relevant.   However, since these patients are 
not reportedly allergic to brown rice or navy bean, the clinical relevance of the binding to 
these proteins in brown rice and navy bean is questionable.  Since patient 668 had a 
history of an anaphylactic reaction to soy milk, the binding to this protein in soy product 
extracts may be of greater significance but this requires further evaluation. 
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Figure 5 – Serum 422 IgE immunoblot of soy products under non-reducing conditions. Sample gels 
(25 µg extract protein per lane) were run under SDS-PAGE non-reducing conditions and transferred to 
PVDF membranes. Membranes were blocked in PBS-T with 5% NFDM followed by incubation with 
serum diluted 1:10. Bound IgE was detected using monoclonal HRP conjugated anti-human IgE diluted 
1:1000 in 2.5% NFDM in PBS-T. Chemiluminescent substrate was used for detection and membrane 
images were captured using a Kodak Gel Logic 440 Imaging System. 
Patient 422 had a history of anaphylaxis to soy milk and is allergic to peanuts.  
The serum from this patient (Serum 422) had moderate CAP and ISAC scores to Gly m 5 
and 6 but had no response to Gly m 4. Higher CAP and ISAC scores for Gly m 5 and 6 
correlated to strong binding to a number of high molecular weight proteins in non-
reduced IgE immunoblots (Figure 5). Binding was strong for both the soy flours and soy 
milks. Again, there was lack of or diminished binding to hydrolyzed SPI, but this may not 
be clinically significant. Patients 668 and 422 both had a history of anaphylaxis to soy 
milk, but have very different binding profiles. Patient 668 seemingly reacts to Gly m 4 
while patient 422 seemingly reacts to Gly m 5 and 6. While these sera 668 and 422 have 
binding to a broad range of proteins, sera from 3 other patients (155, 339, 925) with a 
positive soy CAP and a mild or anaphylactic reaction history had little to no binding to 
soy proteins under non-reducing conditions (data not shown).  
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Figure 6 – Serum 681 IgE immunoblot of soy products under non-reducing conditions. Sample gels 
(25 µg extract protein per lane) were run under SDS-PAGE non-reducing conditions and transferred to 
PVDF membranes. Membranes were blocked in PBS-T with 5% NFDM followed by incubation with 
serum diluted 1:10. Bound IgE was detected using monoclonal HRP conjugated anti-human IgE diluted 
1:1000 in 2.5% NFDM in PBS-T. Chemiluminescent substrate was used for detection and membrane 
images were captured using a Kodak Gel Logic 440 Imaging System. 
Patient 681 had a history of positive food challenge to soy milk. Moderate CAP 
scores to Gly m 4 were observed with serum 681 but the overall soy CAP was low. 
Curiously, strong binding is present to high molecular weight proteins in the majority of 
soy products (Figure 6).  A low soy CAP did not correlate to low binding to high 
molecular weights in this serum. Little, if any, binding was noted to proteins in the 17kDa 
region where Gly m 4 would be expected.  The serum from patient 32 had a similar 
history and CAP scores and showed very weak binding to high molecular weight proteins 
in soy flour and soy milk (data not shown).  
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Figure 7 – Serum SP902 IgE immunoblot of soy products under non-reducing (A) and reducing (B) 
conditions. Sample gels (25 µg extract protein per lane) were run under SDS-PAGE non-reducing and 
reducing conditions and transferred to PVDF membranes. Membranes were blocked in PBS-T with 5% 
NFDM followed by incubation with serum diluted 1:10. Bound IgE was detected using monoclonal HRP 
conjugated anti-human IgE diluted 1:1000 in 2.5% NFDM in PBS-T. Chemiluminescent substrate was used 
for detection and membrane images were captured using a Kodak Gel Logic 440 Imaging System. 
Patient SP902 had a positive challenge to soy milk after passing a soy flour 
challenge. This individual had low a soy CAP but a high CAP for Gly m 4. The low soy 
CAP scores are reflected in minimal binding observed with serum SP902 in both the non-
reduced and reduced IgE immunoblots (Figure 7). Binding was observed to a ~15 kDa 
protein in the non-reduced blots and the protein could be Gly m 3 or 4 based on 
molecular weight. The relatively weak binding observed in these gels is consistent with 
the low amount of these proteins determined by LC/MS-MS.  No pattern can be found for 
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individuals with this clinical history as Figure 8 represents IgE binding from an 
individual with similar manifestations of soy allergy. 
  
 
Figure 8 – Serum SP909 IgE immunoblot of soy products under non-reducing conditions. Sample gels 
(25 µg extract protein per lane) were run under SDS-PAGE non-reducing conditions and transferred to 
PVDF membranes. Membranes were blocked in PBS-T with 5% NFDM followed by incubation with 
serum diluted 1:10. Bound IgE was detected using monoclonal HRP conjugated anti-human IgE diluted 
1:1000 in 2.5% NFDM in PBS-T. Chemiluminescent substrate was used for detection and membrane 
images were captured using a Kodak Gel Logic 440 Imaging System. 
Similarly, patient SP909 had a positive challenge to soy milk after passing a soy 
flour challenge. This individual had a moderate soy CAP score and an extremely high 
Gly m 4 CAP (>100). Strong binding was observed to a number of high molecular weight 
proteins in soy milks and isolates, including the hydrolyzed SPI2, but this same intensity 
was not observed in soy flours and concentrates (Figure 8). Binding to a ~15 kDa protein 
was observed in 9 soy products and this protein could be Gly m 3 or 4, but is most likely 
Gly m 4 due to this individual’s extremely high CAP to Gly m 4. Although this serum is 
unique with its strong binding to the ~15 kDa protein, strong binding to higher molecular 
weight proteins in soy milks and protein isolates was observed with one other serum 
(SP905) that had a positive challenge to soy milk after passing a soy flour challenge.   
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Figure 9 – Serum SP903 IgE immunoblot of soy products under non-reducing conditions. Sample gels 
(25 µg extract protein per lane) were run under SDS-PAGE non-reducing conditions and transferred to 
PVDF membranes. Membranes were blocked in PBS-T with 5% NFDM followed by incubation with 
serum diluted 1:10. Bound IgE was detected using monoclonal HRP conjugated anti-human IgE diluted 
1:1000 in 2.5% NFDM in PBS-T. Chemiluminescent substrate was used for detection and membrane 
images were captured using a Kodak Gel Logic 440 Imaging System. 
Patient SP903 had a positive food challenge to soy flour. A low soy CAP was 
obtained but serum SP903 displayed strong IgE binding to high molecular weight 
proteins in all soy products except the hydrolyzed protein isolate (Figure 9).  A low soy 
CAP did not correlate to low binding to high molecular weights in the immunoblots using 
this serum. Two additional individuals (SP904, SP906) with a positive food challenge to 
soy flour, 1 individual with a history of OAS to soy (791), and 2 individuals with 
unknown histories but positive soy CAPs (219, 450) shared similar binding profiles.  
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Figure 10 – Serum ACG IgE immunoblot of soy products under non-reducing conditions. Sample gels 
(25 µg extract protein per lane) were run under SDS-PAGE non-reducing conditions and transferred to 
PVDF membranes. Membranes were blocked in PBS-T with 5% NFDM followed by incubation with 
serum diluted 1:10. Bound IgE was detected using monoclonal HRP conjugated anti-human IgE diluted 
1:1000 in 2.5% NFDM in PBS-T. Chemiluminescent substrate was used for detection and membrane 
images were captured using a Kodak Gel Logic 440 Imaging System. 
 Patient ACG had a positive soy CAP, a positive ISAC to Gly m 4, and a history of 
respiratory symptoms after soy ingestion. IgE binding with serum ACG was observed to 
high molecular weight proteins of nearly all soy products, but not to the highly heat 
treated SF3 (Figure 10). Serum ACG had an extremely high ISAC score to Bet v 1, a 
moderate score to Gly m 4, and a negative ISAC result to Bet v 2 indicating the binding 
to the ~15 kDa protein is likely to Gly m 4. Four other individuals from the same study as 
patient ACG had positive soy CAP scores and/or a history of anaphylaxis. One 
anaphylactic individual (DDB) shared a similar binding profile as patient ACG, but the 
other 3 patients (HS, JL 007, AB 008) had little or no binding to high molecular weight 
proteins and very little IgE binding to soy overall. 
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Figure 11 – Serum 893 IgE immunoblot of soy products under non-reducing conditions. Sample gels 
(25 µg extract protein per lane) were run under SDS-PAGE non-reducing conditions and transferred to 
PVDF membranes. Membranes were blocked in PBS-T with 5% NFDM followed by incubation with 
serum diluted 1:10. Bound IgE was detected using monoclonal HRP conjugated anti-human IgE diluted 
1:1000 in 2.5% NFDM in PBS-T. Chemiluminescent substrate was used for detection and membrane 
images were captured using a Kodak Gel Logic 440 Imaging System. 
 Patient 893 had a clear history of mild reactions to soy and a positive Gly m 4 
CAP but a negative soy CAP score.  Serum 893 displayed minimal IgE binding to soy 
products (Figure 11). Eight other subjects with negative soy CAP scores and various 
allergic histories had similar binding profiles of weak IgE reactivity to one or a few 
proteins or no IgE binding at all (JENB, JB, MA, SP907, SP908, 42, 48, 579). However, 
serum from patient 138 had an anaphylactic history and negative soy CAP score but had 
binding similar to Figure 4A. Again, no observable IgE binding pattern was found in sera 
from subjects with negative soy CAP scores. 
 
 
250
150
100
75
50
37
25
20
15
10
5
2
250
150
100
75
50
37
25
20
15
10
5
2
7B 
SF
Bakers
SF
Toasted
SF
HM 
Full SF
Arcon
F
Arcon
S
Arcon
SM
Brown
Rice
M.W. Navy 
Bean
PF 
646
Silk
SM
Alpro
SM
Almased WBPPF
781
PF 
955
PF
974
8th
SM
M.W.
SF1 SF2 SF3 SF4 SPC1 SPC2 SPC3
Brown
RiceM.W.
Navy 
Bean
SPI1
Silk
SM
Alpro
SM Almased SBPSPI2 SPI3 SPI4
8th
SM.W.
270 
 
 
Figure 12 – Control serum 1 IgE immunoblot of soy products under non-reducing conditions with 
low (A) and extreme (B) image contrast. Sample gels (25 µg extract protein per lane) were run under 
SDS-PAGE non-reducing conditions and transferred to PVDF membranes. Membranes were blocked in 
PBS-T with 5% NFDM followed by incubation with serum diluted 1:10. Bound IgE was detected using 
monoclonal HRP conjugated anti-human IgE diluted 1:1000 in 2.5% NFDM in PBS-T. Chemiluminescent 
substrate was used for detection and membrane images were captured using a Kodak Gel Logic 440 
Imaging System. 
 The control serum 1 used in this study was from an individual with no known 
food allergies. On extreme image contrast, binding could be observed to navy bean 
(likely CCD reactivity) and very weak binding to a number of soy proteins (Figure 12). 
LC-MS/MS relative quantitation successfully identified the presence of 14 known 
soy allergens in a wide variety of soy products. In the majority of soy-allergic subjects, 
IgE binding studies showed strong binding to abundant allergens and weaker binding to 
less abundant allergens. Gly m 3 is a 14 kDa hydrophilic, heat-labile protein. Gly m 3 
was identified in only 1 of 16 products during our study.  However, others have shown 
soy profilin to be estimated at <1% of soluble protein (Amnuaycheewa and Gonzalez de 
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Mejia, 2010), so the lack of detection by LC-MS/MS could be due to its comparatively 
low abundance. Profilin detected in soy milks ranged from 4.37 ± 0.14 to 7.24 ± 0.30 
mg/g protein (0.4 – 0.7%), while in fermented products profilin ranged from 1.67 ± 0.02 
to 5.47 ± 0.02 mg/g protein (0.2 – 0.5%) (Amnuaycheewa and Gonzalez de Mejia, 2010) 
which correlates well with our findings. A recombinant form of profilin (rGly m 3) was 
shown to bind IgE from 69% soy-allergic sera tested (Rihs et al., 1999). In the current 
study, 11 of 31 (35%) subjects bound to a protein of ~15 kDa in size, most likely Gly m 3 
or 4. The soy allergen Gly m 4 was identified as a cross-reactive protein with Bet v 1, a 
major birch pollen allergen and a cause of reactions in individuals cross-reactive to both 
birch pollen and soy (Kleine-Tebbe et al., 2002). However, rGly m 3 is cross-reactive 
with Bet v 2, birch pollen profilin, and previous studies have shown a number of soy milk 
reactive individuals sensitized to rGly m 3 but not rGly m 4, suggesting that Gly m 3 is 
also involved in cross-reactions between birch pollen and soy (Mittag et al., 2004; Rihs et 
al., 1999). Soy milk is a potentially hazardouss product to Gly m 3 sensitive individuals 
as the food matrix of soy milk affects the thermal stability of profilin (Amnuaycheewa 
and Gonzalez de Mejia, 2010). IgE binding to rGly m 3 depends on the availability of the 
full length protein in its original conformational structure as no IgE binding was observed 
to profilin fragments (Rihs et al., 1999). Pasteurization of soy milk does not alter the 
conformational structure of Gly m 3 and boiling is necessary to reduce conformational 
epitopes (Amnuaycheewa and Gonzalez de Mejia, 2010). While a concern in less 
processed foods, Gly m 3 is not considered a major allergen in boiled or highly processed 
soy products.   
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Gly m 4 is a 17 kDa stress induced, pathogenesis-related starvation associated 
message protein (SAM22). Gly m 4 is found in the roots and leaves of maturing plants 
and can be induced by wounding or stressing young leaves (Crowell et al., 1992). Gly m 
4 related reactions have been reported in individuals consuming raw soy sprouts and a 
low processed soy protein isolate (Mittag et al., 2004). Additionally, reactions to tofu, soy 
milk, and a soy pudding been reported in Gly m 4 sensitive individuals but many could 
tolerate cooked or highly processed soy products (Mittag et al., 2004).  Gly m 4 was not 
found during relative quantitation by mass spectrometry. Published data estimate Gly m 4 
at 0.036 – 0.061 % total seed weight or, assuming a protein content of 40%, 0.09 – 0.15% 
total soy protein (Julka et al., 2012), thus the lack of detection is likely due to the low 
abundance. However, Gly m 4 was detected through immunoblotting with Gly m 4 
specific rabbit antibodies, with the highest reactivity to SF4, the stone ground full fat soy 
flour (data not shown). The 11 individuals that bound to the ~15 kDa protein, binding 
was strongest in SF4, the stone ground full fat soy flour. While the individuals in our 
study may be sensitized to Gly m 4, the protein is present in such low abundance that a 
number of individuals with a positive Gly m 4 CAP score do not show binding at ~15 
kDa of immunoblots. 
Gly m 5, or β-conglycinin, makes up 30% of the total seed proteins and is densely 
packed into trimers composed of three glycosylated subunits, α (67 kDa), α’ (71 kDa), 
and β (50 kDa) (Holzhauser et al., 2009; Maruyama et al., 1998). Across all tested 
products, the current study identified Gly m 5 as 18.4% of the total normalized spectral 
counts by LC-MS/MS and found binding to Gly m 5 in 18 of 31 (58%) soy-allergic 
individuals, with proteins of molecular weight equal to all 3 subunits being recognized in 
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the study. These findings are in line with European and Japanese IgE binding studies that 
respectively found 43% and 100% recognition of Gly m 5 by soy-allergic sera 
(Holzhauser et al., 2009; Ito et al., 2011).  The 3 subunits of Gly m 5 are among the most 
abundant proteins in the 16 studied soy products.  
Gly m 6, or glycinin, makes up 40% of the total seed protein, is a hexameric 
protein, and each subunit (G1, G2, G3, G4, G5) has at least one basic and acidic subunit 
linked by a disulfide bond (Holzhauser et al., 2009; Prak et al., 2005). Five major 
subunits range form 52 – 61 kDa. IgE binding studies respectively found 36% and 100% 
recognition of Gly m 6 by soy-allergic sera (Holzhauser et al., 2009; Ito et al., 2011). All 
five subunits are known to react with IgE (Holzhauser et al., 2009). Across all tested 
products, the current study identified Gly m 6 subunits as 45.7% of the total normalized 
spectral counts by LC-MS/MS and found 15 of 31 (48%) of soy-allergic subjects had IgE 
binding to Gly m 6, with proteins at molecular weights for all subunits demonstrating 
binding. As previously noted, binding at ~15 kDa could be due to Gly m 3 or 4. 
Additional data from Zeece et al. (1999) found the acidic chain of glycinin G1 (A1a) to 
have a single IgE-binding fragment of approximately 15 kDa. While a number of subjects 
are sensitized to Gly m 4, more specific binding studies would need to be conducted to 
determine if any binding at ~15 kDa was due to the A1a fragment.  Houston et al. (2011) 
identified glycinin G3 at low quantities in all tested varieties and although present 
through relative quantitation, it was present at significantly lower concentrations in 
certain specific soybean varieties. The current study did not identify glycinin G3 in 7 of 
16 soy ingredients and products, indicating that processing or varietal genetic differences 
lowered the concentration of glycinin G3 below the LC-MS/MS detection limit and 
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confirmed its status as a lower abundance protein. Two subunits of Gly m 6, glycinins G1 
and G2, have high sequence similarity with peanut Ara h 3 and the acidic chains of A1a 
and A2 share IgE binding epitope regions with Ara h 3 (Beardslee et al., 2000; Rabjohn 
et al., 1999; Xiang et al., 2002). Glycinins G1 and G2 are the two most abundant proteins 
in soybean as shown by mass spectrometry. The high abundance of these shared epitopes 
could in part explain the cross-reactivity found between peanut and soy in some allergic 
individuals.  
Both Gly m 5 and 6 can bind IgE through linear and conformational epitopes 
(Helm et al., 2000; Ogawa et al., 1995; Zeece et al., 1999). Gly m 5 and 6 are stable 
proteins and potent allergens due to the combination of linear and conformational 
epitopes and their structural resistance to denaturation from tight packing and disulfide 
bonds. Accordingly, intense binding was observed in our study between 50 and 70 kDa 
under non-reducing conditions. Previous studies have found a higher prevalence of 
soybean specific IgE to Gly m 5 or 6 in individuals with severe reactions when compared 
to mild or moderate reactors, or those only sensitized to soy but not clinically allergic 
(Holzhauser et al., 2009; Ito et al., 2011). The current study found no difference in the 
prevalence of IgE to Gly m 5 or 6 based on reaction histories, 4 of 7 (57%) with 
anaphylactic histories versus 8 of 17 (47%) with mild or moderate reaction profiles. 
Soy Kunitz trypsin inhibitor (KTI) is an inhalant allergen with a molecular weight 
of 20 kDa and an isoelectric point of 4.5 that represents 4-7% of the total extractable 
protein in soy. The protein is tightly packed, not glycosylated, and trypsin inhibition is 
achieved through reversible binding of KTI to the trypsin enzyme (Barać et al., 2004; 
Baur et al., 1996; Friedman and Brandon, 2001; Kunitz, 1947; Mikić et al., 2009; Quirce 
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et al., 2006). There are three major isoforms of KTI, A, B, and C, with only one amino 
acid difference between A and C and eight amino acid differences between A and B (Kim 
et al., 1985). Isoforms A and B were respectively found in 13 and 6 products; isoform C 
was not able to be distinguished from isoform A due similar sequences. Precursors to the 
trypsin inhibitor, KTI1 and KTI2, were respectively found in 14 and 15 products. 
However, strong IgE binding to 20 kDa proteins was not observed and minor binding was 
only observed in a few cases.  Soy KTI does not appear to be a major ingestion allergen 
in this study population. Additionally, soy KTI has only been found as an ingested 
allergen in one case report, a woman that was previously sensitized to soy KTI through 
work in a laboratory, and is not believed to be a major ingestion allergen in the overall 
soy population (Moroz and Yang, 1980). 
Gly m Bd 30K, also known as soybean vacuolar protein P34, is a 32 kDa oil body 
protein with IgE binding characteristics (Helm et al., 1998; Ogawa et al., 1993). While 
resistant to a number of denaturation treatments, Gly m Bd 30k may be coded by a single 
gene and represents 2% to 3% of the total protein content (Wilson et al., 2005). As 
expected by prediction of percent of total protein content, Gly m Bd 30k was found in all 
16 products during relative quantitation at levels that were comparable but slightly less 
than the levels of KTI. Gly m Bd 30K is a monomeric glycoprotein and has been shown 
to react with 65% of soy-sensitive patients with atopic dermatitis (Helm et al., 1998; 
Ogawa et al., 1993; Wilson et al., 2005). In the current study, 16 of 31 (52%) of sera had 
IgE to proteins near 32 kDa but further identification work would need to confirm if 
binding was to Gly m Bd 30K or another protein. 
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Gly m Bd 28 K is a 26 kDa Asn-linked glycoprotein that has been shown to bind 
IgE from 25% of soy-allergic subjects (Hiemori et al., 2000; Ogawa et al., 2000; Tsuji et 
al., 1997). Additionally, a 23 kDa C terminal fragment of Gly m Bd 28K has been shown 
to have the same IgE reactivity as the 26 kDa form (Hiemori et al., 2000; Hiemori et al., 
2004). In the current study, 11 of 31 (35%) of sera bound to proteins near 23 and 26 kDa 
with the strongest binding in soy flours but also present in soy milk to a lesser extent. 
Previous studies detected high levels of Gly m Bd 28K in tofu, SPI and soy milk (Tsuji et 
al., 1997) but our current study only identified it in 6 products: 2 soy flours, 1 SPC, 1 
SPI, Almased® (SPI), and the soybean powder. No soy milks studied had identifiable 
levels of Gly m Bd 28K.  
4. Conclusion 
 The results from this study show that LC-MS/MS is a viable method to identify 
the majority of allergenic soy proteins.  Additional method refinements or new 
techniques such as antibody detection would be necessary to detect low abundance 
proteins such as Gly m 3 and Gly m 4. IgE binding using sera from soy-allergic subjects 
did not allow the identification of patterns that could be associated with the clinical 
histories and symptoms of these patients.  In fact, patients with similar histories could 
exhibit intense binding or no binding at all. However, when IgE binding was present, the 
relative amount of an allergen in a sample correlated positively to the intensity of IgE 
binding to proteins at the expected molecular weight. Small differences in IgE binding 
were observed based on the form of soy (soy flour vs soy milk) known to elicit an 
allergic reaction.  However, studies with more subjects would be necessary to confirm 
these initial findings. Finally, quantification by LC-MS/MS identified small variations in 
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the amounts of soy allergens per product type, but the results were not as drastic as one 
might expect after the extensive treatments applied to some of these products. 
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